ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9
ii
CONTRIBUTORS
. ...
23 downloads
2045 Views
19MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9
ii
CONTRIBUTORS
. ....... Amer. M . S . . . . . . . . . Archer. R . A . . . . . . . . Bindra. J . S . . . . . . . . Bloch. A . . . . . . . . . . Campbell. W . C. . . . . . . Carlson. R . G . . . . . . . . Chang. A . Y . . . . . . . . . Chignell. C . F . . . . . . . Claridge. C . A . . . . . . . Daly. J . W . . . . . . . . . Dean. R . R . . . . . . . . . DuCharme. D . W . . . . . . . Eargle. D . H., Jr . . . . . . Flanders. L . E . . . . . . . Fleming. J . S . . . . . . . . Francis. J . E . . . . . . . . Fullerton. D . S . . . . . . . Giles. R . E. . . . . . . . . Gordon. M . . . . . . . . . . Gylys. J . A . . . . . . . . . Harbert. C. A . . . . . . . . Hardy. R . A., Jr . . . . . . Adelstein. G W
67 203 253 214 139 115 270 182 280 95 290 67 50 260 162 75 57 260 85 38 27
1
11
........ Hodson. A . . . . . . . . . Holland. G . F . . . . . . . Jerina. D . M . . . . . . . . Johnson. A . G . . . . . . . Katzenellenbogen. J . A . . . Kenyon. G . L . . . . . . . . Leitner. F . . . . . . . . . MacNintch. J . .E. . . . . . McKinney. G . R . . . . . . . Metcalf. R . L . . . . . . . Mrozik. H . . . . . . . . . Mueller. R . A . . . . . . . Partyka. R . A . . . . . . . Pereira. J . N . . . . . . . Rando. R . R . . . . . . . . Rosenthale. M . E. . . . . . Schwartz. A . R . . . . . . . Shadomy. S . . . . . . . . . Tomeszewski. J . E . . . . . Vernier. V . G . . . . . . . Welch. W . M . . . . . . . . Wheelock. E . F . . . . . . . Herzig. D . J
85 151 172 290 244 222 260 95 75 203 300 115 162 27 172 234 193 128 107 290 19
1 151
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9 Sponsored by the Division of Medicinal Chemistry of the American Chemical Society Editor-in- Chief: RICHARD V. HEINZELMAN THE UPJOHN COMPANY KALAMAZOO, MICHIGAN
SECTION EDITORS MAXWELL GORDON
FRANK CLARKE
WALTER MORELAND
WILLIAM WECHTER
ACADEMIC PRESS
@
GEORGE WARREN ROBERT WILEY
New York and London 1974
A Subsidiary of Harcourt Brace Jovanovich, Publishers
ACADEMIC PRESS RAPID MANUSCRIPT REPRODUCTION
COPYRIGHT 0 1974, BY ACADEMIC PRESS, INC. ALL RIGHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION I N WRITING FROM THE PUBLISHER.
ACADEMIC PRESS, INC. 111 Fifth Avenue, New
York. New York 10003
United Kingdom Edition published by ACADEMIC PRESS, INC. (LONDON) LTD. 24/28 Oval Road, London NWl
LIBRARY OF CONGRESS CATALOG CARD NUMBER:66- 26843
PRINTED IN THE UNITED STATES O F AMERICA
V
CONTENTS
............................. ...............................
Contributors
ii
Preface
xi
I. CNS AGENTS Section Editor: Maxwell Gordon, Bristol Laboratories, Syracuse, New York
..............
1
...............
11
1.
Antipsychotic and Antianxiety Agents. Charles A. Harbert and Willard M. Welch, Pfizer, Inc., Groton, Connecticut
2.
Narcotic Antagonists and Analgesics Robert A. Hardy, Jr., Lederle Laboratories, A Division of American Cyanamid Company, Pearl River, New York
3.
Antiparkinsonism Drugs. Vernon G. Vernier, E. I. Du Pont de Nemours & Co., Inc., Newark, Delaware
4.
Psychotomimetic Agents. Richard A. Partyka and Jonas A. Gylys, Bristol Laboratories Syracuse, New York
5.
Abuse of CNS Agents Maxwell Gordon, Bristol Laboratories, Syracuse, New York
.....................
19
.....................
27
.......................
38
11.
Section Editor: 6.
PHARMACODYNAMIC AGENTS
Frank H. Clarke, Ciba-Geigy Corporation, Ardsley, New York
..................
The Etiology of Hypertension. Donald W. DuCharme, The Upjohn Company, Kalamazoo, Michigan
50
vi CONTENTS 7.
.....................
Antihypertensive Agents John E. Francis, Research Department, Pharmaceuticals Division, CIBA-GEIGY Corporation, Ardsley, New York
..............
8. Antiarrhythmic and Antianginal Agents Gilbert W. Adelstein and Richard R. Dean, Searle Laboratories, Chicago, Illinois 9.
......................
Antithrombotic Agents J. Stuart Fleming and John E. MacNintch, Bristol Laboratories, Syracuse, New York
.................
10. Pulmonary and Antiallergy Drugs Ralph E. Giles and David J. Herzig, Warner-Lambert Research Institute, Morris Plains, New Jersey
57
67
75
85
111. CHEMOTHERAPEUTIC AGENTS
Section Editor: George H. Warren, Wyeth Laboratories, Inc., Philadelphia, Pennsylvania
...........................
95
........................
107
......................
115
........................
128
11. Antibiotics F. Leitner and C. A. Claridge, Bristol Laboratories, Syracuse, New York
12. Antifungal Agents Smith Shadomy, Medical College of Virginia, Richmond, Virginia 13. Antiparasitic Agents. W. C. Campbell and H. Mrozik, Merck Institute for Therapeutic Research, Rahway, New Jersey
14. Antiviral Agents.
Andrew R. Schwartz, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania
vii CONTENTS
......................
139
.....................
151
15. Antineoplastic Agents A. Bloch, Roswell Park Memorial Institute, Buffalo, New York
16. Immunotherapy of Cancer Anita Hodson and E. Frederick Wheelock, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
IV. METABOLIC DISEASES AND ENDOCRINE FUNCTION Section Editor: Walter T. Moreland, Pfizer Inc., Groton, Connecticut
. . . . . . . . . . . . . . 162
17. Prostaglandins and Related Compounds. Richard A. Mueller and Lloyd E. Flanders, G. D. Searle and Co., Chicago, Illinois
. . . . . . . . . . . . . . . . . . 172
18. Disorders of Lipid Metabolism Gerald F. Holland and Joseph N. Pereira, Pfizer Inc., Groton, Connecticut
........................
19. Diabetes Mellitus Albert Y. Chang, The Upjohn Company, Kalamazoo Michigan
182
. . . . . . . . . . . . . . 193
20.
Non-steroidal Antiinflamatory Agents Marvin E. Rosenthale, Wyeth Laboratories, Inc., Radnor, Pennsylvania
21.
Cyclic Nucleotides and Drug Discovery M. Samir h e r and Gordon R. McKinney, Mead Johnson Research Center, Evansville, Indiana
. . . . . . . . . . . . . . 203
viii CONTENTS
V.
TOPICS IN BIOLOGY
Section Editor: William J. Wechter, The Upjohn Company, Kalamazoo, Michigan Section Editorial
........................
213
........................
214
22.
Anti-aging Drugs. Jasjit S. Bindra, Pfizer, Inc., Groton, Connecticut
23.
Affinity Labeling of Hormone Binding Sites. John A. Katzenellenbogen, Department of Chemistry, University of Illinois, Urbana, Illinois
24.
Mechanism-Based Irreversible Enzyme Inhibitors. Robert R. Rando, Dept. of Pharmacology, Harvard Medical School, Boston, Massachusetts
25.
Adjuvants to the Immune System. Arthur G. Johnson, University of Michigan Medical School, Ann Arbor, Michigan
26.
The Cannabinoids: Therapeutic Potentials Robert A. Archer, Lilly Research Laboratories, Indianapolis, Indiana
. . . . . . . . . . . 222
. . . . . . . . . 234
. . . . . . . . . . . . . . . . . 244 . . . . . . . . . . . . 253
VI. Section Editor: 27.
TOPICS IN CHEMISTRY
Robert A. Wiley, University of Kansas, Lawrence, Kansas
. . . . . . . . . . 260
Reactions of Interest in Medicinal Chemistry. Dwight S. Fullerton, George L. Kenyon and Dolan H. Eargle, Jr., Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota and University of California, San Francisco, California
ix CONTENTS 28.
29.
The Intramolecular Diels-Alder Reaction in Organic Synthesis. Robert G. Carlson, Department of Chemistry, University of Kansas, Lawrence, Kansas
. . 270
. . . . . . . . . . . . . . . 280
Drug Binding and Drug Action. . . . Colin F. Chignell, National Heart and Lung Institute, Bethesda, Maryland
. . . . . . . . 290
30. Cytochrome P-450 Monoxygenases in Drug Metabolism J. E. Tomeszewski, D. M. Jerina and J. W. Daly, National Institute of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Bethesda, Maryland
31. Use of Chemical Relationships in Design of DDT-Type Insecticides. 300 Robert L. Metcalf, Department of Entomology, University of Illinois, Urbana-Champaign, Illinois
COMPOUND NAME AND CODE NUMBER INDEX.
. . . . . . . . . . . . . . . . . 309
This Page Intentionally Left Blank
xi
PREFACE Our editorial policy continues to be to report annually on the more active fields of interest to medicinal chemists and to cover less regularly new or maturing biomedical topics or fields which have passed their prime. Less than half of this year's topics appeared also in last year's Annual Reports. It may be well to remind the reader that it is not our intent to provide comprehensive literature coverage for the expert in the field; plenty of other publications already serve this purpose. Our aim is to report significant highlights to enable the worker in a related field to recognize developments or concepts which may broaden his approach to his own area or even cause him to delve into a new one. Just as the increasing availability of massive computer-generated bibliographies on a particular topic poses a growing problem for a researcher who wishes to read selectively in a new field, so this same capability makes it more difficult for our chapter authors to be selective in what they choose to discuss. In fact this problem constitutes the editor's most arduous task; the ten-page chapter limit is designed both to achieve desired selectivity of subject matter and to keep the volume within a reasonable price range in this era of soaring costs. For the first time section editors have been given the opportunity to include one-page editorial overviews of their sections; among the objectives of these overviews are to highlight major new developments, emphasize common features in drug actions or disease etiologies or just to permit speculation as a stimulus for new ideas. While only one section editor chose to accept the invitation this year, it is hoped that more will do so in future volumes. A s always, your constructive suggestions for improvement or for new topics are earnestly solicited.
Kalamazoo, Michigan June, 1974
This Page Intentionally Left Blank
Section I
-
CNS Agents
E d i t o r : Maxwell Gordon B r i s t o l L a b o r a t o r i e s , Syracuse, New York Chapter 1. A n t i p s y c h o t i c and A n t i a n x i e t y Agents Charles A. Harbert and W i l l a r d M. Welch P f i z e r I n c . , Groton, Conn. 06340 I n t r o d u c t i o n - Although s e v e r a l promising a g e n t s have p r o g r e s s e d t o advanced c l i n i c a l s t a g e s , no fundamentally new a n t i p s y c h o t i c o r a n t i a n x i e t y a g e n t s w e r e i n t r o d u c e d i n t h e U.S. i n 1973. Clozapine has emerged as t h e focus of c l i n i c a l and t h e o r e t i c a l i n t e r e s t i n t h e a n t i p s y c h o t i c area based on i t s extremely low i n c i d e n c e of e x t r a p y r a m i d a l s i d e r e a c t i o n s . This d i s c o v e r y h a s given new impetus t o r e s e a r c h d i r e c t e d toward an und e r s t a n d i n g of t h e biochemical and n e u r o p h y s i o l o g i c a l c o r r e l a t e s of a n t i p s y c h o t i c a c t i o n and e x t r a p y r a m i d a l m a n i f e s t a t i o n s . A c t 2 v i t y i n t h e a n t i a n x i e t y area a g a i n l a r g e l y focused on a g e n t s s t r u c t u r a l l y and mechani s t i c a l l y r e l a t e d t o t h e benzodiazepines. Extensive treatises have covered t h e c h e m i s t r y , b i o c h e m i s t r y , pharmacology and c l i n i c a l u t i l i t y of t h e b e n z o d i a z e p i n e s l and t h e n e u r o l e p t i c s . 2 A n t i p s y c h o t i c Agents - T r i c y c l i c s - S t r u c t u r e - a c t i v i t y r e l a t i o n s h i p s (SAR) of t h e t r i c y c l i c p s y c h o t h e r a p e u t i c s 3 and c l i n i c a l e x p e r i e n c e w i t h t h e l o n g - a c t i n g n e u r o l e p t i c s 4 9 5 have been reviewed. Emphasis continued t o s h i f t from s t r u c t u r e s w i t h 6 , 6 , 6 r i n g systems t o t h e 6 , 7 , 6 - t r i c y c l i c s . Among t h e l a t t e r , c l o z a p i n e (A) h a s a t t r a c t e d t h e most i n t e r e s t . A r e c e n t review6 h i g h l i g h t s t h e unique p r o f i l e of t h i s agent and t h e a u t h o r p o i n t s out some troublesome s i d e e f f e c t s (hypotension, t a c h y c a r d i a ) t h a t may l i m i t i t s c l i n i c a l use. Regardless, t h e emergence of c l o z a p i n e has reemphasized t h e f e a s i b i l i t y of d i s a s s o c i a t i n g a n t i p s y c h o t i c a c t i v i t y from t h e c a t a l e p t i c p r o p e r t i e s t h a t have been c l a s s i c a l l y regarded as a prerequisite f o r c l i n i c a l therapeutic activity. 7 a)XmH ;ZICH b ) X r C l ; Z n C H c ) X = H ; Z = N d) X I C1 ; Z = N e ) X = O E t ; Z = CH f ) X I OCH3;Z = CH _.
H
6
4
Continuing SAR s t u d i e s i n t h e d i b e n z o [ b , f ] t h i e p i n and r e l a t e d 6 , 7 , 6 systems have shown t h a t s u b s t i t u t i o n by c h l o r i n e i n t h e 9 - p o s i t i o n of p e r a t h i e p i n (&) r e s u l t s i n diminished a c t i v i t y .8 A l l e i g h t p o s s i b l e aryl-monochloro isomers of p e r a t h i e p i n have now been s y n t h e s i z e d , and of
2 -
Sect. I
-
CNS Agents
Gordon, Ed.
t h e s e only t h e 8 - C 1 isomer ( o c t o c l o t h e p i n , &) i s more p o t e n t t h a n t h e p a r e n t compound. Octoclothepin enantiomers and t h e racemate were found t o d i f f e r l i t t l e from each o t h e r i n CNS d e p r e s s a n t e f f e c t s o r i n t o x i c i t y . ' The 4-aza a n a l o g s & and 2d showed markedly reduced depress a n t and c a t a l e p t i c a c t i v i t y compared w i t h 3 and 2, r e s p e c t i v e l y . l O , l l Among s e v e r a l 8-alkoxy analogs prepared, o n l y t h e 8 - E t 0 isomer (&) e x h i b i t e d a c t i v i t y (1OX chlorpromazine [CPZ] i n t h e r o t a t i n g rod t e s t ) e q u i v a l e n t t o t h e known 8-Me0 d e r i v a t i v e ( 2 f , octometothepin) .I2 Oxid a t i o n of t h e S atom and/or 4'-N atom i n a number of d i b e n z o [ b , f ] t h i e p i n s r e l a t e d t o 1. r e s u l t e d i n a uniform l o s s of CNS d e p r e s s a n t a c t i v i t y . 1 3 EX 11-582A (3) p o s s e s s e s p o t e n t a c t i v i t y i n t h e f i g h t i n g mouse (ED50 0.9 mg/kg) and antiamphetamine t o x i c i t y (ED50 0.28 mg/kg) t e s t s . 1 4 Like c l o z a p i n e , t h i s compound was i n a c t i v e a g a i n s t apomorphine-induced emesis.
q y
a) R CF3
c1
CHCHzCHzN(CH3
3 -
)2
-
a;Q CH,;
Z
I
N
I
R
b) R
-4
I
L c1
S
C H 2 9 ; Z
=
N (CH, ) 2
S
-5
A r e c e n t paper of t h e o r e t i c a l i n t e r e s t r e p o r t e d p o t e n t n e u r o l e p t i c a c t i v i t y f o r a number of p i p e r i d y l i d e n e t h i o x a n t h e n e s (4,Z=S) and r e l a t e d s t r u c t u r e s (4, Z=O o r NCH3); f o r example, 4a and 4b were r e s p e c t i v e l y 7 and 1 8 X CPZ i n t h e r a t p t o s i s t e s t . 1 5 S i g n i f i c a n t l y , many of t h e s e compounds were more p o t e n t t h a n t h e i r corresponding t r i c y c l i c congeners w i t h nonr i g i d s i d e c h a i n s . Since k cannot assume t h e s o l i d s t a t e c o n f i g u r a t i o n t h e a u t h o r s q u e s t i o n e d earlier s p e c u l a t i o n s t h a t t h e a c t i v e of CPZ c o n f i g u r a t i o n of a n t i p s y c h o t i c s resembles t h a t of c r y s t a l l i n e CPZ. Rather, t h e i r f i n d i n g s are c o n s i s t e n t w i t h t h e S - c o n f i g u r a t i o n of a n t i p s y c h o t i c d r u g s f r e q u e n t l y d e p i c t e d by Janssen.7 I n a r e l a t e d paper, NMR s h i f t r e a g e n t s were used t o determine t h e s t e r e o c h e m i s t r y of and t r a n s aminoalkylidene xanthenes and thioxanthenes . I 6 As expected, n e u r o l e p t i c a c t i v i t y predominated i n t h e cis series.
(z),
An i m p o r t a n t pharmacokinetic s t u d y c o r r e l a t e d CPZ plasma l e v e l s w i t h t h e r a p e u t i c response and found t h a t plasma l e v e l s i n t h e range of 150-300 ng/ml u s u a l l y corresponded t o c l i n i c a l improvement . I 7 S i g n i f i c a n t l y , concomitant a d m i n i s t r a t i o n of an a n t i p a r k i n s o n agent ( t r i h e x y p h e n i d y l ) tended t o lower plasma l e v e l s of CPZ, an e f f e c t a s c r i b e d t o reduced g a s t r i c mot i l i t y and d e c r e a s e d a b s o r p t i o n of CPZ. Butyrophenones, P h e n y l p i p e r a z i n e s , and R e l a t e d Compounds - Bromoperidol (&) i s e s s e n t i a l l y e q u a l t o h a l o p e r i d o l i n potency and d u r a t i o n of a c t i o n . 1 8 The trans-4-aryl-4-methoxycyclohexylaminobutyrophenone 6b exceeded h a l o p e r i d o l on s e v e r a l b e h a v i o r a l e n d p o i n t s and exhibitedh i g h l y s e l e c t i v e (vs. 5-HT) NE uptake blockade.19 Compound &, t h e most p o t e n t (15X CPZ i n c o n d i t i o n e d avoidance response [CAR]) i n a series of s u b s t i t u t e d pyrazino[2',1':6,l]pyrido[3,4-b]indoles, was r e p o r t e d t o have a prolonged d u r a t i o n of a c t i o n and few c a r d i o v a s c u l a r
Antipsychotic and Antianxiety Agents Harbert, Welch 2
Chap. 1
effects .20 Centpyraquin (6d, compound 69-183) combined neuroleptic activity (ca. CPZ in CAR) with significant hypotensive effects.21 AHR-2277 (lenperone, 6 e ) exerted a rapid and favorable effect on psychotic symptomatology, and was claimed to produce a very low incidence of neurological side reactions.22 A double-blind study of AL-1021 (6f) in hospitalized schizophrenics failed to confirm earlier encouraging results obtained in pilot study.23 Milipertine (&) produced troublesome EPS side effects in schizophrenics at doses well below those required to produce antipsychotic activity.24 Compound j’&was one of a series reported to exhibit CNS depressant activity in animals roughly in the CPZ range.25 Oxazolidinone 7c blocked isolation-induced aggression in mice (ca. 0 . 5 X CPZ);26 a similar level of activity in this test was seen with the related compounds 8a and &.27
-6
H
7 m
7b) X
I
OCH3; Y
= H; R =
-
R
-8
COCH3 CH2CHOHCH206
8b)
R
(CH,),OCONHCH,
Miscellaneous Compounds - A benzodiazep ne, SCH- 2,041 (2, halazepam), showed evidence of efficacy against acute psychotic symptoms in an uncontrolled tria1.28 CI-686 (10)was predicted to have major tranquilizer activity of short duration on the basis of quantitative pharmaco-EEG studies.29 Butaclamol (11, - AY-23,028) possessed pharmacological actions resembling fluphenazine, with activity residing solely in the (+)-enantiomer.30,31 The SAR of several cannabinoids nas been reexamined and
Sect. I
4 -
-
CNS Agents
Gordon, Ed.
found to differ significantly from earlier reports.32 A comparison study in the same paper showed 12 to be 3-15X CPZ in decreasing motor activity and in blocking fighting behavior in mice.
10 -
-9
11 -
OH
12 -
Antianxiety Agents-Benzodiazepines and Related Compounds - The drug therapy of anxiety33~34 and the effect of benzodiazepines in controlling aggressive behavior35 were reviewed. It was argued that conformational similarities between diphenylhydantoin and diazepam36 do not constitute an appropriate basis for comparing their biological activities.37 A series of benzodiazepines with a,a-dihydroperfluoroalkyl groups at N-1 were found to successfully block metabolism at N-1 as predicted. One of these, nalazepam (Sch 12,041, 2 ) , appeared to be more specific than diazepam in anticonvulsant (pentylenetetrazole, PTZ) and traction endpoints, with lower side effect potential (therapeutic index 4X diazepam). 38 The ,39 and ID-540 (13b)hO related compound, fletazepam (Sch 15,698, were claimed to be skeletal muscle relaxants. Clonazepam (Ro 5-4023, 13c) was more active against seizures induced by i.v. lidocaine than Ro 8-4192 (E) or diazepam.41 Compound from a novel series =her of 7-azidobenzodiazepines, demonstrated sedative and anticonvulsant properties equivalent to diazepam.42
e)
e,
1 ‘
2
7 5
13 2
K 3 -N
c1
14a) 2 -NHOCH2CH2=CH2 14b) 2-NHCONHCOOC2 Hcj 14c) 2 - N 7 - H
\’. 14 -
0
Chap. 1
Antipsychotic and Antianxiety Agents
Harbert, Welch
2
Pharmacological studies indicated uldazepam (U-31,920, 3) to be an effective antianxiety drug with weak sedative and muscle relaxant prowas nearly equivalent to diazepam in perties.43 The urea derivative several behavioral and convulsant (thiosemicarbazide) end points ,44 wherewere less active in the same tests. as the related 2-imidazolidones (&) A number of 1,3-dialkylpyrazolo[4,3-e]diazepinones exhibited potent CNS activity and one of these, pyrazapon (CI-683, 2) showed anxiolytic activity equivalent to diazepam in man.45 SAR studies showed that hydrogen is preferred at N-4 and that 1,3-dialkyl substitution is superior to the 2,3-pattern of the isomeric series (16).
=
15 -
16 -
18 -
Several series of triazolobenzodiazepines (17) with CNS depressant the most potent of the 3activity have been reported. D-40TA (E), unsubstituted triazoles, was highly active as a tranquilizer, sedativehypnotic and muscle relaxant in animal^.^^-^^ Triazolam (U-33,030, =) exhibited hypnotic activity in man at 0.25-2.0 mg. 49 The anticonvulsant and antiaggressive potencies of U-31,957 (G) and U-35,005 (G) exceeded those of the corresponding diazepam analogs, but they were only weakly active in end points measuring overt depression (traction, EtOH) .50 Alprazolam (U-31,889, 17e)51 demonstrated a marked and rapid anxiolytic effect in man as had been predicted from its EEG profile.52 Chlordiazepoxide isosteres in the triazolobenzodiazepine series (e.g. 17f) were consistently inactive.46,53 The triazinodione 18was equal to diazepam on several behavioral end points and was 0.3X diazepam against PTZ convulsions and EtOH narcosis.44 The 1,5-benzodiazepine triflubazepam (ORF-8063, =)possessed antianxiety properties in man at 40-160 mg/day,54,55 with a profile similar to diazepam.56 Like most lY4-benzodiazepines it was primarily metabolized through N-dealkylation, but was otherwise hydroxylated in the N-phenyl ring rather than at C-3.57 Pharmacokinetic studies with
6 -
Sect. I
-
CNS Agents
Gordon, Ed.
t r i f l u b a z e p a m showed c l i n i c a l improvement t o b e c o r r e l a t e d w i t h blood l e v e l s of 0.5 t o 1 . 0 ng/m1.58 Clobazam w a s claimed t o be b e t t e r t o l e r a t e d t h a n c h l o r d i a z e p o x i d e i n pharmacological and t o x i c o l o g i c a l s t u d i e s . 59 The 1,5-benzodiazepine r e l a t i v e s of c h l o r d i a z e p o x i d e , 20a and E , p r o t e c t e d mice a g a i n s t c o n v u l s i o n s produced by PTZ, s t r y c h n i n e (ST) and t r e m o r i n e , and were less d i s r u p t i v e t h a n c h l o r d i a z e p o x i d e on tests of motor c o o r d i n a t i o n . 6 0
(w)
2
CH3
7
Q;Jo I 19
C6H5
OZN
19a) 7-CF3 19b) 7-C1
l o C6H5
20 -
20a) 2-M12 20b) 2-N(CH3 )2
Other S t r u c t u r e s w i t h A n t i a n x i e t y A c t i v i t y - The o x y p e r t i n e a n a l o g s 21a and 21b induced a t a x i a , d e c r e a s e d locomotor a c t i v i t y and antagonizede l e c t r o s h o c k (ES) and ST c o n v u l s i o n s i n mice 0.25 diazepam).61 I n d o l e d e r i v a t i v e s U-5092 and U-13,625 (G) p r o t e c t e d mice a g a i n s t ES-induced c o n v u l s i o n s and produced a CPZ-like t r a n q u i l i z i n g e f f e c t . 62 I n a double-blind s t u d y a g a i n s t a n x i e t y , 200 mg opipramol (22) w a s e q u i v a l e n t t o 30 mg c h l o r d i a z e p o x i d e .63 The i s o q u i n o l i n e d e r i v a t i v e 23 and t h e b e n z o t h i a z e p i n e d e r i v a t i v e 2 4 possessed marked CNS a c t i v i t y i n mice c h a r a c t e r i z e d by g e n e r a l d e p r e s s i o n and a n t i c o n v u l s a n t (ES, PTZ, ST) a c t i v i t y . 6 4 , 6 5 The R enantiomers of a series of 1 - a m i n o t e t r a l i n s (e.g. 25) s u p p r e s s e d c o n d i t i o n e d emotional response (CER) i n rats a t 10 I n t e r e s t i n g l y , t h e S isomers were devoid of CER a c t i v i t y , b u t mg/kg. possessed marked a n t i c a t a l e p t i c ( t e t r a b e n a z i n e ) a c t i v i t y . 66 Although 26a and 26b resemble known m e t a b o l i t e s of 1,4-benzodiazepine t r a n q u i l i z e r s , t h e y e x h i b i t e d o n l y v e r y weak anti-PTZ and ES a c t i v i t y , and showed no taming e f f e c t i n i s o l a t e d mice.67
(z)
2l a
(=.
Chap. 1
A n t i p s y c h o t i c and A n t i a n x i e t y Agents
H a r b e r t , Welch
7
$yJ 0
OCH3 25
-
26 -
b)
1-OH
B i o l o g i c a l Observations and Hypotheses - The r o l e of dopamine r e c e p t o r b l o c k i n g a g e n t s i n t h e t r e a t m e n t of schizophrenia68 and t h e m e c h a n i s t i c r e l a t i o n s h i p of t h e a n t i p s y c h o t i c e f f e c t s of n e u r o l e p t i c s t o t h e i r e x t r a pyramidal (EPS) e f f e c t s @ have been reviewed. S e v e r a l hypotheses have been advanced t o account f o r c l o z a p i n e ' s low i n c i d e n c e of EPS r e a c t i o n s , 6 most of which invoke i t s a t r o p i n e - l i k e a n t i c h o l i n e r g i c a c t i v i t y . For example, c l o z a p i n e causes a g r e a t e r i n c r e a s e i n homovanillic a c i d l e v e l s i n t h e l i m b i c system than i n t h e s t r i a t u m , w h i l e h a l o p e r i d o l shows no s e l e c t i v i t y i n t h e s e p o r t i o n s of t h e b r a i n . However, when an a n t i c h o l i n e r g i c agent is coadministered w i t h h a l o p e r i d o l an e f f e c t resembling t h a t of c l o z a p i n e i s o b t a i n e d , 70 c o n s i s t e n t with r e c e n t evidence t h a t c h o l i n e r g i c pathways modulate dopaminergic a c t i v i t y i n t h e s t r i a t u m , but n o t i n t h e l i m b i c system. 7 l T h e r e f o r e , c l o z a p i n e ' s a n t i c h o l i n e r g i c properties may f o r t u i t o u s l y balance i t s EPS e f f e c t i n t h e s t r i a t u m w i t h o u t a t t e n u a t i n g i t s a n t i p s y c h o t i c e f f e c t . The r e c e n t observation72 t h a t CPZ enhances a c e t y l c h o l i n e output i n t h e s t r i a t u m of cannulated c a t s provides t h e f i r s t d i r e c t evidence t h a t n e u r o l e p t i c drugs a c t i v a t e t h e c h o l i n e r g i c s y s t e m and s u p p o r t s t h e p o s t u l a t e d e x i s t e n c e of an interdependent and a n t a g o n i s t i c c h o l i n e r g i c-d op aminer g i c neuronal network .73 F u r t h e r evidence f o r t h e e x i s t e n c e of a neuronal feedback mechanism c o n t r o l l i n g DA t u r n o v e r i n b r a i n came from a r e p o r t t h a t a n t i p s y c h o t i c drugs i n c r e a s e t h e r a t e of f i r i n g of dopaminergic neurons i n t h e s u b s t a n t i a n i g r a and t h e v e n t r a l tegmental area. 74 Recent papers a l s o suggested t h a t y-hydroxybutyric a c i d (GHB) 75,76 and y-aminobutyric a c i d (GABA) 77 may r e g u l a t e t h i s feedback mechanism. I f t h e s e f i n d i n g s are s u b s t a n t i a t e d GHB and GABA w i l l provide v a l u a b l e t o o l s t o s t u d y t h i s feedback mechanism and i t s r e l a t i o n s h i p t o n e u r o l o g i c a l m a n i f e s t a t i o n s such as c a t a l e p s y i n animals, and EPS s i d e e f f e c t s and t a r d i v e d y s k i n e s i a i n man. The import a n c e of i d e n t i f y i n g e x i s t i n g o r new b i o l o g i c a l tests t h a t r e l a t e more s p e c i f i c a l l y t o a n t i p s y c h o t i c a c t i v i t y i n man was emphasized i n two r e c e n t papers which claimed t h a t b i o l o g i c a l endpoints showing t o l e r a n c e (e.g. s t e r e o t y p e d behavior) do n o t assess p o t e n t i a l a n t i p s y c h o t i c e f f e c t s i n man, b u t r a t h e r only measure p r o p e n s i t y t o cause EPS e f f e c t s . 7 8 9 7 9 A new technique t o assess changes i n NE s y n t h e s i s i n rat b r a i n measures t h e accumulation of 3-methoxy-4-hydroxyphenylethyleneglycol (MOPEG), a major NE m e t a b o l i t e . 8 0 This method w a s claimed t o be more convenient than c o n v e n t i o n a l methods u t i l i z i n g exogeneous a-methylp-tyrosine o r l a b e l e d t y r o s i n e , and t o avoid e r r o r s t h a t might b e
8
Sect. I
-
CNS Agents
Gordon, Ed.
introduced by i n t e r a c t i o n of t h e s e agents w i t h t h e t e s t compound. The s e d a t i v e a c t i v i t y of n e u r o l e p t i c s appears t o c o r r e l a t e w e l l w i t h t h e i r a b i l i t y t o i n c r e a s e MOPEG levels i n b r a i n . 8 1 S e v e r a l r e c e n t r e p o r t s have i m p l i c a t e d enzyme def i c i e n c e s o r a b n o r m a l i t i e s i n t h e pathophysiology of s c h i z o p h r e n i a . Post-mortem b r a i n specimens of s c h i z o p h r e n i c s showed a s i g n i f i c a n t r e d u c t i o n i n dopamine-8-hydroxylase a c t i v i t y vs. normals i n a l l b r a i n r e g i o n s examined.82 Monoamine oxidase (MAO) a c t i v i t y w a s found t o be s i g n i f i c a n t l y lower i n t h e p l a t e l e t s of s c h i z o p h r e n i c and non-schizophrenic monozygotic twin p a i r s when compared t o normal c o n t r o l s , s u g g e s t i n g t h a t decreased MA0 a c t i v i t y might be a g e n e t i c marker f o r v u l n e r a b i l i t y t o s c h i z o p h r e n i a . 83 An N-methyltransferase capable of forming dimethyltryptamine (DMT) , a known h a l l u c i n o g e n , was found i n human red blood c e l l s , plasma, and p l a t e l e t s . 8 4 S i g n i f i c a n t l y t h e a c t i v i t y of t h i s enzyme i n p l a t e l e t s w a s h i g h e r i n p s y c h o t i c s u b j e c t s than i n nonpsychotics, a f i n d i n g a p p a r e n t l y r e l a t e d t o an u n i d e n t i f i e d d i a l y z a b l e i n h i b i t o r pres e n t i n normal s u b j e c t s , b u t n o t i n p s y c h o t i c s . A non-specific N-methylt r a n s f e r a s e i s o l a t e d from rat b r a i n w a s found t o be s i m i l a r l y c o n t r o l l e d by a d i a l y z a b l e i n h i b i t o r . 8 5 DMT and b u f o t e n i n have been i d e n t i f i e d i n t h e u r i n e of a u t i s t i c c h i l d r e n 8 6 and c h r o n i c s c h i z o p h r e n i c s , 87 b u t no d i f f e r e n c e between plasma DMT l e v e l s i n c o n t r o l s and s c h i z o p h r e n i c s w a s e v i d e n t i n a r e c e n t study.88 Although S-adenosylmethionine h a s been viewed f o r many y e a r s as t h e methyl donor r e s p o n s i b l e f o r t h e 0- and N-methylation of b i o g e n i c amines, t h e involvement of 5-methyltetrahydrof o l i c a c i d i n t h e s e t r a n s f o r m a t i o n s h a s now been f i r m l y e s t a b l i s h e d . 8 9 , g 0 Accordingly, i t h a s been p o s t u l a t e d r e c e n t l y t h a t t h e cause of schizop h r e n i a might b e an overabundance of f o l a t e coenzymes, r e s u l t i n g i n e x c e s s i v e N-methylation of b i o g e n i c amines i n b r a i n . 8 9 Diazepam appears t o e x e r t a d i r e c t a c t i o n a t t h e s p i n a l level by i n c r e a s i n g segmental p r e s y n a p t i c i n h i b i t i o n and by d e c r e a s i n g o r s u p p r e s s i n g p r e s y n a p t i c c o n t r o l s of s u p r a s p i n a l o r i g i n . 91 Benzod i a z e p i n e s appear t o d e c r e a s e NE turnover by reducing impulse a c t i v i t y i n t h e l o c u s coeruleus r a t h e r t h a n by a d i r e c t i n t e r f e r e n c e w i t h release of NE from t h e nerve terminals.92 R e p e t i t i v e dosing may, however, r e v e r s e t h i s i n h i b i t o r y e f f e c t i n t h e "reward s t r u c t u r e s " w h i l e m a i n t a i n i n g t h e i n h i b i t o r y e f f e c t upon t h e "aversive s t r u c t u r e s .'Ig3 Benzodiazepines may f o r t i f y t h e mechanisms of p h y s i o l o g i c a l s t a b i l i z a t i o n of n e u r o n a l nerve t e r m i n a l membranes by f a c i l i t a t i n g t h e formation, release o r a c t i o n of p r o s t a g l a n d i n s .94 A combination of i n h i b i t i o n of 2-M phosphodiesterase a c t i v i t y and i n h i b i t i o n of 5-HT turnover i n t h e midbrain raph6 region i n rats may be r e s p o n s i b l e f o r c h l o r d i a z e p o x i d e ' s a b i l i t y t o s u p p r e s s a g g r e s s i v e behavior .95 REFERENCES
1 2.
"The Benzodiazepines", Eds. S . Garattini, E . Mussini and L . 0 . Randall, Raven Press, New York. 1 9 7 3 , 685 pp. " I c r d u t r l a l Pharmacology, Neuroleptics", Vol. 1, Eds. S . Fielding and H . Lal, Futura Publishing (ompauy, Mount Kisro, New York, 1974. 349 pp.
Chap. 1
3. 4. 5. 6. 7. 8.
9. 10. 11. 12 * 13.
14. 15. 16. 17. 18.
10. 20. 21. 22 *
23. 24. 25. 26. 21.
28. 29.
30.
31. 32.
33. 34. 35. 36. 37.
38. 39. 40. 41.
42. 4).
44. 45. 40.
47. 48. 49.
SO. 51.
52.
Antipsychotic and Antianxiety Agents
Harbert, Welch
J. Schumtz, Pharm. Acta. Helv., 68, 117 (1973). 0 . Bakke, Acta P s y c h i a t . Scand. 9, Suppl. 246,32 (1973) and o t h e r articles i n Suppl. 246. N . W . lmlah and K. P. Murphy, T h e r a p i e , 28, 587 (1973) and o t h e r a r t i c l e s i n T h e r a p i e . 28, No. 3 (1973). F. J. Ayd, J r . , I n t . Drug Ther. Newsletter, E ( 2 - 3 , 5 (1974). P. A. J. Janssen i n "Modern Problems in Pharmecopsychiatry. The Neuroleptcis". Vol. 5 , D. P. Bobon, P. A. J. Janssen, and J. Bobon, Eds., S. Karger, Baael, 1970, p. 33. K. S i n d e l l r , B. Kaklc, J. Metysovl. and M. P r o t i v a , Farmaco, Ed. S c i . , 28. 256 (1973). J . 0. J f l e k , K. S i n d e l l r , J. Pomykdcek, 0. Horesovekf. K. P e l z , E. S v l t z , 8 . Knklc. J. Holubek, J. Metysovl and M. P r o t i v a , C o l l e c t . Czech. Chem. Comun., 38, 115 (1973). V. B d r t l , J. Metysovl. and M. P r o t i v a , 38, 1693 (1973). 38, 2778 (1973). V . B d r t l , J. Metysovl and M. P r o t i v a , S., K. S i n d e l l r , B. KakBc, E. S v l t e k , J. Metysov6 and M. P r o t i v a , 38, 1579 (1973). J . 0. J f l e k , K. Metysovl. E. S v l t e k , F. J a n f i k , J. Pomykdcek and M. P r o t i v a , 38. 599 (1973). F. P. Miller, D. Gauger and G. Garske. Fed. Proc., Fed. Amer. S O C . Exp. B i o l . , 32, 785 Abs. (1973). L. Kaiser, P. J. Fowler, D. H . Tedeschi, 8. M. Lester. E. Garvey, C. L. Z i r k l e . E . A. N o d i f f , and A. J. Saggiomo, J. Med. Chem., 17,57 (1974). L. K a i s e r , R. J. Warren and 5. L. Z i r k l e , J. Med. Chem., l7, 1 3 1 (1974). L. Rivera-Calimlim, L. Castaneda and L. Lasagna, Clin. Pharmcol. Therap.. 16, 978 (1973). c. J. E. Niemegeers and P. A, J. J a n s s e n , Arnzeim.-Forech., 24, 45 (1974). u. L e d n i c e r , D. E. Enmert, R. L a h t i and A. D. Rudzik, J. Med. Chem., 16. 1251 (1973). A. K . Saxena, P. C. J a i n , N. Anand and P. R. Dua, l6, 560 (1973). G . u. Singh, S. Nityanand, R. C. S r i m a l , V. A. Rao. P. C. J a i n and 8. ti. Dhawan. E x p e r i e n t i a , 29, 1529 (1973). H. C. Denber, Ann. Med. Psychol., 131, 1 3 1 (1973). J. L. Gendron, R. L. Zimmerman and B. C. S c h i e l e , Curr. Therap. Res., C l i n . Exp.. 2, 333 (1973). I). Mielke, D. M. G a l l a n t and M. P. Bishop, g,324 (1973). 5 . N . R a s t o g i , N. Anand. P. P. Gupta and J. N . Sharma, J. Mad. Chem., 16, 797 (1973). M. L. F i e l d e n , W. J . Welstead, J r . , N. D. Dawson. Y.-H. (hen, R. P. Mays, J. P. DaVanzo and C . D. Lunsford, .6, 1124 (1973). W . 1 . Welstead, J r . , G . C. H e l s l e y , C. R. T a y l o r , L. B. T u r n b u l l . J. P. DaVmtO, W. H. Funderburk and R. S. Alphin, g,1129 (19731. K. Y . Ota, A. A. Kurland and P. Ferro-Diaz, Curr. Therap. Res.. C l i n . Em., 15, 327 (19731. T . M. I t i l , J. Maraaa, A. Bigelow and 8. S a l e t u , 16,80 (1974). K . Voith, Abstr. of Papers. 167th Nat. Mtg. Amer. Chem. SOC., Loa Angafep. C a l i f o r n i a . March 31-April 5 , MEDI 6 , 1974. 1 . G . Humher and F. B r u d e r l e i n , MEDI 5 , 1974. R. Loev, P. E. Bender, F. Dowalo, E . Macko and P. J . Fowler, J. Med. Chem., 16. 1200 (1973). G . N . Aagaard and H. W. E l l i o t , P o s t g r a d u a t e Medicine, & 159 (1973). u . Kelly, P r a c t i t i o n e r , 210, 44 (1973). A. DiMascio, Psychopharmacologia, 2,95 (1973). A . Camerman and N . Camerman, J. Amr. Chem. SOC., 96, 268 (1972). I . It. Sternbach, F. D. S a n c i l l i o and J . F. Blount, J . Med. Chem., 17,374 (J974). M . steinman, J. G . T o p l i s s , R. A l e k e l , Y . - S . Wong, and E. E . York, 16. 1354 (1973). 1 . Aner. Med. Assor., 227. 938 (1974). U n l i s t e d Drugs, 22. 2 (1974). (,. Gogollk, C h . Stwnpf and Ch. T s c h a k a l o f f , Arzneim.-Forech., 23, 545 (1973). R . Y . Ning and L. 0 . R a n d a l l , 1 . Med. Chem., 16,879 (1973). J. 8. H e e t e r , Jr. and A. D. Rudzik, G., 17, 293 (1974). R . 8. Moffett and A. D. Rudzik, W., 1 6 , 1256 (1973). H . A . DeWald, I . C. Nordin, Y. J. L ' I t a E e n and R. F. P a r c e l l . 16,1346 (1973). K . Meguro and Y . Kuwada, Chem. Phann. B u l l . (Tokyo), 21, 2375 (1973). rake, Y. I t o h and Y . Nagawa, Jap. J. Pharmacol., 23. Suppl., 77 (1973). Ikeda, Y. H. 5 . Chiba and Y. Nagawa, G., 2,83 (1973). r . Roth, M. Kramer and J. L. Schwartz, Curr. Ther. Res., C l i n . Exp., 16,1 1 7 (1974). 205 (1973). A . I). Rudzik, J. B. H e s t e r and W. F r i i s , Pharmacologist. g, T . M. I t i l , N. Polvan, S. Egilmez, B. S a l e t u and J. Marasa. Curr. Ther. M a . , C l h . Exp., 15, 603 (1973). T. PI. I t i l , B. S a l r t u , J . Mnrasa and A. N . Mucciardi, Pharmakopsychist., 2, 225 (1972).
w..
u.,
s.,
u.,
-
a.,
m.,
w.,
a..
a.,
s.,
w.,
9
10 -
53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78 * 79. 80. 81. 82 * 83. 84. 85.
86. 87. 88.
89. 90. 91.
92. 93.
94. 95.
Sect.
I
-
CNS Agents
Gordon, Ed.
Y. Kuwada, Chem. Pharm. B u l l . (Tokyo), 2382 (1973). L). M. G a l l a n t , W. C. Swanson, D. H. Mielke and R. Guerrero-Figueroa. Curr. Therap. Res.. Clin. Exp., 14, 664 (1972). S . Gershon, Psychopharm. B u l l . 9, 92 (1973). R. D. Heilman, E. W. Bauer and J. P. DaVanzo, Pharmacologist, 15. 254 (1973). R. M. Grimes, K. B. A l t o n and C. Shaw, Is, 254 (1973). G. S a k a l i s , E. Pearson. E. Kermani and S . Gerahon. Curr. Ther. Us.. C l i n . Erp., Is, 268 (1973). F. Barzaghi, R. Fournex and P. Mantegazza. Armelm.-Forsch., 23. 683 (1973). A. Bauer, P. Danneberg, K.-H. Weber and K. Minck, J. Med. Chem., l6, 1 0 1 1 (1973). G. R. A l l e n , J r . , V. G. De Vries, E. N. G r e e n b l a t t , R. L i t t e l l . F. J. HcEvoy and D. 8 . %ran, ibii., 1 6 , 949 (1973). K . P. S z g h and 0. S. Bhandari, Arzneim.-Forach., 23, 973 (1973). K . Jepson and G. Beaumont, J. I n t . Mad. Rea., 1 .145 (1973). J. L. Neumeyer and K . K . Weinhardt, J. Med. Chem., 2,808 (1973). V . Nacci, G. F i l a c c h i o n i , G. C. P o r r e t t a . G. S t e f a n c i c h and A. G u a i t a n i , Farmaco, Ed. Sci.. 28, 949 (1973). R. S a r g e s , J. R. T r e t t e r , S. S . Tenen and A. Weissman, J. Med. Chem., l6. 1003 (1973). H . OelschlYger, W. A. Behrendt and H. Hoffmann, Arzneim.-Forsch., 23, 802 (1973). J . R. Stevens, Arch. Gen. P s y c h i a t r y , 29. 177 (1973). S . Matthysse, Fed. P r o c . , Fed. Amr. SOC. Exp. B i o l . , 32, 200 (1973). N.-E. Anden and G. S t o c k , J. Pharm. Pharmacol., 25, 346 (1973). G. B a r t h o l i n i , K . G. Lloyd and H. S t a d l e r , L i f e Sci., l3. No. 4 , v i (1973). H . S t a d l e r , K. G. Lloyd, 14. Gadea-Ciria and G. B a r t h o l i n i . B r a i n R e 8 . . 55, 476 (1973). H. Corrodi, K . Fuxe and P. Lindbrink, 43, 397 (1972). B. S . Bunney. J . R. Walters. R. H . Roth and .K.G Aghajanian. J. Pharmacol. Exp. Ther.. 560 (1973). G. S t o c k , T. Magnusson and N.-E. Anden, Naunyn-Schmiedeberg'a Arch. F'harmakol. Exp. P a t h o l . 278, 347 (1973). R. Roth, J. R. Waltars and G. K . Aghajanian, L i f e S c i . , 12, No. 8. CxXXiX (1973). R. A. L a h t i and E. G. Losey, Res. Cormrmn. Chem. P a t h . Pharmacol.. 1. 31 (1974). H . Asper, M. B a g g i o l i n i . H. R. Burki, H. Lauener, W. Ruch and G. S t i l l e , 287 (1973). I. M. N i e l s e n , B. F j a l l a n d , V. Pedersen and M. Nymark, Psychopharmecologia. 2,195 (1974). J. L. Meek and N . H. Neff, J. Pharmacol. Exp. Ther.. 570 (1973). H. H. Keller, G. B a r t h o l i n i and A. P l e t s c h e r , Eur. J. Pharmacol.. 23, 183 (1973). C. D. Wise and L. S t e i n , S c i e n c e , 181,344 (1973). R. J . Wyatt, D. L. Murphy, R. Belmaker, S . Cohen, C. H. Donnelly and W. P o l l i n , 1 7 9 , 916 (1973). R. J. Wyatt, J. M. Saavedra and J. Axelrod, Am. J. P s y c h i a t r y , 130, 754 (1973). J. M. Saavedra, J. T. Coyle and J. Axelrod, J. Neurochem., 0, 743 (1973). N . Narasimhachari and H. E. Himrich, L i f e S c i . XI, g, 475 (1973). H . E . Himwich, N . Naraaimhachari, B. Heller, J. S. Spaide, L. Haakovec, M. Fujimori and K. Tabushi, "Chem1C.d l i o d i f i c a t i o n of Brain Function", Ed. H. C. S a b e l l i , R a w n P r e s s , New York, 1973. p. 297. R. J. Wyatt, L. R. Mandell, H. S. Ahn, R. W. Walker and W. J. A. Vanden Heuvel, Peychopharmacologia, 31, 265 (1973). P. Ladiiron, L i f e S c i . , 12,No. 6 , x c i i i (1973). W. C. Korevaar, M. A. Geyer, S. Knapp, L. L. Hsu and A. J. Mandell, Nature, Nev B i o l . , 245, 244 (1973). D. hlen6trey. J. Decaud-Gasarabwe and J. N. Besson, Eur. J. Pharmacol.. 2 4 , 158 (1973). P. Lidbrink and L.-0. Farnebo, Neuropharmacology, l2, 1087 (1973). R . Guerrero-Figueroa. E . Guerreo-Figueroa, G. A. Sneed and M. J. Kennedy, Curr. Ther. Res., C l i n . Exp., Ifr. 137 (1974). M. Doteuchi and E . Costa, N e u r o p h a m c o l o g y . 12,1059 (1973). L. F. Quenzer, R. S. Feldman and J. W. Moore, Psychopharmacologia. 3, 8 1 (1974). K. Meguro, H . Tawada. H. Miyano. Y. S a t 0 and
u.,
u.,
185,
w...g,
184.
-
u..
Chapter 2.
Narcotic Antagonists and Analgesics
Robert A. Hardy, Jr., Lederle Laboratories, A Division of American Cyanamid Company, Pearl River, New York
-
m i n g 1973, c l i n i c a l t r i a l reports on new agents remained Introduction few. Further d e t a i l s on agonists and antagonists described i n 1972 abs t r a c t s and preliminary reports appeared, indicating continuation of these investigations. !Be variety of new s t r u c t u r e types with analgesic or antagonist a c t i v i t y appears t o have declined i n 1973. Ebth analgesics and antagonists are t r e a t e d together i n s t r u c t u r e - a c t i v i t y discussion as d i f ferences between them remain very subtle indeed (e.g. diastereomers and enantiomers w i t h opposite actions ). Several reviews are noteworthy: IIhe well known analgesic publicat i o n s of the l a t e Dr. &than B. Eddy were brought t o a close w i t h an overview of 75 years of research toward solutions f o r morphine-type drug dependence .1 m e proceedings of an International Symposium on Agonists and Antagonists (1971) were published.2 Reviews on pentazocine3,4 and strong analgesics5 appeared.
-
New Clinical Studies Current reports do not provide d e f i n i t i v e informat i o n on any new compounds. Previous investigations a r e continuing and it remains premature t o assess t h e i r c l i n i c a l importance. However, the outlook is optimistic that significant c l i n i c a l advances a r e i n progress considering the variety of agonist and antagonist agents being studied. A 1O:l thadone:naloxone combination evaluated i n man provoked few side effects? advancing t o c l i n i c a l trials the previously described concept of using a parenterally e f f e c t i v e antagonist co bined with an o r a l l y a c t i v e narcotic t o prevent abuse of o r a l medication.
7
b, -c%j
H Q---
I
I1
An e a r l y c l i n i c a l t r i a l of oxilorphan [(- )-Bc-2605, Ia] as an antagonist f o r potential narcotic ad i c t i o n treatment indicated a d i u r e t i c e f f e c t a t low doses (2-4 mg sc).' In laboratory animals Ia was a naloxone-like antagonist, w a s almost equally e f f e c t i v e o r a l l y as parenterally, and had a prolonged d ~ r a t i o n . ~Preliminary c l i n i c a l r e s u l t s a r e cons i s t e n t with this p r o f i l e . Ihe N-cyclobutylmethyl analog (-)-I3 was a highly potent, dependence-free agonist i n animals, and preliminary c l i n i c a l t ials have been i n i t i a t e d with r e s u l t s comparable t o the animal model5 (See a l s o m p t e r 5 1.
12
Sect. I
-
CNS Agents
Gordon, Ed.
Structure-Activity; Agents under Investigation iates and Wrphinans - Details of the total synthesis of the BC-2605 zries (1)were described.9 A new synthetic approach was utilized representing a &jor advance in synthetic methods for Grphinans and related compounds, including isomorphinans and hasubanan analogs. It provides naloxone analogs which are not derived from the opium alkaloid thebaine, but which have comparable activities. (- )-Ib shared antagonist signs in monkeys, and was a potent analgesic equivalent to morphine in mice (hotplate and Nilsen tests).1° Ib racemate was morphine-like in monkeys (suppression of abstinence) and was similar to (-)-Ib in mice.1° The (+)isomer was morphine-like in monkeys, less potent but somewhat longer acting, and was weak to inactive in mice. From a series of morphine derivatives recently synthesized in Hungary, azidomorphine (IIa)and azidocodeine (IIb) proved to be about 300 times and about 1 times more potent than morphine, respectively (rat hotplate).113’ -ever, physical dependence capacity (pDc) in mice, rats and monkeys was low at equianalgesic doses, unusual for a potent N-methyl opiate structure. A levallorphan metabolite isolated from rat urine was established by X-ray analysis as the @-hydroxy derivative 111.13 It was then synthesized and, like the parent drug, was an antagonist without analgesic activity. An analogous 68-h oxy metabolite of naltrexone, formed by mese examples represent the first reports reduction, was found in of C-6 isomorphine configuration metabolites.
-.IF
The bicyclic 5-;-hydroxyphenylmorphan series was extended to include the N-propyl, N-cyclopropylmethyl (CPM and N-ally1 derivatives Na,b,c, both as racemates and the (+)-is0mers.~5 They were pentazocine-like analgesics with weak or no antagonist actions, and showed no PDC in monkeys. Thus, potent antagonists cannot be obtained in this series by replacing the N-methyl group of a potent agonist with claseical antagonist substituents (IVd-3 x morphine; high PM:). 6,7-%nzomorphans - Very little new structure-activity information concerning benzomorphans appeared during 1973. The s=-amine @-hydroxy6,7-benzomorphan had analgesic activity about 4 that of codeine (mouse hot-plate) while the corresponding N-methyl derivative was inactive, the reverse of the usual relative potency.16 Rntazocine underwent a chemical change in aqueous acid conditions used to hydrolize glucuronides.17 The mass spectral fragmentation of 93- and gg-alkyl-6,7-benzomorphans, including pentazocine, indicated that the configuration at C-9 could be assigned even when only one isomer of a diastereomeric pair was
Chap. 2
Narcotic Antagonists, Analgesics
Hardy
13
18
available.
Aminotetralins - Additional details of the synthesis of 49 1,3-bridged-2aminotetralins (V) were pub1ished;lg several were equal to or more potent than morphine (rat tail-flick). V was the longest acting a tagonist tested in the Univ. of Michigan morphine-dependent monkeys." It displayed twice the duration of cyclazocine and was about 1/5 as potent as nalorphine as an antagonist. In mice it was equivalent to morphine (hotplate ).
C,
-OH
VI
V
Three diastereomeric pairs of tetralins VI were synthesized as methadone analogs.20 VIa were analgesics comparable to meperidine (mouse hotplate) with little differences-in the potency of the hiastereonkrs; substitution of hydroxyl for hydrogen increased potency somewhat. Among a series of potential antiparkinson agents, 2-methylamino-5-methoxytetralin shared analgesic activity in the codeine-propoxyphene range (mouse tailpinch), but was more toxic.21 Piperidines and Pyrrolidines - New antagonist-analgesics were reported in the N-alkyl-norketobemidone series.22 The N-awl, hexyl and heptyl compounds VIIa,b,c were strong agonists with weak antagonist properties, and no PIX! in monkeys. VIIa was an analgesic nearly 3 times more potent than the parent VIId (mouse hot-plate). This contrasts with the more traditional N-propyl, CPM and allyl analogs which were not antegonists but weak to medium strength agonists with high mX:.
c, -Heptyl d, - M VII
VIII, (- )-isomer
In the pyrrolidine series, additional details of the selective antagonist actions of N-CPM and N-ally1 analogs of profadol appeared,23,24 and CI-747 (VIII) was selected for detailed evaluation. Its analgesic potency was 40-50 times pentazocine (mouse antiwrithing ) with antagonist properties 5-6 times pentazocine. Ihe absolute stereochemistry and analgesic properties of the diastereomeric 3-allyl-prodine analogs who deduced similar conclusions. M was 13-15 times more potent than morphine (mouse hot-plate), and its (+)-enantiomer was 40 times morphine and 260 times its (-)-isomer. It was suggested that the equatorial allyl group enhanced receptor association.
14
Sect. I
-
CNS Agents
Gordon, Ed.
Similar a solute stereochemical studies of other prodines were also described.2 r29
ll
CON(C5
l2
(c6'5 a, R
-
L
R X p-C1; b, R = 3-CF -4-Cl 3
A series of 2,2-diphenyl-4-piperidinobutyramides (X) were studied in which the goal was separation of analgesic and antidiarrheal (constipating) activities.3° Ioperamide (Xa) and fluperamide ( X b ) were selected for further investigation each being more potent than diphenoxylate and codeine in protecting against castor-oil-induced diarrhea and very weak analgesics (rat,warm water tail-withdrawal). Closely related analogs combined strong analgesic properties with strong antidiarrheal activity. In this study, potent analgesic activity was an unwanted side effect. Several additional piperidines were active analgesics. The 3-methyl derivative of the potent narcotic fentanyl was 10 times more potent than the parent drug .3l N-[2- (2-Oxazolidinone-5-yl)ethyl]-4-phenyl-4-propionoxypiperidine shared morphine-like analgesic$ t e n ~ y , 3and ~ an N-(2indanyl )-analog had meperidine-like potency.
Diphenylpropylamines and Mscellaneous Compoundg - Among a series of thiophthalanes studied for analgesic activity,j4 Iu 6-062 (XI) was the most active. It was approximately equal to morphine (mice, hot-plate, tail-pinch and Nilsen tests ), produced a Straub-tail reaction and was antagonized by nalorphine. Similar thiophthalanes with a propylamino side chain had been previously studied as antidepressants, but were not analgesics and did not produce a Straub-tail.
XI
XI1
Another approach to the separation of antidiarrheal from narcotic analgesic activity was the comparison of Straub-tai V8. CoMtipating effects.35 CI-750 (XII), selected for evaluation,3 did not produce a Straub-tail, showed only weak analgesic activity and had a constipating effect about equal to diphenoxylate. Piperidinoethyl and pyrrolidinoethyl analogs of XI1 with a 1-dimethylamino group had potent narcotic actions.
2
Agonist and antagonist properties of vimi 1 stereoisomers (XIII, previously known as diviminol) were described.j? This compound has 3 asymmetric centers and 6 stereoisomers. Analgesic activity resided in a
Chap. 2
Narcotic Antagonists, Analgesics
Hardy
15
(-)-isomer (€$; several times morphine, some PDC) and antagonist activity in a (+)-isomer (S,; nalorphine-like)which were not enantiomers of each other. No other isomers had analgesic or antagonist activity. In the
racemate, the agonistic activity of % is apparently partially opposed by the antagonistic E$ isomer. The result is a racemate with codeine-range analgesic activity and a low order of pzx;'. Analgesic activity was found in a group of N-substituted cyclohexylmethylbenzamides, and AH 791 (XIV) was equipotent to morphine (mice, antiwrithing and hot-plate) and showed high PDC in monkeys. !Bis represents a structurg distinctly different from previous high PDC narcotic-like compounds . 3 The dissociative anesthetic etoxadrol ( X V ) produced analgesia at low subanesthetic doses (0.5-1 mg), measured by elevation of the electrical stimlation threshold in monkeys.39 It was comparable to morphine,but shorter in duration. XV was not active in mice (antiwrithing), perhaps since dissociative anesthetics produce different effects in rodents vg. higher species. Further studies as a parenteral analgesic were suggested. 0
(c21f,
xv
XVI A study of 24 monoaryl- and diarylphosphorus analogs of methadone revealed moderate analgesic activity in several compounds; XV was 1/4-1/5 the potency of morphine (mice, hot-plate and antiwrithing Unfortunately, the toxicity was highest in compounds with the best analgesic activity. Pharmacological implicat of the conformations of methadone and isomethadone were analyzed. Aniinflanmttory Analgesics - !&is class of compounds is discussed in detail in Chapter 20. Studies of arylalkanoic acids and derivatives continue unabated. Details of analgesic testing of these agents are frequently incomplete PharmacolORy, Biochemistry and bktabolism - !be variety of studies covering methods, mechanism of action, biochemistry, etc. continues to increase. Detailed discussion of these is outside the scope of this review; however, the following selected examples are illustrative of current trends. A full paper on biodegradable poly-lactic acid long-acting delivery
.
16
Sect. I
-
CNS Agents
Gordon, Ed.
systems f o r narcotic antagonists a ~ p e a r e d , ~following 3 up the i n i t i a l a b s t r a c t s . The use of chronic spinal dogs dependent on morphine w a s described f o r quantitative assays of antagonists .44 &tho@ f o r producing antibodies t o morphine f o r radioinnnunoassay were reviewed. F’urther studies of specific opiate rece or s i t e s based on stereos p e c i f i c binding i n nervous t i s s u e a eared.a The i n i t i a l r e s u l t s were confirmed by other investigators. 471@ m e r o l e of sodium i n enhancing antagonist binding but decreasing agonist binding i n v i t r o w a s found as an important q u a l i t a t i v e difference t h a t may be relevant t o the divergent pharmacological properties of antagonists and agonists .46 Several additional metabolic findings a r e of i n t e r e s t . The formation of codeine from morphine (or heroin) w a s observed i n a significant increase of 0-methyl transferase a c t i v i t y leading t o increased codeine i n addict urine could be a specific marker f o r the addiction s t a t e . The long sought primary amine metabolite from levomethadyl acetate was i d e n t i f i e d by combined gas chromatography-mass spectrometry (gc-ms) of r a t t i s s u e and plasma samples, and was found t o be a highly potent analgesic (1.5 mg/kg sc, mouse antiwrithing).5O Thus, the general tendency of mono- and d i demethyl congeners t o have a low order of a c t i v i t y does not apply i n t h i s s e r i e s . Both mono- and di-demethyl metabolites of g-propoxyphene were observed i n man, using combined gc-ms and deuterium-labelled propoxyphenes .51 a-(+)-Norpropoxyphene was the major metabolite, and was about 1/10as active as the parent drug (mouse antiwrithing, and rat t a i l f l i c k ) .52 The r o l e of biogenic amines a8 r e l a t e d t o narcotic e f f e c t s continues t o be an active f i e l d . Further studies appeared concerning enhanced cerebral serotonin turnover ,53 balance w i t h the catecholamine s y ~ t e m , 5 ~ dopamine turnover i n p e striatum,55 and homovanillic acid content i n t h e caudate nucleus .5 Additional d e t a i l s of the cyclic-AMP antagonism of mo phine analgesia,57 and i t s e f f e c t on tolerance and physical dependence5 were a l s o published.
fi
Referenees 1. N. B. Eddy and E. L. b y , Science, 181, 407 (1973). 2. H. W. Kosterlitz, H. 0. J. Collier and J. E. Villarreal (Eds), Agonist and Antagonist Actions of Narcotic Analgesic Ih-ugs, Univ. F’ark Press, Ehltimore (1973). 3. J. P. h p e , h g s , b 1 (1973). 4. R. N. Brogden, T. M. Speight and G. S. Avery, Rrugs, 6 (1973). 5. W. B. b a n and J. D. Wrrison, Drugs, b 108 (1973). 6. S. D. Aarwatikar and R. R. Knowles, Clin. Fharmacol. ?her., 14, 941 (1973) l 230 (1973). 7. I. J. Pachter, Science, & 8. J. G. M t t and D. R. Jasinsky, Rmmacologist, lI_, 240 (1973). 9. I. Wnkovi6, T. T. Conway, H. Wong, Y. G. Fkrron, I. J. Pschter and 7910 (1973); cf a l s o Qem. Abstr., B. Belleau, J. Am. Chem. SOC., 79, 18931~(1973).
Chap. 2
Narcotic Antagonists, Analgesics
17
Hardy
H. H. Swain, J. E. V i l l a r r e a l and M. H. Seevers, Addendum, Report 35th Ann. M t g . Corn. on Problems o f Rrug Dependence, Chapel H i l l , N. c., MY 21-23, 1973. 11. J. Knoll, S. Mrst and K. Kelemen, J. Pharm. pharmacol., 22, 929 (1973 1 12. J. Knoll, pharmacol. Res. Commun., 175 (1973). 13 J. F. Blaunt, E. Mhacsi, F. M. Vane and G. J. Wnnering, J. E d . Chem., 16, 352 (1973). 14. E. J. Cone, Tetrahedron I e t t e r s , 2607 (1973). 1.5 * H. H. Chg, T. a - i s h i and E. L. My, J. E d . Chem., 17 133 (1974). 16. J. J. Fauley and J. B. IaPidus, l6, 181 (1973f 17 * D. P. Vaughan and A. H. Beckett, J. Pharm. Pharmacol., 2_2 993 (1973 1. 18. D. I?. Vaughan and A. H. E c k e t t , i b i d . , 22, 895 (1973). 19. M. E. Freed, J. R. Potoski, E. H. Freed, G. L. Conklin and J. L. &Us, J. E d . Chem., 16, 595 (1973). 20. E. M. Kandeel and A. R. W r t i n , LbL., 16, 947 (1973). 10.
z.,
21. 22. 23
Y. C. W t i n , C. H. Jarboe, R. A. Krause, K. R. I p n , D. k n n i g a n and J. B. W.land, 6, 147 (1973). T. a - i s h i and E. L. Wy, 16,1376 (1973). R. E. B3wman, H. 0. J. C o l l i e r , P. J. Hattersley, I. M. Lockhart, D. J. Peters; C. Schneider, N.-E. Webb and M. Wright, g., 16,
z. , s.,
~
1177 (1973). 24. 25 26. 27. 28. 29.
30
31
33 34.
36 35
38
u.,
u., u., w., u.,
u.,
(19731
W. J. Welstead, Jr., G. C. Helsley, C. R. Taylor, L. B. Turnbull, J. P. DaVanzo, W. H. Funderburk, and R. S. Alphin, J. &d. Chem., 16,
32
37
R. E. EOwman, H. 0. J. Collier, I. M. Lockhart, C. Schneider, N. E. Webb and M. Wright, l6, 1181 (1973). K. H. kll and P. S. Fbrtoghese, 16 203 (1973). K. H. k11 and P. S. Portoghese, 589 (1973). M. A. B r i o , G. Camia and A. F. Casy, 16, 592 (1973). D. L. k s o n and P. S. Portoghese, l6, 1%(1973). P. S. Portoghese, Z. S. D. Gomaa, D. L. k s o n and E. Shefter, ibid., 16, 199 (1973 1. R. A. Stokbroekx, J. Vandenberk, A. H. M. T. Van Heertum, G. M. L. W. van Iaar, M. J. M. C. Van der Aa, W. F. M. Van Ever and P. A. J. Janssen, 16, 782 (1973). T. N. Riley, D. B. Hale and M. C. Wilson, J. Pharm. Sci., 62, 983
-
m9 (1973).
z.,
E. Solomons and J. Sam, l6, 1330 (1973). B. Fjalland, V. Pedersen, N. lassen, P. V. Petersen and I. M l l e r Nielsen, Acta pharmacol. Toxicol., 32, 278 (1973). D. E. J h t l e r , R. F. Myer, S. M. Alexander, P. €kiss and J. A. Kennedy, J. Md. Chem., 16, 49 (1973). P. Ittss, J. A. Kennedy, J. N. Wiley, J. V i l l a r r e a l and D. E. J h t l e r , J. pharmacol. Exp. 'lher., 186, 183 (1973 ). D. Della Bella, V. Ferrari, V. Frigeni and P. Iualdi, Nature New Biol., 241, 282 (1973 ). R. T. Brittain, D. N. Kellett, M. L. Neat and R. Stables, Brit. J. Pharmacol., 158P (1973).
9,
18 39 40. 41. 42. 43
9
Sect. I
- CNS Agents
Gordon, Ed.
A. H. Tang and J. D. Kirch, Anesth. Analg. Curr. Res., 52, 577 (1973). W. H. Shelver, M. Schreibman, N. S. Tanner and V. Subba Rao, J. Md.
Chem., 17, I20 (1974 ). H. B. m g i , J. D. l b n i t z and E. Shefter, Nature New Blol., 244, 186 (1973 ) * J. G. Henkel, K. H. Bell and P. S. Brtoghese, J. Wd. Chem., 17 -, 124
(1974 1
J. H. R. Woodland, S. Yolles, D. A. Blake, M. Eelrich and F. J. Myer, 16, 897 (1973 ) * W. R. Mutin, C. G. Eades and J. A. ?hapson, Fed. Proc. 32, 687 j
44. 45
46. 47. 48. 49 50
(1973 1-
S. Spector, B. Brkowitz, E. J. Flynn and B. Fkskar, pharmacol. Rev. 25, 281 (1973 1. C. B. Fkrt, G. Pasternak and S. H. Snyder, Science, 182, 1359 (1973). E. J. Simon, J. M. Hiller and I. Edelman, €?roc. Natl. Acad. Sci., 70,
1947 (1973 1.
54.
L. Terenius, Acts pharmacol. Toxicol., 377 (1973). U. Edrner and S. Abbott, Experientia, 24, 180 (1973). R. E. BLllings, R. Booher, S. b i t s , A. Pohland and R. E. kbkhon, J. Wd. Chem., l6, 305 (1973). R. E. McMhon, H. R. Sullivan, S. L. lXle and F. J. &shall, Life Sci, 12 Pt 11, 463 (1973). R. Nickander and S. Smits, Pharmacologist, 1L 203 (1973). G. G. Yarbrough, D. M. Bxbaum and E. Sanders-&sh, J. Eharmacol. %P. !her., 14, 328 (1973). D. M. Wbaum, G. G. Yarbrough and M. E. Carter, G., %1 317
55 *
E. Costa, A. Carenzi, A. Guidotti and A. Revuelta, Life Sci.,
52
53
56 57 58.
(1973 1
m i (1973).
12(4),
L. Ahtee and I. Kd&idinen, Amopean J. pharmacol., 22, 206 (1973). I. K. Ho, H. H. Loh and E. L. Way, J. Fharmacol, Ekp. !her., l@j,
336 (1.9731.
I. K. Ho, H. H. Loh and E. L. Way,
u.,%1
347 (3.973).
Chapter 3.
Antiparkinsonism Drugs
Vernon G. V e r n i e r , E. I . du Pont de Nemours
?C
Co., I n c . , Newark, De.
-
General Knowledge of t h e n a t u r e o f t h e biochemical l e s i o n of P a r k i n s o n ' s d i s e a s e and t h e a v a i l a b i l i t y of r a t i o n a l c o r r e c t i v e t h e r a p y c o n t i n u e s t o s p u r a c t i v i t y t o f i n d improved and novel e n t i t i e s w i t h e x i s t i n g and d i f f e r e n t nodes of a c t i o n . Many u s e f u l reviews are a v a i l a b l e i n t h i s f i e l d . T h i s c h a p t e r updates t h e compilation by Vernier1. Levodopa i s reviewed by McDowell' and it and o t h e r developments are covered by Calne3. The l a r g e and growing amantadine l i t e r a t u r e i s w e l l analyzed by P a r k e s 4 . T h i s review w i l l cover t h e r a p e u t i c a g e n t s and leads under f o u r mechanisms of a c t i o n : 1. dopamine replacement, 2. dopamine r e l e a s e , 3. dopamine r e c e p t o r s t i m u l a n t s and 4. a n t i c h o l i n e r g i c s . Each agent w i l l be d i s c u s s e d under i t s presumed major mode of a c t i o n even though t h e evidence f o r it may not be d e f i n i t i v e o r t h e agent may a c t by s e v e r a l mechanisms.
-
Dopamine replacement This most e f f e c t i v e t r e a t m e n t f o r P a r k i n s o n ' s disease i s s u p p l i e d by t h e - n a t u r a l l y - o c c u r r i n g amino a c i d levodopa ( I, L3,4-dihydro~yphenylalanine~'~), I n t h e u s u a l o r a l doses o f 2 . 5 t o 6 g d a i l y it e n t e r s t h e b r a i n and i s decarboxylated t o form dopamine (11)
I
I1
which presumably r e p l e n i s h e s t h e d e f i c i e n t n e u r o t r a n s m i t t e r s t o r e s i n t h e basal g a n g l i a r e s u l t i n g from midbrain s u b s t a n t i a n i g r a l e s i o n s . I n 60 t o 80% o f c a s e s a k i n e s i a , r i g i d i t y and t o a lesser e x t e n t tremor a r e moderately t o markedly improved, b u t management i s d i f f i c u l t . T h i s i s due t o numerous s i d e e f f e c t s , t h e n e c e s s i t y o f g i v i n g many doses d a i l y , and t h e slowly i n c r e a s i n g dose t i t r a t i o n , l e a d i n g t o a long induct i o n time f o r o p t i m a l e f f e c t s . Some p a t i e n t s have a s h o r t and/or v a r i a b l e t i m e of symptomatic r e l i e f f o l l o w i n g each dose. Sudden f r e e z i n g , t h e "ono f f e f f e c t , " i s o f t e n noted0. I t s causes are under study and s e v e r a l approaches t o i t s a l l e v i a t i o n are i n development ( d e t e r m i n a t i o n s o f levodopa plasma l e v e l s f o r optimal t i m e and dose t i t r a t i o n , s u s t a i n e d r e l e a s e formulations, e tc )
..
P r i n c i p a l levodopa s i d e e f f e c t s are i n d e c r e a s i n g o r d e r of incidence: 1. Nausea and vomiting, 2. p o s t u r a l hypotension, 3. c a r d i a c a r r h y t h m i a s , 4. abnormal i n v o l u n t a r y movements and 5. p s y c h i a t r i c d i s t u r b a n c e s . Considerable r e s e a r c h e f f o r t i s d i r e c t e d toward t h e d e t e r m i n a t i o n of how much o f t h e o r i g i n a l t r e a t m e n t r a t i o n a l e can b e s u b s t a n t i a t e d . Although g e n e r a l l y a g r e a t e r t h a n o r i g i n a l l y expected complexity i s being
20
Sect. I
-
Gordon, Ed.
CNS Agents
found, most r e s u l t s a r e consistent with o r i g i n a l expectations. Carbidopa and benserazide, two agents which a r e potent aromatic amino acid decarboxylase i n h i b i t o r s in v i t r o and in V
.
Early r e p o r t s of t h e biochemistry and pharmacology of carbidopa (111, MK 486, t h e L form of MK 485, a l s o r e f e r r e d t o as HMD) indicated i t s
I11
IV
e x t r a c e r e b r a l d i s t r i b u t i o n and potent in v i t r o and in v i v o i n h i b i t i o n of aromatic amino a c i d decarboxylasell. I t s i n t e r a c t i o n s with levodopa i n Carbidopa enhanced t h e animals were characterized by L o t t i and Porter’’. a b i l i t y of levodopa t o increase motor a c t i v i t y of mice and rats and t o reverse reserpine-induced hypothermia and suppression of locomotion and p t o s i s . Brain dopamine l e v e l s were concomitantly enhanced. I n c o n t r a s t levodopa emesis i n dogs and pigeons was attenuated. C l i n i c a l e y e r i e n c e with carbidopa and levodopa has been extensive
and f a ~ o r a b l e l ~, , ~Carbidopa alone had no influence on Parkinsonian p a t i e n t s and i s reported t o be q u i t e non-toxic. It r a i s e d plasma l e v e l s of levodopa about five-fold, thus i n d i c a t i n g about an 80% reduction of t h e required levodopa alone dose. Carbidopa doses of 100-300 mg/day combined with levodopa i n c o n t r o l l e d t r i a l s r e s u l t e d i n a rapid onset of therap e u t i c e f f e c t ( a few days o r weeks compared with months with levodopa alone) , and s t r i k i n g l y reduced t h e incidence of nausea and vomiting. P a t i e n t s on long term combined therapy achieved superior r e l i e f . Combined treatment m a y reduce cardiac arrhythmias , but t h e incidence of involuntary movements i s increased. Several groups found a 1:lO combination most usef u l with a d a i l y dose of carbidopa 100 mg: levodopa 1000 mg. Marsden14 suggests t h a t it may become t h e treatment of choice. The pharmacology of and c l i n i c a l experience with benserazide (IV,
Ro 4-4602) i s generally similar t o t h a t of carbidopalO. It i s somewhat l e s s potent in v i t r o as a decarboxylase i n h i b i t o r but in V i V O and i n t h e ~ ,d~i f~f e.r s i n c l i n i c i t s potency i s similar t o t h a t of c a r b i d ~ p a ~ , ~It penetrating t h e b r a i n i n animals at high doses. Benserazide administrat i o n , l i k e carbidopa, increases absorption of levodopa from t h e g u t , increasing plasma l e v e l s , and blocks p e r i p h e r a l conversion t o dopamine. I n t h e b r a i n t h e i n h i b i t o r s increase levodopa penetration and catecholamine ( dopamine and norepinephrine) l e v e l s .
Chap. 3
Antiparkinsonism Drugs
Vernier
21 -
C l i n i c a l l y benserazide+levodopa treatment improved t h e t h e r a p e u t i c r e s u l t s , decreased t h e required levodopa dose ( t o about 1 / 5 ) and decreased t h e incidence of nausea and vomiting. It generally did not decrease t h e involuntary movements but increased them. Benserazide seems t o be well t o l e r a t e d on a long term administration a t t h e 100-400 mg/day l e v e l s , with few t r a n s i e n t changes i n l i v e r biopsies and enzyme levels15.
-
Dopamine r e l e a s e r s Schwab noted i n 1968 t h e antiparkinsonism e f f e c t of amantadine ( V ) , an a n t i v i r a l agent which has s i n c e been extensively
V
VI
t e s t e d 1 7 and approved f o r t h a t a d d i t i o n a l i n d i c a t i o n . Amantadine a f f e c t s catecholamines, primarily dopamine, and had no a n t i c h o l i n e r g i c e f f e c t s 1 8 . I t caused pressor responses i n t h e dopamine-primed dog with much l e s s e f f e c t upon norepinephrine , suggesting predominately dopamine r e l e a s e l a 3 19. Amantadine antagonized e f f e c t s of major t r a n q u i l i z e r s on s e v e r a l kinds of behavior, including t h e conditioned avoidance response22 , a f f e c t e d t h e r o t a t i o n a l a c t i v i t y of s t r i a t a l - l e s i o n e d rats and mice23 and i n t e r a c t e d wit*h a p ~ m o r p h i n,25. e ~ ~ This and considerable other biochemical and pharmacological evidence i s generally consistent with t h e r e l e a s e of s t o r e d dopamine as a m a o r element i n i t s action together with f a c i l i t a t i o n of neural release2g-28. Amantadine a l s o increased synthesis of levodopa and presumably dopamine i n rat striatum2’. Although many recent r e p o r t s d e a l with t h e s e aspects of t h e animal pharmacology, t h e exact mechanism i s not y e t f u l l y established. I n p a t i e n t s t h e onset of a c t i o n i s prompt, faster than levodopa but of l e s s i n t e n s i t y , with fewer s i d e e f f e c t s than levodopa, p a r t i c u l a r l y nausea and vomiting and dyskinesias. A t doses of 200-300 mg/day maximum b e n e f i t i s achieved soon a f t e r beginning drug and t h i s e f f e c t may be sust a i n e d over long periods, although some r e p o r t s i n d i c a t e a decline i n effect. Although no c l i n i c a l r e p o r t s on D 145 (VI, DMAA) have been found, it i s a c l o s e congener of amantadine which shows catecholamine i n t e r a c t i o n s generally similar t o it, suggesting capacity f o r dopamine r e l e a s e . I t may a l s o have some capacity f o r d i r e c t stimulation of dopamine receptors3’. Moderate t o high i . v . doses of D 145 decreased decerebrate r i g i d i t y i n cats31. Other biochemical findings have been noted32. Carmantadine (VII, Sch 15427) i s s t r u c t u r a l l y r e l a t e d t o amantadine33. It shares some of i t s pharmacological a c t i o n s , w a s e f f e c t i v e i n a
22 -
Sect. I
- CNS Agents
Gordon, Ed. 0
HO VIII v1 I
head-turning t e s t 3 4 , and i s i n e a r l y c l i n i c a l t r i a l s . Dopamantine ( V I I I ) combined elements of both mantadine and dopamine i n i t s s t r u c t u r e , shares some pharmacological e f f e c t s of amantadine and i s i n e a r l y c l i n i c a l trials35.
-
Dopmine receptor stimulants A chemical rearrangement of morphine y i e l d s apomorphine ( I X ) which i s now known t o s t i m u l a t e dopaminergic r e c e p t o r s .
Hd
X
’OH IX
S ~ h w a bdiscovered ~~ i n 1951 t h a t it r e l i e v e d tremor and r i i d i t y of parkinsonism. T h i s has been confirmed by CotziasJ7, Castaignef8 and others. It markedly diminished tremor i n monkeys39. Apomorphine i s not a p r a c t i c a l t h e r a p e u t i c agent (poor o r a l absorption requiring p a r e n t e r a l admini s t r a t i o n , s h o r t duration of a c t i o n , high incidence of nausea and emesis , i n s t a b i l i t y ) but i s an important s y n t h e t i c and b i o l o g i c a l s t a r t i n g point i n t h e search f o r new agents, s i n c e it contains common elements of t h e dopamine s t r u c t u r e . Experiments w i t h apomorphine have shed l i g h t on t h e a c t i o n of levodopa and dopamine i n t h e treatment of parkinsonism and a l s o t h e nature of drug-induced parkinsonism which accompanied t h e use of major t r a n q u i l i z e r s which antagonize apomorphine emesis and stereotypy4’. Originally tested i n cardiovascular disease , t r i v a s t a l (X, ET 495) has been proposed as a dopamine receptor stimulant w i t h b e t t e r o r a l a b s o r p I n. addition t o i t s t i o n and longer duration of a c t i o n t h a n a p ~ m o r p h i n e ~ ~ d i r e c t e f f e c t on t h e receptors t h e data suggested a weak dopamine and norepinephrine r e l e a s i n g e f f e c t . T r i v a s t a l blocked caudate EEG spindles as d i d a p ~ m o r p h i n eand ~ ~ reduced tremor i n monkeys w i t h midbrain lesions43. Others have reported i t s drug dynamics and pharmacological actions44 ,45. Reports of c l i n i c a l t r i a l s 4 6 i n 125 p a t i e n t s at doses of 20 t o 240 mg/day l e d t o p o s i t i v e conclusion of b e n e f i t i n 4 s t u d i e s (involving 83 p a t i e n t s ) and negative assessment i n 3 s t u d i e s (involving 42 p a t i e n t s ) . Side e f f e c t s were s t r i k i n g and seen i n most p a t i e n t s but could be reduced w i t h lowered doses. Dyskinesias, l i k e those w i t h levodopa, were most frequent , w i t h nausea and vomiting, daytime drowsiness ( w i t h insomnia a t
Chap. 3
Antiparkinsonism Drugs
Vernier
23 -
n i g h t ) a l s o found frequently. Less common were confusion, headaches and dizziness. Most t r i v a s t a l t r i a l s continued p a t i e n t s on previous medicat i o n including levodopa s o t h a t t h e t h e r a p e u t i c r o l e of t r i v a s t a l i s not yet clear. P r e c l i n i c a l data suggest t h a t NBTI ( X I ) a t f a i r l y high doses (40 mg/ kg i . p . ) caused tremors and stereotypy i n rodents reminiscent of apomor-
XI
phine, which was blocked by chlorpromazine and other major t r a n q u i l i z e r s but not by a n t i c h o l i n e r g i c s . It r e s t o r e d locomotor a c t i v i t y i n reserpinea ~ ~ It may stimulate dopaminergic depleted rats l i k e l e v o d ~ p ,47. receptors4*. Reports of i t s c l i n i c a l s t a t u s have not appeared.
-
The peripheral a n t i c h o l i n e r g i c e f f e c t s of benapryzine Anticholinergics (XII, BRL 1288) were considerably weaker than those o f trihexyphenidyl
XI1
XI11
In but i t s c e n t r a l e f f e c t s were nearly equivalent i n animals and man4'. a p i l o t t r i a l benapryzine a t higher doses than those of trihexyphenidyl was found t o be equivalent t o i t , but w i t h possibly fewer s i d e e f f e c t s 5 0 . Two o t h e r p a r t i a l l y c o n t r o l l e d t r i a l s (13 and 28 p a t i e n t s ) indicated Benapryzine may represent a t e f f e c t i v e n e s s and s a f e t y a t 200 mg/day5'. least p a r t i a l success i n separating c e n t r a l from p e r i p h e r a l a n t i choliner i c e f f e c t s , possibly as a r e s u l t of d i f f e r e n c e i n pharmacok i n e t i c s f 3 . Direct e f f e c t s have been demonstrated by iontophoretic a p p l i c a t i o n t o c o r t i c a l neurons5". The morphanthridine e l a n t r i n e (XIII, Ex 10-029) has been t e s t e d i n man and i t s pharmacological a c t i o n appears t o be mainly, but not exclus i v e l y , r e l a t e d t o i t s a n t i c h o l i n e r g i c action55. Two c l i n i c a l t r i a l s ( 2 5 and 13 p a t i e n t s ) r e p o r t e f f i c a c y alone a t doses of 30-60 mg/day and w i t h levodopaS6,57, Side e f f e c t s were predominately of t h e a n t i c h o l i n e r g i c type. A recent s u b s t a n t i a l m u l t i c l i n i c c o n t r o l l e d study58 i n 89 p a t i e n t s found t h a t e l a n t r i n e , 40 mg d a i l y , e f f e c t i v e l y reduced tremor and possibly r i g i d i t y more than t h e same dosage of trihexyphenidyl. E l a n t r i n e caused more dry mouth, Thus e l a n t r i n e was e f f e c t i v e but not c l e a r l y more select ive
.
24
Sect. I
-
CNS Agents
Gordon, Ed.
-
Comment E a r l i e r r e s e a r c h i n t e r e s t has s h i f t e d from a n t i c h o l i n e r g i c t o catecholamine a c t i o n s . Is t h e formation o f 6-hydroxydopamine, which causes a d r e n e r g i c nerve t e r m i n a l d e s t r u c t i o n , t h e cause of t h e biochemical l e s i o n of Parkinson's d i s e a s e ? If t r u e , new p o s s i b i l i t i e s f o r c u r e o r p r e v e n t i o n through i n f l u e n c i n g t h e cause could emerge from t h e i n t e n s i v e catecholamine r e s e a r c h e f f o r t . A d d i t i o n a l dopamine releasers w i l l probably be t e s t e d s i n c e t h i s mode of a c t i o n h a s been i d e n t i f i e d . E f f e c t i v e and s e l e c t i v e dopamine reuptake b l o c k e r s should be explored as another t h e r a p e u t i c approach. D i r e c t dopamine r e c e p t o r s t i m u l a t i o n i s probably t h e most a c t i v e p r e s e n t area, I n view o f t h e complex catecholamine physiology o t h e r n e u r o l o g i c a l t a r g e t u s e s f o r t h e s e l e a d s w i l l be sought and undoubtedly found. Comb i n a t i o n s of t h e l a s t 3 approaches w i l l b e p r i m a r i l y i n i t i a t e d by c l i n i cians.
New small animal methods , supplementing oxotremorine tremor , e t c , , have made p o s s i b l e s t u d y of a d r e n e r g i c a c t i o n s based mainly upon t h e changes i n locomotor a c t i v i t y and s t e r e o t y p y e x e r t e d by amphetamine and apomorphine and by drug e f f e c t s upon t u r n i n g behavior a f t e r s t r i a t a l l e s i o n s caused by 6-hydroxydopamine, e l e c t r o l y s i s and s u c t i o n . References V. G. V e r n i e r , i n "Annual Reports i n Medicinal Chemistry, 1970,"
2.
3.
4. 5.
C. K. Cain, ed., Academic P r e s s , N.Y. (1971) p. 42. F. H. McDowell, e d . , Symposium on Levodopa i n P a r k i n s o n ' s Disease, Neurol., 22 (5, P a r t 21, 1 (1972). D. B. Calne, e d . , "Progress i n t h e Treatment o f Parkinsonism," Advances i n Neurol., 2, 1 (1973) Raven P r e s s , N.Y. J . D. P a r k e s , Amantadine, i n Recent Advances i n Drug Research, Academic P r e s s , N.Y. (1974) i n p r e s s . G. C. C o t z i a s , M. H. Van Woert and L. M. S c h i f f e r , New Eng. J . Med.,
276, 374 (1967).
L a n g r a l l and C. Joseph, Neurol. , 22 ( 5 , P a r t 2) , 3 (1972). R. B. Godwin-Austen, Advances i n Neurol., 3, 23 (1973). A. R. Damasio, A. Castro-Caldas and A. L e e , Advances i n Neurol.,
6. H X . 7. 8.
3,
11 (1973).
9. C. C. P o r t e r , Fed. P r o c . , 2,871 (1971). 10. A. P l e t s c h e r , Advances i n Neurol., 2, 49 (1973). 11. C. C . P o r t e r , L. S. Watson, D. C . T i t u s , J. A. Totaro and S . S . Byer, Biochem. Pham,. , l l , 1067 (1962). 12. V. L o t t i and C . C. P o r t e r , J. Pharmacol. Exp. T h e r . , 172, 406 (1970). 13. S. K. Rao and D. B. Calne, Advances i n Neurol. , 2, 7 3 T 9 7 3 ) . 14. C. D. Marsden, J. D. Parkes and J. E. Rees, Advances i n Neurol., 2, 79 (1973).
15.
U. K. Rinne, V. Sonninen and T. S i i r t o l a , Advances i n Neurol.,
. Schwab,
3,
(1973
16.
R. S. A. C . England, D. C . Poskanzer and R. R . Young, J . h e r . Med. ASSOC., 208, 1168 (1969).
59
Chap. 3
18.
Antiparkinsonism Drugs
Vernier
25
J . D. Parkes, R. C. Baxter, A. G a l b r a i t h , C . D . Marsden and J. E. Rees, Advances i n Neurol., 3, 105 (1973). R. P. Grelak, R. C l a r k , J. M. Stump and V. G. V e r n i e r , S c i e n c e , 2,
203 (1970). B. A. S p i l k e r and K. M. Dhasmana, E x p e r i e n t i a , 30, 64 (1974). 20. V. G. V e r n i e r , J. B. Harmon, J . M. Stump, T. E. Lynes, J. P. Marvel and D. H. Smith, Tox. Appl. Pharmacol., 2,642 (1969). 21. J . Offermeier, i n P a r k i n s o n ' s Disease, A New Approach t o Treatment, ed. G. F. B. Birdwood e t al., Academic P r e s s , London (1971)p . 85. 735 22. J. A. Davies, B. Jackson and P. H . Redfern, Neuropharmacol., ,2.l
19
(1973). 23. U. Stromberg and T. H. Svensson, Acta Pharmacol. T o x i c o l . , 30, 161
(1971). 24. R . Hackman, 25.
26. 27.
P. P e n t i k a i n e n , P. J. Neuvonen and H. Vapaatalo, E x p e r i e n t i a , 3, 1524 (1973). B. Cox and S. J . Tha, Europ. J. Pharmacol. , 24, 96 (1973). P. F. Von Voightlander and K. E. Moore, S c i e n c e , I& 408 , (1971). P. F. Von Voightlander and K . E. Moore, J. Pharmacol. Exp. Therap.,
184, 542 (1973). 28. R X , H e i k k i l a and G. Cohen, Europ. J. Pharmacol. , 20, 156 (1972). 29. B. S c a t t o n , A. Cheramy, M. J . Besson and J. Glowinski, Europ. J . Pharmacol. , 2,131 (1970). 30. T. H. Svensson, Europ. J. Pharmacol., 23, 232 (1973). 31. K. H. Sontag and P. Wand, Arzneim.-Forsch. , 23, 1737 (1973). 32. W. Wesemann and J. D. Schollmeyer, Agents and A c t i o n s , 2, 195 (1973). 33. J. Amer. Med. ASSOC., 226, 1117 (1973). 34. A. B a r n e t t , J. Goldstein and E. F i e l d e r , Fed. Proc. , 33, 293 (1974). 35. J . Amer. Med. ASSOC., 228, USAN Council, L i s t 134, May (1974). 36. R . S. Schwab, L. V. Amador and J . Y. L e t t v i n , Trans. Am. Neurol. Assoc. , 76, 251 (1951). 37. G. C. C o t z i a s , P. S. P a p a v a s i l i o u , C. F e h l i n g , B. Kauf'man and I . Mena, New Eng. J. Med. , 282, 31 (1970). 38. P. Castaigne, D. Laplane and G. Dordain, Res. Commun. i n Chem. P a t h o l . Pharmacol. , 2, 154 (1971). 39. V. G. Vernier and K. R . Unna, J. Pharmacol. Exp. T h e r . , 103,365 (1951). 40. J . Maj , M. Grabowska and L. Gajda, Europ. J . Pharmacol. , 17,208 (1972). 41. H. C o r r o d i , K. Fuxe and U. Ungerstedt, J . Pharm. Pharmacol. , 23, 989 42.
.
(1971) . _ . . W . H. Funderburk, D . N . Johnson and J. W. Ward, Fed. Proc.
, 32, 247
(1973). 43. M. G o l d s t e i n , A . F. Battista, T. Ohmoto, B. Anagnoste and K. Fuxe, S c i e n c e , 179, 816 (1973). 44. D. B. Campbell, P. Jenner and A. R. T a y l o r , Advances i n Neurol., 3, 199 (1973). 45. B. C o s t a l l and R. J . Naylor, Advances i n Neurol., 2, 281 (1973). 46. S. D. V a k i l , D. B. Calne, J. L. Reid and C . A. Seymour, Advances i n Neurol. , 2, 121 (1973). 47. M. K. Menon, W. G. Clark and D. Aures, Europ. J. Pharmacol., 19, 43 ( 19-72
.
26
Sect. I
I
48. 49. 50.
51.
- CNS
Agents
Gordon, Ed.
R . M. P i n d e r , Advances i n Neurol. , 3, 295 (1973). D. M. Brown, B. 0. Hughes, C . D. Marsden, J . C. Meadows and B. 476 (1973). S p i c e r , B r i t . J. Pharmacol., 0. P. W. Robinson, Advances i n Neurol., 3, 97 (1973). K. R . Hunter and 0. P. W. Robinson, C l i n i c a l Trials J o u r n a l , 2, 3
9,
(1972). 53.
D . J . Vicary, P. M. Horrocks, J . E. Rees, J , D. Parkes and C . D . Marsden, C l i n i c a l T r i a l s J o u r n a l , l0, 3 (1973). D . J . J e f f e r y , D. M. Brown and P. F. Langley, Xenobiotica, 5 , 169
54. 55.
G. Clark and J . Davies, B r i t . J . Pharmacol., 465 (1973). R . C. U r s i l l o and J. A . McCulloch, Arch. I n t . Pharmacodyn., 197,132
56. 57. 58.
E. A. S p i e g e l and H. T . Wycis, Confinia Neurol., 2,176 (1969). H. T. Wycis, Confinia Neurol. , 34, 130 (1972). E . R. Blonsky, A. D. E r i c s s o n , A . S . McKinney, A. Rix, R . I . H. Wang and A . A. Rim, C l i n i c a l Pharmacol. Therap. , 2, 46 (1974).
52.
(1971).
3,
(1972)
-
Chapter 4.
Psychotomimetic Agents
Richard A. Partyka and JOMS A. Gylys B r i s t o l Laboratories, Syracuse, New York 13201
-
'-'
Comprehensive suryeys on t h e chemistry, pharmacology2 and metabolism o f General The proceedings of conferences d e a l i n g w i t h marihvsna a n n a b i n o i d s have ap7e red. have been published. Governmental p u b l i c a t i o n s which cover t h e b i o l o g i c a l , s o c i a l An e x c e l l e n t account of e r g o t and l e g a l a s u e c t s of marihuana have a l s o appeared.'-'' has been published i n which the t a x o n o q and d i s t r i b u t i o n of the Claviceus s p e c i e s , t h e c o n s t i t u e n t s o f e r g o t and t h e i r b i o s p t h e t i c o r i g i n , and t h e production 3f e r g o t a l k a l o i d s a l l have Seen reviewed.lZ Extensive reviews on t h e ~ h e r n i s t r y ~ a:d ~ - bio~ synthesis15 o f peyote a l k a l o i d s have appeared. The biochemistr] o f psychosesL6 a s w e l l a s t h e r o l e of adrenochromel' a s a psychotomimetic agent have been t h e s u b j e c t s of reviews. -4 review o f che chemistry and pharmacology o f W m e t h v s t i c u m , t h e 18 pepper p l a n t from which t h e n a r c o t i c d r i n k kava-kava i s prepared, has been pubiished.
-
I. Chemistry A. Cinnabinoids A d e f i n i t i v e paper appeared on t h e i s o l a t i o n and s t r u c t u r a l e l u c i d a t i o n o f 1'-retrahydrocannabinol (A1-THC). (2, cannabigerol cannabichromene (3, and cannabicyclol ( 4 A d e s c r i p t i o n o f the a b s o l u f t c o n f i g u r a t i o n 3111 o f both c h i r a l c e n t e r s (C-3 and C-4) i n 1 -THC a s & was also presented. $&fls on t h e t o t 3 1 syntheses o f ( 5 ) cannabidiol (+J d 5 - T H C , (-) d l - T H C , (-) -THC, as well a s t h e racemic and ( + ) l n o d i f i c a t i o n s of t h e l a t t e r two THC'S, were
-
4.
(z),
-
(z),
-3
p
4
-5
-6
published. 20-1 Other cannabinoid r e p a r a t i o n s i n v o l v i n g t h e condensation of terpenoid moieties were a l s o described. 2 2 - 3 ~'32 P opyl and methyl analogs o f cannabinoids 2 and 6 were i s o l a t e d and characterizedz4-' fro111 n a t u r a l sources. A propyl a n a l o g o f 2 was a l s o reported.2i S y n t h e t i c cannabinoids with n i t r o g e n c o n t a i n i n g s i d e chains such a s s t r u c t u r e s i n analogous f a s h i o n according t o p r e v i o u s l y d e s c r i b e d s y n t h e t i c A unique approach t o t h e trans-aza s t r u c t u r e 4 was a l s o reported. 30 routes
7a-c w5gegprepared
L
-8
Unfortunately, b i o l o g i c a l d a t a were n o t reported f o r t h e s e i n t e r e s t i n g s t r u c t u r e s . The ready a v a i l a b i l i t y o f v a r i o u s cannabinoids by i s o l a t i o n and s y n t h e s i s l e d t o a n i n t e n s i f i e d study o f t h e i r metabolism i n v a r i o u s animal specie^.^^'^ I n general, hydroxyIation occurred i n any a v a i l a b l e a l l y l i c o r benzyl o s i t i o n of t h e THC framework with t h e p o t e n t i a l f o r f u r t h e r metabolic conversion."-' I n man, a n important
28
Sect. I
-
CNS Agents
Gordon, Ed.
m e t a b o l i t e o f 4l-TIK was t h e corresponding 7-OH d e r i v a t i v e which a l s o e l i c i t e d p o t e n t cannabinoid-like e f f e c t s . ' 9 - 4 2 S y n t h e t i c developments k e p t pace v i t h t h e i s o l a t i o n and i d e n t i f i c a t i o n the v r i us metaboli p r o ucgs. Thus, procedures f o r t h e s y n t h e s i s of 7-OE-L-f6) -TBCt3-' and 7-GIi4'-THCt6-' were described. 5 8 0 e o g routes. !i9,55,w,
a ed fl-8
m e t a b o l i t e s such a s
9
and l o w e r e a l s o d e r i v e d by s y n t h e t i c
a)
€$-OH;
b)
€$a; R2-OH;
c)
5, R2-=arbanyl;
d)
%dz=H; 1,Za-epoxy;
e)
I(l-Rz=H;
RZM; R fl
3
R34i R3fl
5"
R3.0H
2 a)
5 9 ; R2R3=carbonyl
b)
%<€I3;
c)
\G2H;
OH
R2L,+,
R2-R3=H
10 -
a)
R=OCT(CH3)C5H11
b)
RIC(CH3) <(CH3)C5HI1
c)
RIC(CH3) zC6H13
d)
RG(C5)CH(CH3)C5Hl1
11
3 A v a r i e t y of new 4 -THC d e r i v a t i v e s l l a - c condensation products i n t h e 4' p o s i t i o n . 56-
was prepared i n c l u d i n g Mannich
-
B. Lvsernic Acid S t r u c t u r e s . Sev a 1 u n s u c c e s s f u l a t t e m p t s a t a new s y n t h e s i s of l y s e r g i c a c i d (12a) were sumarized.'f A review on analogs & of. I most of which a r e p a r t i a l s t r u c t u r e s , appeared. 52 An e f f i c i e n t p r o c e s s f o r t h e p r e p a r a t i o n of v a r i o u s secondary and t e r t i a 8 ly5ergamides and t h e corresponding d i - and t e t r a h y d r o d e r i v a Nu-Demethylation o f l y s e r g i c a c i d diethylamide (LSD) was t i v e s was d e s ribed. accomplishedJz 2 s well a s t h e d i F e r i z a t i o n of a wide v a r i e t y o f e r g o t a l k a l o i d d e r i v a t i v e s t o s t r u c t u r e s of type 13.-'5 A convenient p r e p a r a t i o n o f t h e t 7 t g l y s e r g i c a c i d e s t e r 15 from t h e corresponding N-oxide 1L;was d i s c l o s e d . 56 Cyclic o r t h o t h i o esters were used i n a novel F r i e d e l - C r a f t s type approach t o t h e p r e p a r a t i o n o f v a r i o u s 2 - s u b s t i t u t e d 9,lO-dihydrolysergic a c i d d e r i v a t i v e s 12b i n c l u d i n g (R1"CH3). 5 7 A t o t a l s y n t h e s i s of (3- i s o s e t o c l a v i n e (l:c)was described.
RICH2C1,
14
Ls.
C 0 2 9 , cBzcN
13 -
S t u d i e s involving t h e unraveling of t h e complex b i o s y n t h e t i c sequence of t h e review on t h e biosyne r g o t a l h l o i d s continue 20 be r e p ~ r t e d . ~ ~A- ~comprehensive l t h e s i s of e r g o t a l k a l o i d s was publishcd.62 Of p a r t i c u l a r i n t e r e s t w a s t h e d i s c l o s u r e t h a t t h e e n o l a c e t a t e 12d was a n e f f i c i e n t l y s e r g i c a c i d precursor.63 A new a l k a l o l d 1 6 (R=(+) -1ysergyl) from a Claviceps purpurea s t r a i n was i s o l a t e d and c h a r a c t e r i z e d .
-
''
Partyka, Gylys
Psychotomimetic Agents
Chap. 4
2
z
?&.
-
PhenylalXvlaiine T,;?(?s. Anolozs o f Go?I 18a (R=C1 3r,I,X02,NH,)65 as w e l l a s t h e were prepdred. A series o f b-ajor ? - t a b o l i t a s oi ;.C:.l i n t‘.e r a t (18, R.C:12CH, C0,H)’6 bromonethoxyphe=y;isoproplrlamrnes 19 ( n i l , 2) was a l s 6 described, w i t h b r i e f r e f e r e n c e s t o phar2co:oCical a c t i v i t y . 67-i3 A h i s h l y u s e f u l method f o r the a s p e t r i c s y n t h e s i s o f p h e n y l i s o p r o p y l a ~ i n c s a s well as t h e nethodoloFy f o r t h e determination o f t h e i r Numerous analogs o f the psychotonimetic e n a n t i o n e r i c p u r i ? ” Tiere published, pheny1isopropyLznines Irere preoared \:herein the s t r u c t u r a l f e a t u r e s were i n c o r p o r a t e d i n t h e nore c o c s t r a i n e d frans::ork o f a 2-amino-1, 2 3 4-tetrahydronaphthalene ( a n i n o t e t r a l i n ) s y s t e z 21 (R=CH3, OH, @Ke, H, -0CX20-).71-g The aminoindan and aminoC.
20
19 (COH)
a)
R
bj
R
C)
a=ar
a) b)
n-1 D-2
N(W3)
(WET)
(DOJ)
21 -
t e t r a l i n 2(ib analogs o f N M were a l s o prepared.
74
The p r e p a r a t i o n o f t h e s u l f u r analog 22b o f p s i l o c i n (22a) was described. Weak s e d a t i v e and vasopressor a c t i v i t y w a s found.
--
75 -6
I n v i t r o experiments provided evidence f o r t h e bioconversion o f n y r i s t i c i n (23) t o t h e corresponding phenyliso?ropylanine d e r i v a t i v e , PNDA 77 Other workers, u s i n g t h e i n t a c t animal, demonstrated t h e presence o f s t r u c t u r e s m a s major m e t a b o l i t e s
z.
o f t h e r a t and guinea pig, r e s p e c t i v e l y . 7 8 The f u l l i m p l i c a t i o n o f t h e s e bioconvers i o n s with respect t o b e h a v i o r a l o b s e r v a t i o n s i n animals79 a s w e l l a s i n man remains t o be determined. X review on nutmeg was published.80
D.
O t h e r - S t u a i e s continued on t h e measurement o f p h y s i c a l chemical parameters o e l f i d a t e s t r u c t u r e a c t i v i r y p a t t e r n s i n psychotomimetic compounds. Thus X-ray, in ordlif-’ nu& and t o t a l o r b i t a l e n e r g i e s a 4 were used t o study molecular conformation and i t s r e l a t i o n s h i p t o psychotonimetic a c t i v i t y i n t h e l y s e r g i c a c i d series. The conformations o f p s i l o c i n and mescalice we85 examined by molecular o r b i t a l and c l a s s i c a l p o t e n t i a l function calculations C o r r e l a t i o n s o f uv s p e c t r a , ‘6 n a t i v e fluorescence87 and a s s o c i a t i o n constants*8 with t h e psychotomimetic a c t i v i t y of v a r i o u s methoxylated phenylisopropylanines were made. Quantum mechanical s t u d i e s Of
30
Sect. I
- CNS Agents
Gordon, Ed.
t h e r e l a t i o n s h i p between p s y c h o t o n i n e t i a t i v i t y and t h e s t r u c t u r e s o f v a r i o u s a n t i c h o l i n e r g i c a g e n t s were a l s o published. g9-Fo
-
11. Pharnacolow. A. Cannnbinoids. Acute and Fhronic t o x i c i t y , t e r a t o l o g y , and reproduction c, t u d i e s on crude m a r i h u n a e x t r a c t , lL-TMC and o t h e r cannabinoids were p e r f o m e d i n animals. Concrolled human s t u d i e s f a i l e d to r e v e a l any drug r e l a t e d p e m n e n t e f f e c t s 2 * 11, 95althuugh chronic narihuana smokers had impaired 96 c e l l u l a r mediated i m l i n i ty. I n animals, b L - T H C showed s i o n s o f a n a l g e t i c , a n t i p y r e t i c , a n t i i n f l a m a t o 97-100 +f
r,,
and anticonvi?lsant p r o p e r t i e s , lo'-' but no a n t i d e p r e s s a n t e f f e c t s . lo3 I n man, 5 THC was i n a c t i v e a s a n a n a l g e g i c i n experimental ? a i n . l o 4 A'-THC caused hypothermia i n s e v e r a l a n i r a l s p e c i s ? i''-i v h i l e camplex and b i p h a s i c e f f e c t s were seen on rodent a g g r e s s i v e behavior. *L*h-lll ll-THC p o t e n t i a t e d t h e e f f e c t s o f d e p r e s s a n t compounds, 'I2 b u t e x h i b i t e a no c l e a r cut antzgonism towards amphetamine. S i m i l a r f i n d i n g s were a l s o r e p o r t e d f o r s y n c n e t i c cannabinoids. Cannabidiol and cannabinol, which were considered t o b e b i o l o g i c a l l y i n a c t i v e , e x h i b i t e d a n t i c o n w l s a n t a c t i v i 114 and i n t e r a c t e d with J l - T H C both p h a m c o l o g i c a l l y and m e t a b o l i c a l l y i n animals Furthermore, intravenously, cannabinol was found t o be weakly a c t i v e i n man."7 The phannac o l o g i c a l m o p e r t i e s of s e v e r a l s y n t h e t i c 13-THC d e r i v a t i v e s have been d e s c r i b e d i n animals. 7 , f O
'
I n animal o p e r a n t procedures, ?'-THC impaired performince mainly a f f e c t i n g t y p o r a l d i s c r i m i n a t i o n and s h o r t term mecory. 2,5 However, t h e e w re r e p o r t s t h a t A -THC n i g h t f a c i l i t a t e a c q u i s i t i o n of avoidance perfonrance. l l L 1 2 % Tolerance t o t h e e f f e c t s o f LI-THC developed r a p i d l y , was long l a s t i n g , and d i d rigi in.^ Hovev r, t h e r e were s e v e r a l b e h a v i o r a l parameters which f a i l e d t o e x h i b i t tolerance.121'e Thus f a r , only t h e fhesus monkey I n man, e x h i b i t e d s i g n s resen'nling p h y s i c a l dependence upon withdrawal of 1 t o l e r a n c e t o cannabis p r e p a r a t i o n s was less apparent and no t r u e p h y s i c a l dependence The s o - c a l l e d "reverse" t o l e r a n c e p o s t u l a t e d i n Fan could n o t b e was seen.8, lo, r e c e n t l y confirmed.125-6 ll-THC decreased s l e e p d u c t i o n time i n man, however, a Extensive humen s t u d i e s on "hangover" phenomenon was observed the nexc day. cannabinoids d e a l i n g with s u b j e c t i v e e f f e c t s mental function, memory, w t o r and d r i v i n g performance were published. 5 , 11, 128-31
not appear t o b e metabolic i n
'"
The s i m i l a r i t y o f cannabinoids t o o t h e r known psychotomimetic compounds was appeared t o be d i f f e r e n t from LSD i n terms of p h y s i o l o g i c a l i n v e s t i g a t e d . \'-THC and psychotomimetic p r o f i l e s i n man ( r e f . 4 , p. 196). Howe er, c e r t a i n s i m i l a r i t i e s and d i f f e r e n c e s wereaceen between marihuana and e t h a n 0 1 ~ ~w ~ i t h- ~an i n d i c a t i o n o f No c r o s s - t o l e r a n c e could b e demonstrated between ll-THC and c r o s s - t o l e r a n c e . li, IJ5 morphine, mescalice o r LSD. '7 136 I n animals,
;.I -THC produced hypotensive responses, bradycardia
reduced venous
r turn137 and a n t i h y p e r t e n s i v e e f f e c t s i n c e r t a i n l a b o r a t o r y models. 138-9 Xn nan, Ap-THC caused tachycardia, c o n j u n c t i v a l reddening, p r e s s o r e f f e c t s , impairment of Some r e c e n t evidence i n d i c a t e d t h a t ll-THC v a s o r e f l e x e s and ECG changes. reduce i n t r a o c u l a r p r e s s u r e and p u l m n a r y a i r r e s i s t a n c e i n man.
might
S t u d i e s an a b s o r p t i o n , p l a s m l e v e l s orwan d i s t r i b u t i o n , 143-7 u r i n rv and fecal excretio.., and n e t a b o l i c conversion^'^, 3g7 14'-' o f 'll-THC a n d / o r hi$6)-THC i n animals and man were published.3i,33 The c u e s t i o n o f whether A1-THC o r 7-OHdI-THC was m i n l v t e s p n s i b l e f o r t h e e f f e c t s observed w i t h A1-THC ha n o t been resolved.106,1J8 However, i t has been e s t a b l i s h e d t h a t 7-OH-A -THC was p r e s e n t in t h e m u s e b r a i n a f t e r A1-TXC admLnistration, and was found t o be more p o t e n t than L1-THC based on b r a i n concentrations.151-2. On t h e b a s i s of lasma l e v e l s , e x c r e t o r y p a t t e r n s , and concomitant drug e f f e c t s i t appeared t h a t 7+)H-l7-THC most l i k e l y w a s r e s p o n s i b l e hydroxylated m e t a b o l i t e s , such a s s t r u c t u r e s f o r t h a c t i v i t y i n m n . 39, 41, 153 ga.b15&and fi proved t o be inactit:fi31 The metabolism o f DlClP was s t u d i e d i n several animal s p e c i e s . 155
H
The s t r u c t u r e - a c t i v i t y r e l a t i o n s h i p s and r e l a t i v e p o t e n c i e s of v a r i o u s
Chap. 4
Psychotomimetic Agents
31
Partyka, Gylys
cannabinoid; were ?resented. 339156 i t should be noted t h a t d t f f e r e n c e s i n t h e potency of h1-~f1cand .?,1(6)-.IHC, a s w e l l as v a r i o u s 33-T%C d e r i v a t i v e s and analogs, e x i s t e d depending on t h e test animal and procedure ~ s e d . ~ ' , ' ~ ' Despite i n c r e a s e d knowledge, t h e pharmacological c l a s s i f i c a t i o n o f cannabinoids remains e l u s i v e . Any 1.abeling such a s "depressant" o r "hallucinogenic" should be avoided because o f t h e complex and unique p r o p e r t i e s of t h i s c l a s s o f compounds.
-
B. Lyseroic Acid and Tr;ot.-iie Tvxs. I r p o r t a n t c o n t r i b u t i o n s towards t h e unders t a n d i n g of t h e a c t i o n s of psychotomimetic substances, e.g. t h e r o l e o f s e r o t o n e r p i c neurones, s i t e s o f c e n r r a l a c t i o n , and development o f t o l e r a n c e and c r o s s - t o l e r a n c e were revie:ied. 16, 15s-62 The i n f l u e n c e of e q o t a l k a l o i d s on p i c u i c a r y p r o l a c t i n and prolactin-dependent processes :.:as a l s o reviewed. '63 The metabolism o f n i c e r g o l i n e (17) was s t u d i e d i n v a r i o u s a i i m l s p e c i e s , including nan. LSD appeared t o e x e r t s e l e c t i v e e f f e c t s on s e r o t o n e r g i c neurones i n t h e b r a i n stem raphe n u c l e i , however, it i s u?.dctermined whether i t a c t s by blocking o r mi.micking 5-hydroxytryptamine ( 5 - h i ) . 165-r Sufotenin and N, N-dimethyltryptamine (DHT) appeared t o a c t s i m i l a r l y t o LSD on t h e raphe n u c l e i , w h i l e mescaline and DOY appeared t o be d i f f e r e n t . Atropine, 2-3r-LSD, 2nd c h l o r o p r o r a z i n e v e r e i n a c t i v e on raphe The p o s s i b l e involvement o f a c e t y l c h o l i n e , y-aminobutyric a c i d I;A3A) neurones. 1'L-Z -and tryptaminc i n t h e c e n t r a l a c t i o n o f Fsychotomirnetic a g e n t s was imp1icated.l
5'
The phenomena o f t o l e r a n c e and c r o s s - t o l e r a n c e among psychotomimetic a e e n t s were i n t e n s i v tud'ed. A c r o s s - t o l e r a n c e was observed between LSD and tryptamine o r mes a i n e , n4z, Q 7 6 - f b u t n o t Setween LSD o r mescaline and amphetamine o r LSD and DKT. 17'-' I n t e r o c e p t i v e e f f e c t s induced by mescaline, p s i l o c y b i n and LSD were poorly d i f f e r e n t i a t e d by t h e rat. ls'-l D e s p i t e s t r u c t u r a l h e t e r o g e n e i t y , t h e psychoto2imetic a g e n t s i n
e n e r a l caused
an i n c r e a s e i n b r a i n 5-;iT l e v e l s and a decrease i n i t s turnover rate.1'9,184-5 The e f f e c t s on b r a i n norepinephrine (NE) and dopamine were l e s s c l e a r l y defined, b u t a l o v e r i n g o f b r a i n l e v e l s and h i g h e r turnover r a t e s o f NE have been reported. i82-5 S p e c i f i c and s e n s i t i v e r a d i o i m u n e a s s a y s were developed f o r a n a l y s i s o f LSD and mescaline i n b i o l o g i c z i f l u i d s . 186-8 Turthermore, a n t i b o d i e s were o b t a i n e d which e x h i b i t e d high s p e c i f i c i t y t o LSD and c r o s s - r e a c t i v i t y t o o t h e r psychotomimetics r e l a t e d t o tryptarnine and phenethylamine. ls9
The d i s t r i b u t i o n o f LSD i n t h e r a t b r a i n e x h i b i t e d p a t t e r n s mimicking r e g i o n a l l o c a l i z a t i o n o f g-kT.l'o The c e n t r a l e f f e c t s of LSD were antagonized by s e v e r a l s t e r o i d a l agentsAg1 and 3, N-diethyl-l-methyl-l,Z, 5 , 6 - t e t r a h y d r o n i c o t i n a n i d e . 192 Furthermore, an a c t i v e i m u n i z a t i o n by p r o t e i n c o n j u g a t e s coPtaining l y s e r g i c a c i d o r tryptophan prevented c e r t a i n c e n t r a l e f f e c t s of LSD i n mice. L53 LSD f a c i l i t a t e d a c q u i s i t i o n of l e a cd behavior and improved l i g h t d i s c r i m i n a t i o n and r e c e n t memory i n rats and monkeys. 1'e-7 There TJBS l i t t l e w e l l &ocumented evidence t o i m p l i c a t e LSD f o r causing chromsomal damage and t e r a t o l o g i c e f f e c t s b o t h i n r a n and animals. The d e t e r m i n a t i o n of a N-ethyltransferase i n h m n blood1" and brainzo0 t h a t was capable o f converting t r y p t a n i n e i n t o DMT vas d e s c r i b e d . The presence o f a n endogenous substance capable of E e t a b o l i z i n q C:T i n normal s u b j e c t s was p o s t u l a t e d . lg9 Chronic schizophrenics excreted EXC and bufotenin i n t h e i r urine, v h i l e normal s u b j e c t s d i d not. 201-2
-
C. Phenvlnlkvlamine Types. The human p h a m c o l o g y of mescaline, i t s congeners and phenylisopropylamine a n a l o s s was reviewed. '03 X comprehensive study on t h e a c u t e t o x i c i t i e s 0 5 mescaline and i t s d e r i v a t i v e s revealed t h a t t h e do was n o r e s e n s i t i v e than t h e rhesus monkev t o t h e t o x i c e f f e c t s o f t h e s e compounds. 264 Rats f a i l e d t o d i f f e r e n t i a t e 2,3,4-trimetho?cyphen lethylamine, a non-psychotomimetic a n a l o g of mescaline, from mescaline i t s e l f . 25'
A e e o s e l e c t i v i t y o f LSD, DO31& tl DOB !8c. and DOET 18b f o r c e n t r a l ::ns demonstrated i n t h a t the g - c o n f i g u r a t i o n e l i c i t e d t h e n o t e p o t e n t effects2"-' e f f e c t , w h i l e p e r i p h e r a l l y such a d i f f e r e n t i a t i o n w a s not shown. 209-10 110 such clear
32
Sect. I
_.
-
Gordon, Ed.
CNS Agents
d i f f e r e n t i a t i o n with r e s p e c t t o psychotomimetic e f f e c t s could be shown w i t h g-(-) o r 5-(+)-am hetamine, although t h e 2 - i s o s e r was more p o t e n t a s a s t i m u l a n t than t h e 11isomer. 2P1
-
S t r u c t u r e - a c t i v i t y requirements i n t h e phenylisopropjllamine s e r l e s were presented. 203 R e l a t i v e potency r e l a t i o n s h i p s i n v a r i o u s experimental procedures f o r phenylisopropylsmine and D>fT analogs were discussed. 212-3 A t r a n s o i d conformation f o r mescaline a t t h e r e c e p t o r l e v e l was supported by t h e g r e a t e r b e h a v i o r a l e f f e c t s o f 28a over 28b i n t h e
'''
W M caused a b e r r a n t g r o s s b e h a v i o r a l p a t t e r n s w i t h a concomitant h persynchronous i t a l s o produced a l e t h a l hyperthermia i n r a b b i t s . The c a r d i o v a s c u l a r a c t i v i t y of X?.lwas c h a r a c t e r i z e d by z p r e s s o r response, tachyphylsxis and p e r i p h e r a l v a s o d i l a t i o 2 folloved by v z s o c o n s t r i c t i o n . 217 The e n t r a l and p e r i p h e r a l e f f e c t s induced by 3 O Y 57ere s u s c e p t i b l e t o 5-iiT a n t a g o n i s t s . 21s-7 Or%3n d i s t r i b u t i o n , , metabolic conversions and t h e e x c r e t o r y p a t t e r n o f 20014 were s t u d i e d i n l a b o r a t o r y ~ d t o b e responsible f o r the a c t i v i t y animals.218-22G The unchanoed C O ~ ? D O U E appear observed. 219 I n man, 30XT,r23E0B221 and M..DA2'2 caused a d l d euphoria a l o n ? w i t h a f e e l i n g of enhanced awareness a t r e l a t i v e l y lot.! doses. Various a m i n o t e t r a l i n s produced smooth muscle c o n t r a c t i o n s i n v i t r o probably through 5-HT r e c e p t o r s . 223 2 h i n o - 7 - h y d r o x y t e t r a l i n caused c e n t r a l e f f e c t s s i m i l a r t o those seen with mescaline and LSD i n rats. 224
EEG i n t h e cat.215
-
A new thebaine d e r i v a t i v e 2 6 p r o v e d t o be a n extremely p o t e n t psychotoD. Other mimetic agent, q u a l i t a t i v e l y mimickinz cyclazocine i n man 225 A novel c h o l i n e s t e r a s e inhibitor caused s e v e r e sensory d i s t u r b a n c e s i n man. 2i6 Low doses of N, N-dipropyltryptamine were evaluated a s a p o t e n t i a l a d j u n c t i n psychothera v 227 The biochemical e f f e c t s o f psychotomimetic a n t i c h o l i n e r g i c drugs were reviewed. 52i I n man, sensory d i s r u p t i v e e f f e c t s produced by a t r o p i n e , scopolamine and D i t r a n were similar and could
a
27 -
20 -
b e c l a s s i f i e d a s simple d e l i r i u m r a t h e r than a s psychotomimetic syndromes. 229
In rats,
c y c l a ~ o c i n e 2 3and ~ l e ~ a l l o r p h a nproduced ~~~ similar e f f e c t s t o t h o s e seen w i t h LSD.
Chap. 4
Psychotomimetic Agents
Partyka, Gylys
33
References
1. 2.
3. 4.
5. 6. 7. 8.
9.
10. 11. 12.
13. 14. 15. 16. 17. 18.
19. 20. 21. 22.
23. 24.
25. 26. 27. 28. 29. 30.
31. 32.
33. 34.
as. 36. 37.
38. 39. 40.
41. 42. 43.
66. 45. 46. 47.
R. K. Razdan, i n "Progress i n Organic Chemistry," Vol. 8, W. C a r r u t h e r s and J. K. S u t h e r l a n d , Eds., B u t t e r u o r t h s , London, 1973, C h a p t e r 3. L. Hills and P. Brawley, Agents and A c t i o n s , & 201 (1972). R Hechoulam, Ed., "Harijuana, I' Acadenic P r e s s , New York, N.Y., 1973. A. S i n g e r , Ed., "Y!riJuana: Chemistry, PharmacoloRy, a n d P a t t e r n s o f S o c i a l Use," Vol. 191, New York Academy o f S c i e n c e s , Xew York, N.Y. 1971. M. P. Lewis, Ed., "Current Research i n Marijuane," Academic P r e s s , New York, N.Y. 1972. W. Paton and J. Crown, Eds., "Cannabis and i t s D e r i v a t i v e s , Pharmacology and Experimental Psychology, " Oxford U n i v e r s i t y Press, London, 1972. M. deV. Cotten, Ed.. P h a m a c o l . Rev. 2_?, (1971). " M a r i h u n a : A S i c r u l of ?lisunderstanding, t h e T e c h n i c a l P a p e r s o f t h e F i r s t Report o f t h e N a t i o n a l C o m i s s i o n o n ?larihuana and Drug Abuse" Appendix, Vol. 1, U.S. Government P r f n t i n g O f f i c e , 1972. "Cannabis-A Report o f t h e Comnission of I n q u i r y i n t o t h e Non-Medical Use o f Drugs," I n f o r m a t i o n Canada, Ottawa, O n t a r i o , 1972. "Marihuana and H e a l t h , " Second Annual Report t o Congress, U.S. Government P r i n t i n g O f f i c e , 1972. "Marihuana and Health, " T h i r d Annual Report t o Congress, U. S. Government P r i n t i n g O f f i c e , 1974. D. Groger i n "Microbial Toxins,'' Vol. 8, S. Kadis, A. C i e g l e r , and S. A j l , Eds., Academic P r e s s , New York, X.Y., 1972, Chapter 12. J. McLaughlin, Lloydia, 1 (1973). G. Knpadia and M. i a y e z , Lloydia, 9 (1973). A. G. Paul, Lloydia, 36 (1973). H. Weil-Malherbe and S. I. Szara, "The B i o c h e m i s t r y of F u n c t i o n a l a n d E x p e r i m e n t a l Psychoses, " C. C. Thomas, S p r i n g f i e l d , I l l i n o i s , 1971, C h a p t e r 17. R A. Heacock, Chin. Ther., 5 300 (1971). A. T. Shulgin, B u l l . N a r c o t i c s , 25, 59 (1973). Y. Caoni and R. Hechoulam, J. Amer. Chem. Soc., fi 217 (1971). R Hechoulam, P. Braun, and Y. Caoni, ibfd. 6159 (1972). R. Mechoulam, 2. Ben-Zvi, H. Varconi, and Y. Samuelov, Tetrahedron, 3 1615 (1973), L. Cronbie and R. Ponsford, J. Chem. SOC. C, 796 (1971). B. C a r d i l l o , L. H e r l i n i and S. S e m i , T e t r a h e d r o n Lett., 945 (1972). E. W. G i l l , J. Chen. SOC. C, 579 (1971). T. Vree, D. Breimer, C. van Ginneken and J. van Rossurn, J. Pharm. Pharmacol., 2i?, 7 (1972). R. d e Zeeuw, J. Wijsbeek, D. Breimer, T. Vree, C. van Ginneken and J. van R o s s q S c i e n c e f75. 778 (1972). R d e Zeeuw, T. Vree, D. Breimer, and C. van Ginneken, E x p e r i e n t i a , 3 260 (1973). T. P e t r z i l k a a n d W. Lusuardi, Helv. Chim. A c t a , 510 (1973). T. P e t r z i l k a , M. Demuth and W. Lusuardi, i m . , 519 (1973). K Cushman and N. C a s t a g n o l i , Jr., J. Org. Chem., 440 (1973). L. Lemberger, Advan. P h a n a c o l . Chemother. &l 221 (1972). R Mechoulam, H. Varconi, 2. Ben-Zvi, H. Edery, a n d Y. G r u n f e l d , J. h e r . Chem. SOC., 7930 (1972). M. Wall, Ann. N. Y. Acad. S c i . , 191. 23 (1971). 0. Gurny, D. Maynard, R P i t c h e r , and R. K i e r s t e a d , J. h e r . Chem. SOC., 7928 (1972). R. Mechoulan, 2. Ben-Zvi, S. A g u r e l l , I. Nilsson, J. Nilsson, 8. Edery, and Y. C r u n f e l d , Experientia, 1193 (1973). I. Nilsson. S. ARurell. J. Nilsson. A. Ohlsson. J. Lindgren a n d R. Hechoulam. Acta. Pharm. Suecica, &I 97 (1973): D. Maynard. 0. Gurny. .. R. P i t c h e r , and R. K i e r s t e a d . w e r i e n t i a , 21. 1154 (1971). V. Esievez; L. E n g l e r t , a. T. Ho; Res. Comrmn. Chek. Pnthol. P h a G c o l . , & 8 2 1 (1973). L. Lemberger, R. C r a b t r e e , a n d H. M. Rowe, Science, 177. 62 (1972). L. Lemberger, N. Tanurkin, J. Axelrod, and 1. Kopin, Science, 173. 72 (1971). L. Lemberger, J. Weiss, A. Watanabe, I. G a l a n t e r , R Wyatt, a n d P. Cardon, New Eng. J. Med. 286. 685 (1972). M. Wall, D. Brine, C. P i t t , M. Perez-Reyes, J. h e r . Chem. SOC., & 8579 (1972). K. Weinhardt, R. Razdan, and H. D a l z e l l b T e t r a h e d r o n L e t t . , 4827 (1971). J. Nilsson, I. Nilsson, S. A g u r e l l , B. Akenmrk a n d I. Lagerlund, Acta Chem. Scand., 2 768 (1971). T. P e t r z f l k a , M. Demuth, and W. Lusuardi, Acta Pharm. Suecica, 5 679 (1971). 8578 (1972). C. P i t t , F. Hauser, R. Hawks, S. S a t h e K. I l a l l , J. Anar. Chem. SOC., 2361 (1973). R. Razdan, D . U l i s s , H. D a l z e l l ,
a
,
u.,
34
48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63.
64. 65. 66. 67. 68. 69.
70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87.
88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98.
Sect.
I
-
CNS Agents
Gordon, Ed.
K. Fahrenholtz, J. Org. Chem., 22, 2204 (1972). 2. Ben-Zvi, R. Mechoulam, H. Edety, and G. Porath, Science, 174. 951 (1971). B. Loev, P. Bender, F. Dowalo, E. a c k o , and P. Fowler, J. Wed. Chem., & 1200 (1973). It. Bovrun, D. Evans, J. Cuyett, J. Weale, and A. White, J. Chem. SOC., Perkin Trans 1, 760 (1973). E. Canmicne and D. k p p , J. Pharm. Sci., 809 (1971). F. Johnson, 1. A r y , D. Tciqer, and R. Kassel, J. Med. Chem., 532 (1973). Y. Nakahara and T. !:fwaquchi, Chen. Pharm Bull., 2337 (1971). N. Bach and E. Kornfeld, Tetrahedron Lett., 3315 (1973). P. S t u t z and P. S t a d l e r , ,.-I 5095 (1973). P. S t u t z and P. S t a d l e r , Helv. Chin. Acta, 75 (1972). E. Kornfeld and N. Sach, Ckern. and Ind. (London), 1233 (1971). C. Abou-Chaar, H. Guenther, M. Manuel, J. Robbers, and H. Floss, Lloydia, 3_1, 272 (1972’1 R. Floss, G. Basmadjian, ?L Tcheng, C. Spalla, and A. Minqhetti, fbid.,& 442 (1971). R. Bassett, E. Chain, and K. Corbett, Biochem, J., 134. 1 (1973). R. Thorns and R. Bassett. Progr. Phytochem., 2, 47 (1972). C. L e s l i e Lin, C. BLair,.J. Cassady, D. GrogeK W. Maier, and A. Floss, J. Org. Chem., - 2249 (1973). P. Stutz, R. Brunner, and P. S t a d l e r , Experientia, 2 936 (1973). R Courts and J. I b l i c k y , Can. J. Chem., I I , 1402 (1973). B. Ho and L. Tnnsey, J. Med. Chem., LLt, 156 (1971). C. Barfknecht and D. Nichols, 370 (1971). S. Seplilveda, R. Valenzuela, and B. Cassels, 413 (1972). D. Nichols, C. Barrknecht, D. Rusterholtz, F. Benington, and R. Motin, & 480 (1973). L. Pohl and W. Trager, $& 475 (1973). R. Violland, N. Violland-Duperret, H. Pacheco, C. T r o u i l l e r , and A. Leblanc, Chim. Ther., 4 196 (1971). L V i o l l a n d , N. Violland-Duperret, B. Pacheco, M. Chazarian, B u l l SOC. Chim. Fr., 307(1971). C. Barfknecht, D. Nichols, D. Rusterholtz, J. Long, J. Engelbrecht, J. Beaton, R Bradley, and 3. Dyer, J. Med. Chem.. 804 (1973). D. Nichols, C. Barfknecht, J. Long,.R-Standridge, R. Howell, R. Partytu, and D. Dyer, fbfd., II, 161 (1974). E. Campaigne and R Rogers. J. Heterocycl. Chem.. , 10. 297 (1973). N. Chapan, R. Scrowston, and T. Sutton, J. Chem. S O ~ . , Perkin Trans. 1, 3011 (1972). U. Braun and D. Kalbhen, Pharmacology, % 312 (1973). E. Oswald, L. Fishbein, B. Corbett, and M. Walker, Biochim. Biophys. Act., 244. 322 (1971). A. deMello and E. C a r l i n i , Psychophamcologia, 349 (1973). J. F o r r e s t and R. Heacock, Lloydia, 35, 440 (1972). R. Baker, C. Chothia, P. Pauling, and H. Weber, Mol. Pharmacol., % 23 (1973). R Baker, C. Chothia, P. Pauling, and H. Weber, Science, 178. 614 (1972). K Bailey and A. Grey, Can. J. Chem., 3 3876 (1972). M. Kumbar and D. V. Siva Sankar, Res. Cormun. Chem. Pathol Phannacol., & 65 (1973). S. Ksng, C. Johnson, and J. Green, Ebl. Pharmacol., 640 (1973). K. Bailey and D. Verner, J. Pharm. Sci., 480 (1972). P. Antun, J. Smythies, F. Benington, R. Morin, C. Barfknecht, and D. Nichols, Experientia, 3 62 (1971). M. Sung and J. Parker, Proc. Nat. Acad. Sci., 1346 (1972). S. Ehayani, H. Weinstein, S. Cohen, and M. Sokolovsky, Proc. Nat. Acad. Sci., 3 3103 (1973). li. Weinstein, S. Maayani, S. Srebrenik, S. Cohen, and M. Sokolovsky, Mol. Pharnucol., 820 (1973). C. Thcmpson, H. Rosenkrantz, U. Schaeppi, M. Braude, M. Mason, Toxicol. Awl. P h a m c o l . , 3 363 (1973). C. Thompson, EL Phson, H. Rosenkrantz, and M. Braude, fbid., 25, 373 (1973). L. Borgcn, W. Davis, and H. Pace,Phamucol. Biochem and Behav., 203 (1973). H. Replinger, H. Braude, and J. Calandra, Toxicol. Appl. Phamicol., 450 (1973). M. B o m n , and R. Pihl, PsychophamucoloRia, 159 (1973). C. N a b s , N. Suciu-Foca, J. Arnund, and A. Ebrishima, Science, 163. 419 (1974). U. Dewey, L. Harris, and J. Kennedy, Arch. I n t . Phamcodyn. Ther., 133 (1972). D. Bwtbaum, Psychophamcologia, 275 (1972).
a
u.,& u.,
u.,
u.,
a
a
a
a
a
Chap. 4
Psychotomimetic Agents
Partyka, Gylys
35
Dewey, and L. Hnrris, Eur. J. Pharmacol., 24, 1 (1973). R Sofia, S. Nalepa, J. Harakal, and H. Vassar, J. Phannacol. Exp. Ther., 186. 646 (1973). 429 (1973). 101. P. Conaroe and D. Kin, L i f e Sci, 102. W. Bopran, R. S t e e l e , and D. Freedmin, Psychonhennacolopia, 3 101 (1973). 103. R. Sofia, R. Kubena, and H. Barry, tbfd., 2 1 2 1 (1973). 104. S. H i l l , R. Schwin, D. Goodwin, and B. Powell, J. Pharmacol. Exp. Ther., 188. 415 (1974). 105. R. Sofia, Res. C o m n . Chem. Pathol. P h a m c o l . , 4, 281 (1972). 106. C. Haavik and H. Hardnun, L i f e Scf., 3 1 7 7 1 (1973). 107. C. Haavik and H. Hilrdmn, J. P h a M c o l . Exp. Ther., 187. 568 (1973). 108. E. C a r l i n i , A. kmaoui, and R. h r t z , B r i t . J. P h a m c o l . , & 794 (1972). 585 (1972). 109. S. Uekf, M. Fujiwara, and N. Ogawa, Physiol. Behav., 110. B. Carder and J. Olson, Physiol. Behav., 4 599 (1972). 157 (1973). 111. M. Kilbey, J. Moore, 3nd X. Hall, Psychophamcologia, 185 (1973). 112. R. Sofia and L. Knobloch, 113. J. Howes, Res. Comnun. Chen. Pathot P h a m c o l . , 5 895 (1973). 1527 (1973). 114. R. Karler, W. Cely, and S. Turkanis, L i f e Sci., 115. 1. Karniol and E. C a r l i n i , Psychophamcologia, 12, 53 (1973). 116. C. Jones and R. Pertwee, B r i t . J. Phannacol., 9 375 (1972). 1368 (1973). 117. El Perez-Reyes, X Timons, K. Davis, and E. Wall, Experientia, 401 (1972). 118. B. Herring, Psychophamcologia, 119. J. Pirch, K. Osterholm, E. B a r r a t t , and R. Cohn, Proc. Soc. Exp. Biol. Med., 141. 590 (1972). 1 (1973). 120. R Robichaud, M. Hefner, J. Anderson, and K Coldberg, Pharmacology, 297 (1972). 121. R Harris, W. Waters, and D. MeLendon, P s y c h o p h a ~ c o l o g i a , 122. D. Ferraro and D. C r i l l y , Science, 179. 490 (1973). 171 (1973). 123. M. tenHam and J. van Noordwijk, Psychophamacologia, 373 (1973). 124. D. Lawrence and R. Pertwee, Brit. J. P h a m c o l . , 125. L. H o l l i s t e r and J. Tinklenberg, Psychopharmacologia, 3 247 (1973). 126. S. Casswell and D. Marks, Science, 179. 803 (1973). 127. K. Cousens and A. DiMascio, Psychophannacologia, 22, 355 (1973). 373 (1973). 128. P. Bech, L. Rafaelsen, and 0. Rafaelsen, 129. 0. Rafaelsen, P. Bech, J. Chrfstiansen, H. Christrup, J. Nyboe, and L. Rafaelsen, Science, 179. 920 (1973). 130. M. Hosko. M. Kochar, and R Wang, Clin. Pharnncol. Ther.,. -& 344 (1973). 131. H. Evans; R. b h r t z , - D . Brown, B..Rodda, C. Kiplinger, L. Lemberger, and R Forney, Ik, 936 (1973). 132. L.- Rafaelsen, H. Christrup, P. Bech, and 0. Rafaelren, Nature (London), 242. 117 (1973). 812 133. J. Tinklenberg, B. Kopell, F. Helges, and L. t l o l l i s t e r , Arch. Cen. Psychfat.,= (1972). 134. H. Cappell, C. Webster, B. Herring, and R Cinsberg, J. Pharmacol. Exp. Ther., 182. 195 (1972). 1022 (1972). 135. L. N e m n , M. Lutz, M. Could, and E. Domino, Science, & I 831 (1972). 136. P. Bailey and S. Pradhan, Neurophannacology, &I 137. I. Cavero, J. Buckley and B. Jandhyala, Eur. J. Pharmacol., 3 243 (1973). 138. C. Nahas, I. Schwartz, J. Adanec, and W. Manger, Proc. Soc. Exp. Biol. Pkd., && 58 (1973). 169 (1073). 139. I% Biwfngham, Brit. J. P h a m c o l . , 140. W. Roth, J. Tinklenberg, B. Kopell, and L. H o l l i s t e r , C l i n Pharmacol. Ther., 533 (1973). 3 671 (1972). 141. J. Weiss, A. Watanabe, L. Lcmberger, N. Tawrkin, and P. Cardon, 142. M. Kochar and M. Hosko, J. h e r . Med. Ass., 225. 25 (1973). 1613 (1973). 143. E. Leighty, Biochem. P h a m c o l . , 144. 1. Ryrfcldt, C. Ramsay, I. Nilsson, M. Widmn, and S. Agurell, Acta Pham. Suecica, && 13 (1973). 4 244 (1972). 145. R Freudenthal, J. Martin, and M. Wall., Brit. J. P h a m c o l . , & 146. M. Shannon and P. Fried, Psychophararacologia, 22, 141 (1972). 147. E. G i l l and D. Lawrence, J. Phnna. Pharmacol., 3 948 (1973). 148. M. Perez-Reyes. , M. Lipton. M. Timons. M. Wall. D. Brine. and K. Davis, Clin. P h a ~ c o l .Ther., & .48 (1973). 488 (1973). 149. B. Ho, V. Estever, L. Englert, J. Pharm. Pharmacol., 99. 100.
D. Kosersky, W.
m.,
a
a
a
a
a
w.,
u.,
a
u.,
a
36 150.
151. 152. 153. 154.
155. 156. 157.
158. 159. 160. 161. 162. 163.
164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184.
185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200.
Sect.
I - CNS Agents
Gordon, Ed.
H. Perez-Reyes, M. T i m n s , H. Lipton, K. Davis, and H. Wall, S c i e n c e , 127, 633 (1972). H. C h r i s t e n s e n , R. F r e u d c n t h s l , J. Gidley, R. Rosrnfeld, C. Boe pli, L. T e s t i n o , D. Brine, C. P i t t , a n d M. iia11, Science, 172, 165 (1971). E. G i l l , C. Jones, and D. Lawrence, fllochern. P h a m c o l . , 22, 175 (1973). L. Lemberger, R. % r t z , B. Rodds, R. Forney, and H. Rowe, J. Clin. I n v e s t . 2411 (1973). M. Perez-Reycs, .sL Tirr.ons, M. Lipton, 11. C h r i s t e n s e n , K. Davis, and M. Wall, E x p c r i entia, 1009 (1373). L. L e r b e r c e r , R. YcPhhon, R. Archer, K. Matsunoto, and H. Rowe, J. P h a m c o l . Exp. Ther., 187, 169 (1973). H. Edery, Y. C r u n f e l d , G. Porath, Z. Ben-Zvi, A. Shani and R. Mechoulam, ArzneinForsch., 1995 (1972). I. K a r n i o l and E. C a r l i n i , Pharnacolor;y, % 115 (1973). S. Cohen, Progr. Drug Res., _II, 68 (1971). P. B r z v l e y and J. D u f f i e l d , P h a m c o l . Rev., 3 31 (1972). C. Aghajanfan, A m . N.Y. Acad. Sci., 193. 86 (1972). C. Aghajanian, Annu. Rev. P h a m c o l . , 157 (1972). Symposium o n " F u n c t i o n a l S i q n i f i c a n c e of S e r o t o n i n in Neuronal Systems': in Fed. Proc. Fed. h e r . Soc. 30.Biol., 2 81 (1972). H. F l o s s , J. Cassady, and J. Robbers, J. Phann. Sci., 699 (1973). F. Arcamone, A. Glasser, J. G r a f n e t t e r o v a , A. Minghetti, a n d V. N i c o l e l l a , Bfochem. 2205 (1972). Pharmacol., -Zl P. Bradley, Progr. B r a i n Res., 3 183 (1972). G. Bramwell and T. Gonye, Brit. J. Pbarmacol., 9 3573 (1973). H. H a i g l e r and C. Aghajanian, Fed. Proc., Fed. Amer. SOC. Exp. Biol., 22, 492 Abs. (1973). R. SamaniqL. V a l z e l l i and W. Gumulka, Psychophamacologia, 373 (1972). G. Guilbaud, J. Besson, J. O l i v e r a s , a n d J. Liebeskind, B r a i n Res., 417 (1973). H. H a i g l e r a n d G. Aghajanian, Eur. J. Pharmacol., & 5 3 (1973). H. Haigler andC. Aghaianian, Fed. Proc,Fcd. Amer. SOC. Exp. Biol, 2 2170 Abs. (1972). G. Aghajanian, W. Foote, and M. Sheard, J. Pharmacol. Exp. Ther., 171. 178 (1970). N. Scholes, Proc. SOC. Exp. Biol. Wed., 144. 623 (1973). W. M a r t i n and C. Eades, Psychopharmacologia, 2L, 93 (1972). E. Domfno and A. B a r t o l i n i , Neurophamacology, & 703 (1972). J. Winter, J. Pharmacol. Exp. Ther., 178. 625 (1971). IL T i l s o n , and S. Sparber, ibfd., 184. 376 (1973). J. Cole and W. P i e p e r , Psychophannacologia, 2 107 (1973). S. S p a r b e r and H. T i l s o n , 3 220 (1972). M. S c h e c h t e r and 3. Rosecrans, 3 313 (1972). 0. Cameron and J. Appel, 22, 117 (1973). J. Stolk, J. Barchas, M. C o l d s t e i n , W. Boggan and D. Freedman, J. Pharmacof. Exp. Ther., (1974), in p r e s s . H. Rosengarten and H. Denber, Psychopharmacologia, !a (Suppl. ) 1 2 1 (1972). N. Anddn, H. Corrodi, and K. Fuxe, J. Pharmacol. E x p . Ther., 179. 236 (1971). B. Leonard, Psychopharmacologia, 2 33 (1973). A. Taunton-Rigby, S. Sher, and P. Kelley, Science, 181. 165 (1973). A. C a s t r o , 2. C r e t t i e , F. Bartos, and D. Eartos, Res. Commun. Cheai. Tathol. P h a m c o l . , 5 879 (1973). S. S c h n o l l , W. Vogel, C. O d s t r c h e l , Fed. Proc., Fed. Amer. SOC. Exp. Biol., 2852 Abs. (1973). 8. VanVunakis, J. Farrow, H. C j i k a and L. Levine, Proc. Nat. Acad. Sci., 3 1483 (1971). I. Diab, D. Freedmn, and L. Roth, Science, 173. 1022 (1971). H. Selye, L i f e Sci., ( P a r t I), 1135 (1971). J. Smythies, J. Beaton, F. Benington, and R. Morin, Eur. J. Pharmacol., 11, 270 (1972). E. W. Voss and 8. Berger, P s y c h o p h a m c o l o g i a , 3 140 (1972). C. Bignami, 146 (1972). H. S c h e c h t e r and J. Winter, Arch. I n t . Pharmacodyn. Ther., 196, 64 (1972). A. King, I. : a r t i n , and K. Seymour, B r i t . J. P h a m c o l . , l 6 l P (1972). P. 8. Bradley in "Hcmory and T r a n s f e r of Information," H. Zippel, Ed., Plenum P r e s s , Nev York, 1973. S. Y. Long, Teratology.. & _ 75 (1972).
a
a
a
u., u., u.,
a
a
u., a
R. Wyntt, J. Saavedra, and J . Axelrod, Amcr. J. Psychiat., J. Saavedra and J. Axelrod, Science,
175. 1365
(1972).
130. 754
(1973).
Chap. 4 201. 202.
Psychotomimetic Agents
Partyka, Gylys
37
N. Narasimhacharl and H. Hinwich, J. Psychfat. Res., $ 113 (1972).
N. Narasfmhacharl, J. Avalos, H. F u j i m r l and H. H i m i c h , Biol. P s y c h i a t . ,
311
(1972).
203. 204. 205. 201. 207. 208. 209.
A. T. Shulgln, Lloydfa, & 46 (1973). H. Hardmn, C. I h a v i k , and M, S e e v e r s , Toxicol. Appl. P h a m c o l . , 3 299 (1973). J. C. Winter, J. P h n r n i c o l . Exp. Thcr., 185. I01 (1973). H. Depoorterc and D. Loew, B r i t . J. P h a m c o l . , 354P (1972). A. T. ShulRin, J. Pharm. P h a m c o l . , 21, 271 (1973). F. BenfnEton. R. Porin. J. Beaton. J. Smythles. a n d R Bradley, .. K a t u r e (London). Hew Biol., i 8 S (1973): H. Cheng, J. Long, D. Nichols, and C. Barfknecht, J. Pharmacol. Exp. Ther., 116
",
&
.--.
(1914) I
210. 211. 212. 213. 214. 215. 216. 217.
D.
B. E. A.
P.
M. A.
E
~
-
Dyer, D. Kichols, D. R u s t e r h o l z and C. Barfknecht, L i f e S c i . , E, 885 (1973). A n g r i s t , B. Shopsin, and S. Cershon, Nature (London), 152 (1971). Uyeno, P s y c h o p h n m c o l o g i a , 381 (1971). Kulkarni, Biol. Psychiat., 177 (1973). Cooper and G. W a l t e r s , Nature (London), 238. 96 (1972). Wallach, E. F r i e d m n , and S. Cershon, J. Phannacol. Exp. Ther., 182. 145 (1972). H o r i t a and A. H a n i l t o n , Proc. West. Pharnacol. SOC., & 104 (1972). Cheng, J. Long, C. BarRtnecht, and D. Nichols, J. P h a G c o l . Exp. Ther., 186.
a
345 (1973). 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229.
230. 231. 232.
B. Ro. V. Estevez. L. Tansev. - , L. E n-z l e r tr. P. C r e a v e a and W. *Isaac.
&
J. Med. Chem..
158 (1971). ' 8. Ho. V. E s t e v e z and G. F r i t c h i e . B r a i n Res.. 29. 166 (1971). S. S n i d e r , H. Weingartner, and L . . F a i l l a c e , Arch. Cen. P s y c h i a t . , 3 50 (1971). A. T. Shulgin, T. S a r g e n t , and C. Naranfo, Pharmacology, 103 (1971). A. T. Shulgin, T. S a r g e n t , and C. Naranjo, Pharmacology, u, 12 (1973). 8. Cheng, J. Long, D. Nichols, C. Barf.mecht, P h a r u l c o l o g i s t , 326 Abs. (1973). J. Green, K. D r e s s l e r , and N. Khazan, L i f e Sci., 12 ( P a r t I), 475 (1973). B. A n g r i s t and S. Cershon, Psychophamacologia, 2 109 (1973). S. Wray and A. Comn, Neuropharnecology, Iz, 397 (1973). R Soskin, S. Grof and W. Richards, Arch. Cen. P s y c h i a t , 817 (1973). J. O ' N e i l l , T. T e r n i n i , and J. Walker, Advan. Biochem. Psychophannacol., 4 203 (1972). J, Ketchum, F. S i d e l l , E. Crowell, Jr., G. Aghafanira, and A. Hayes, Jr., Psychop b r m a c o l o g i a , &2 ~. 121 (1973). S. Wray, &2 29 (1972). S. Wray, i b i d . , 251 (1973). S. Houry, R. Mechoulam, P. Fowler, E. M a c h , B. Loev, J. Hed. Chem., 11, 287 (1974). r
-
a
m., a
Chapter 5.
Abuse of CNS Agents
Maxwell Gordon, Bristol Laboratories, Syracuse, New York Introduction. The p a s t few years have seen a marked increase i n t h e abuse of CNS agents around the world. It has a l s o seen the passing of Nathan Browne Eddy, who f o r t h i r t y years had done so much t o put a s c i e n t i f i c pharmacological b a s i s 54,55,233(see a l s o 4,8,17,45,58,87,88,131,140,172, 185 under much of the heroin abuse research being done today. Abuse of drugs, both l i c i t and i l l i c i t has been a worldwide e idemic and has involved agents as d i v e r s e as o i a t e s 2,21,31,73,78,83,8~1105,1i6, B7,1 8 8 9 190, 191,215 am hetarnine 5,117,178,307, LSD 16,189,201,202, barbitur a t e s 59,60,61,9bs288, o t h e r hallucino ens 5O,52,93,95,182,183,184,193,2O4 marihuana 20,399 68,85,93, 95 109 110,11f, 141 142,198,211, cocaine 7 1, e t c . , i n a d d i t i o n t o a spate of glue s n i f f i n g , abuse of nutmeg, snuff, oregano and, of course, the ancient scourge alcohol 6. The hallucinogens a r e covered i n chapter 4 of t h i s volume. The l i t e r a t u r e of alcoholism is so v a s t t h a t no attempt can be made i n t h i s limited space t o cover i t . Furthermore t h e r e is a r e a l question i n our s o c i e t y whether w e consider i t t o be a drug s i n c e , f o r example, i t s use is not regulated by the Food and Drug Administration. Sedative abuse (hypnotics, t r a n q u i l i z e r s ) is a serious, much studied problem. However, not even suggestions of a s o l u t i o n a r e a t hand,so t h i s c l a s s of drugs too w i l l not be reviewed.
=ate Abuse. The o p i a t e area of abuse q u a l i f i e s f o r review i n these pages on two counts. F i r s t , i t is one of t h e most s e r i o u s medicallsociological1 legal/economic problems of our times, and secondly, approaches t o the treatment o r prevention of o p i a t e abuse have yielded c o n t r i b u t i o n s t o medicinal chemistry of the c l a s s i c a l kind, and thus a review of t h e s e approaches is appropriate t o t h e readership of t h i s volume. Economic Aspects of Opiate Abuse. One of the driving forces behind t h e rapid expansion of heroin abuse has been the enormous p r o f i t 92,128,132 t o be made from heroin processing, smuggling 9s99, and s a l e . This p r o f i t motive, when added t o t h e ease of contagion of the heroin h a b i t among s u s c e p t i b l e populations (e.g. peer groups), has made the drug abuse battle a d i f f i c u l t one f o r a l l concerned. Only now, a f t e r extensive e f f o r t s t o i n t e r d i c t heroin t r a f f i c , t o a r r e s t and convict t r a f f i c k e r s , and t o e n r o l l as many a d d i c t s as possible i n t o treatment programs, has the explosive growth of heroin abuse shown signs of leveling o f f . Regrettably t h e t o t a l number of a d d i c t s is s t i l l r i s i n g , a l b e i t more slowly, and estimates of t h e number of heroin a d d i c t s i n the U.S. range as high a s 800,000 38, a l though estimates of 300,000 t o 400,000 a d d i c t s are more coarmonly c i t e d . Opium harvesting i s q u i t e labor i n t e n s i v e (about 200 man-hours per kg opium 92 a d hence opium tends t o be grown commercially i n a r e a s where lowc o s t , short-term labor is a v a i l a b l e . Climatic requirements f o r the opium poppy a r e not g r e a t , and Papaver somniferum grows i n areas as d i v e r s e as Bulgaria, China, Greece, India, I r a n , Laos, Mexico, North Africa, Pakistan, Thailand, Turkey, and t h e U.S.S.R.
Chap. 5
Abuse of CNS Agents
Gordon
2
Most i l l e g a l opium products smuggled i n t o t h e U.S. i n recent y e a r s have from Turkey v i a France, where morphine was converted t o heroin. However, Turkey has only accounted f o r about 5% of t h e world production, so c l o s i n g out opium c u l t i v a t i o n i n Turkey (subsidized by t h e U.S.) had little o r no e f f e c t on i l l i c i t heroin supplies i n t h e U.S., although it d i d cont r i b u t e t o a shortage of medicinal opium exacerbated by crop f a i l u r e s i n India. Furthermore, l e g a l c u l t i v a t i o n of opium i n Turkey i s about t o be r e i n s t i t u t e d f o r economic reasons. copne
Recent p r i c e s paid t o Turkish farmers f o r l e g a l opium have been about $7.00 per kilogram, but black market p r i c e s have been as high a s $250,000 per kilogram. A t t h i s p r i c e of crude opium, the c o s t of t h e heroin i n a $5.00 "bag" i n t h e U.S. i s less than one cent. Hence, because of t h e p r o f i t s made by farmers, i t was u n l i k e l y t h a t a u t h o r i t i e s would succeed i n completely choking o f f Turkish black market supplies, and even i f they did, t h e world black market has access t o even less expensive Southeast Asian opium. The l a t t e r source developed t o a high degree during t h e U.S. involvement i n t h e V i e t Nam war, and enormous amounts of heroin were smuggled i n t o t h e U.S. using m i l i t a r y p o s t a l systems. With t h e phasing out of U.S. m i l i t a r y a c t i v i t i e s i n Southeast Asia, a l t e r n a t i v e delivery systems w i l l doubtless be developed. An a d d i t i o n a l problem i n dealing with o p i a t e abuse i s t h a t i f opium prices should rise p r o h i b i t i v e l y , s y n t h e t i c a l t e r n a t i v e s l i k e methadone would be made a v a i l a b l e to s o p h i s t i c a t e d black market organizations. Methadone has been found by a d d i c t s t o be i n d i s t i n i s h a b l e from heroin on i n j e c t i o n i n double-blind experiments 103,216, 21r218,219. The e x t r a c t i o n of morphine from crude opium and i t s conversion t o heroin a r e r e l a t i v e l y simple processes t h a t r e q u i r e only rudimentary equipment o r t r a i n i n g . The synthesis of o p i a t e s de novo r e q u i r e s more equipmerc and t r a i n i n g , but should be q u i t e a v a i l a b l e t o the black market c o n s i d e r i m t h e economic rewards. Bearing i n mind t h e $25.00/kg p r i c e paid f o r Turki s h crude opium (which re r e s e n t s a c o s t of about $2.50/kg of morphine), it has been reported 128*p32 t h a t morphine base sells f o r up t o $2000/kg, t h a t 407. pure heroin sells f o r $20,00O/kg, and t h a t 1-37, pure heroin sells f o r $400,00O/kg on the 'street'. The l a r g e p r o f i t s from heroin production and d i s t r i b u t i o n underline the d i f f i c u l t y i n stopping smuggling of heroin. A look a t t h e l o g i s t i c s of i n t e r n a t i o n a l movement of f r e i g h t provides f u r t h e r discouragement s i n c e the e n t i r e U.S. heroin requirements are less than f i v e tons a year, which can e a s i l y be l o s t amid t h e more than 100,000,000 t o n s of cargo t h a t e n t e r the U.S. by sea each year 221 o r aboard t h e thousands of f l i g h t s t h a t e n t e r t h e U.S. from abroad each year carrying about 200,000,000 persons through customs. Since t h e d a i l y heroin requirement i s only about 1 2 kg, and considering t h a t a s i n g l e person can r e a d i l y c a r r y $500,000 worth of heroin on one t r i p , the problem of i n t e r d i c t i n g heroin smuggling can be appreciated. Government E f f o r t s . The epidemic of heroin abuse i n t h e U.S. has led t o considerable a c t i v i t y by Federal, S t a t e and Local Governments 144 t o d e a l with t h e problem. I n the White House a Special Action Office f o r Drug Abuse Prevention was established. The FDA has exerted considerable e f f o r t i n the area of policing drug treatment program~56,57,~04. The National
_ I _
40
Sect. I
-
CNS Agents
Gordon, Ed.
I n s t i t u t e s of Health mounted and funded considerable research e f f o r t i n t h e a r e a of 0 i a t e abuse 24,~5,~6,~6,49,76,134,135,136,138,143,160,166,167, 170*177918192p2 he Con r e s has contributed m n e and focussed attention on t h e problem 28,~3,8~,9~,1~1,118,129,144,157,159,~74,210, the kpartment of J u s t i c e has increased i t s e f f o r t s 97, and the c o u r t s have made use of devices l i k e c i v i l commitment t o encourage treatment 29,108. On the i n t e r n a t i o n a l scene, the UN has likewise addressed t h e problem of o p i a t e abuse 98,150,203.
Geographic
D i s t r i b u t i o n of Heroin Abuse. Although o p i a t e abuse o r i g i n a t e d i n China and Southeast Asia L14 i t has f i r s t of a l l spread t o the major population c e n t e r s of the U.S. 1,12,37,38,40,41,54,55,69,L21,180, p a r t i c u l a r l y New York 165, Puerto Rico 148 and California, where the HaightAshbury scene became infamous 195*140s 191 From the U. S. t h e heroin epidemic i n the past decade spread t o En land i 3 , t h e Continent 5 3 , 1 1 3 ~ 1 ~ O , e s p e c i a l l y Sweden 79, and t o Japan Ifo6, and t h e rest of the more a f f l u e n t p a r t s of t h e world l i k e Australia, South Africa, e t c . Opiate Antagonists. Martin e t a1 133 have shown t h a t an i n j e c t i o n of a n a r c o t i c antagonist i n t o a non-dependent s u b j e c t w i l l block t h e s u b j e c t i v e o p i a t e - l i k e e f f e c t s of a subsequent i n j e c t i o n of heroin o r o t h e r o p i a t e . Thus, he postulated t h a t a long-acting antagonist could "immunize" an addict from the subjective e f f e c t s of o p i a t e abuse. The e x i s t i n g antagon i s t s l i k e naloxone, cyclazocine and naltrexone have c e r t a i n drawbacks l i m i t t h e i r usefulness a s blocking agents i n t r e a t i n g heroin
Naloxone
Cyclazocine
Naltrexe.e_
Naloxone, although a "pure" antagonist, has a short duration and poor o r a l a c t i v i t y . Hence, a 24-hour o r a l blocking dose must be measured i n grams. Thus, considerations of cost and p a l a t a b i l i t y would tend t o r u l e out t h i s substance. Cyclazocine has a d e s i r a b l e duration of a c t i o n (about 24 hours) and good o r a l a c t i v i t y . However, i t s hallucinogenic l i a b i l i t y may prevent i t s a c c e p t a b i l i t y and widespread use. For example, an "induction" period of two weeks o r longer i s required t o build up t o a 24-hour o r a l blocking dose of 4 mg. Naltrexone has a duration of a c t i o n i n t e r mediate between naloxone and cyclazocine and i s r e l a t i v e l y devoid of "agonist" s i d e e f f e c t s . However, although i t has the most promising prof i l e of the t h r e e agents, i t s r e l a t i v e l y s h o r t duration of e f f e c t and i t s r a t h e r high o r a l dose requirement (approximately 60-100 mg f o r 24-hour blocking a c t i v i t y ) a r e disadvantages, e s p e c i a l l y i n considering i t for incorporation i n t o sustained r e l e a s e implants. Both naloxone and naltrexone s u f f e r frola the drawback t h a t they provide no "reinforcement" t o the heroin addict being t r e a t e d with them. Cyclazocine s u f f e r s from the serious disadvantage of dysphoric a c t i v i t y a t e f f e c t i v e dose levels. Thus, new agents which a r e devoid of these problems a r e d e s i r a b l e . Antagonists
Chap. 5
Abuse of CNS Agents
Gordon
41 -
Oxilorphan, a new t o t a l l y s y n t h e t i c antagonist synthesized by Monkovic e t a1 146,147, has many of the p r o p e r t i e s of t h e i d e a l antagonist agent. The s t u d i e s of J a s i n s k i e t a1 comparing cyclazocine t o oxilorphan 234 showed t h a t oxilorphan had a n o r a l potency about equal t o t h a t of cyclazoc i n e and a d u r a t i o n of e f f e c t a t least equal t o t h a t of cyclazocine, thus p r o j e c t i n g 24-hour heroin blocking a c t i v i t y f o r a 4 mg dose. A r e l a t i v e lack of hallucinogenic s i d e e f f e c t s a t 4 mg doses were seen i n former a d d i c t s 230. Thus, a projected 24-hour blocking dose of 4 mg can be given o r a l l y t o the post a d d i c t without any induction period and without any hallucinogenic e f f e c t . Additionally,oxilorphan produces some "euphoric" component which may assist i n keeping post a d d i c t s i n a n antag o n i s t program 230.
It should be mentioned t h a t oxilorphan d i f f e r s from cyclorphan only i n t h e presence of t h e 14-hydroxy group. Cyclorphan i s a potent analgesic as w e l l a s a potent hallucinogenic agent i n man, resembling cyclazocine. So it w i l l be seen t h a t introduction of a 14-hydroxy group i n t o cyclorphan 46,147 reduces i t s agonist and hallucinogenic e f f e c t s , much as is seen with naloxone i n comparison with, f o r example. nalorphine.
a6 Nalorphine
Cyclorphrn
Oxilorphan
lcvo-BC-2910
Oxilorphan has been subjected t o p a r e n t e r a l chronic t o x i c i t y and Phase I o r a l and p a r e n t e r a l t e s t i n g . I n a double-blind comparison of oxilorphan with cyclazocine 234 conducted a t t h e Addiction Research Center a t Lexington, Kentucky, oxilorphan was found t o have an hallucinogenic p o t e n t i a l one-fourth t h a t o f cyclazocine. Levo-BC-2910 an analog of cyclazocine, has been evaluated i n sub-acute t o x i c o l o g i c a l t e s t i n g by the NIMH i n preparation f o r Phase I c l i n i c a l t e s t ing. The findings comparing t h e antagonist a c t i v i t y of oxilorphan, LeVO-BC2910 and s e v e r a l reference agents are summarized i n Table I below 230. The most u s e f u l modality f o r dealing with t h e s o c i e t a l a s p e c t s of o p i a t e abuse (as w e l l as some of t h e medical and personal a s p e c t s ) has been methadone maintenance. I n consideration of t h e pharmacology o f o p i a t e dependence 4,17,45,58,87,88,131,140,172,185, Dole and Nyswander 51 proposed t h a t maintenance o f o p i a t e a d d i c t s on r e l a t i v e l y l a r g e doses of o r a l methadone would i n h i b i t drug seeking behavior, "block" t h e subjective e f f e c t s of p a r e n t e r a l heroin i n j e c t i o n because of t h e tolerance induced, break the needle h a b i t because of lack of reinforcement by t h i s route, and make the a d d i c t more a v a i l a b l e f o r p s y c h i a t r i c treatment and r e h a b i l i t a t i o n , breaking t h e cycle of crime and punishment. Methadone maintenance has been
Sect. I
-
Gordon, Ed.
CNS Agents
Table I Narcotic An:agonint and Agonist (Analgesic) A c t i v i t y o f OxilorDhan. . . levo-BC-2910 and Reference /.Pence ED5o rnglkg 8 . c .
Compound Oxilorphan levo-BC-2910 Nal trexone Cyclazocine Cyclorphan Levallorphan Nalorphine Pentazocine Naloxone HC1 Horphfne s u l f a t e
Narcotic Antagonist A c t i v i t y Oxymorphone -orphone Morphine Straub T a i l Narcosis Antag.-RTI 0.19 0.074 0.027 0.81 0.32 0.29 1.14 12.0 0.09
-
.
0.03 0.013 0.006 0.12 0.10 0.32 0.58 10.1 0.02
-
0.012 0.008 0.003
0.040 0.032 0.086 0.38 12.2 0.010
-
Agoaist (Analgesic) Activity Bat nouse Writhing Writhing 12.8
44 9 0
0.046 0.031 26.3 0.77 3.7 XI0
0.70
8.0 30 35.6 0.029 0.028
11.9 0.70 0.95 XI0 0.16
3, 43 947948,s 1,62,66,70, widely em lo ed in the u S 15 s 1 8 ~ 2 2 ~ 2 27~32,36342 72 73 5 78 8 2 91 100 101, i02,107,119, ip1423, 127,145,149,151,152,154,162, 163, l d , 168: 186,192,136 and elsewhere Addicts entering a methadone maintenance program commonly go through a detoxification program 34 and preinduction physical examination. Treatment is commonly started at low daily doses building up to a maintenance level of 40-120 mgfday, tailored to each individual. Most methadone is dispensed and ingested in clinic, since diversion of take-home supplies presents a problem discussed later in this review. Dose adjustment is important since too low a dose will permit heroin abuse, whereas too high a dose can lead to dangers while driving 112 or operating machiner , and can interfere with the rehabilitative process as well 62,65,196,191;. Most methadone treatment centers belong to city or state agencies and are federally funded, althou h private methadone maintenance clinics have been operated as well 15,f56,213 A number of drug free treatment programs also exist 46,161,162,163,164,176,192,196 under names like Synanon, Phoenix,etc. Complications arise due to multiple drug abuse 26,35,67,123, and these are countered by multi-modality treatment and comnunit partici ation and preventive 62 and education programs 1, 10,30,86,126,189*200,20f. The drug abuse of addicts while in treatment programs can usefully be monitored by urinalysis 8*158,176,186 at frequent but irregular intervals, and by following deaths or serious in uries that are reported on addicts by offiMonitoring of crimes, cial sources 7,89,90,115,116,114,130,137,155,179. especially burglaries, shoplifting and robberies, also provides a good quantitative index of heroin addict activity, and large scale treatment in centers like New York or Washington, D.C. has resulted in marked drops in arrest incidence, both in the case of individuals in treatment and for the community as a whole 44,153. Inevitably the epidemic of drug abuse has iven rise to unorthodox a ptoaches ranging from transcendental meditation to heroin maintenance 69991,173 which we deplore. Research on Less Abusable Forms of Methadone and Other Oral Opiates. As mentioned earlier, the diversion of methadone to street use from maintenance programs is a serious problem since Jasinski et a1 lo3 have shown in double blind trials in post addicts that methadone and heroin are indis-
Abuse of CNS Agents
Chap. 5
Gordon
43 -
tinguishable on injection. It has been found 32,103, 230, 224 that a 20:l mixture of methadone-naloxone is indistinguishable from methadone alone when taken orally for maintenance (or analgesia), but taken parenterally by the opium dependent subject it will precipitate abstinence and taken by the non-dependent subject the opiate effect will be eliminated, or postponed for several hours only to appear in an attenuated form. This combination relies on the fact that naloxone given orally is only about 1/100th as effective as it is parenterally. The methadone-naloxone dosage form has been further refined by the development of a gum-formulated tablet that resists dissolution and injection (thus preventing precipitation of severe abstinence in highly dependent subjects like methadone maintenance patients), and by the development of a color coding system for '"take home" methadone-naloxone tablets which permit s tracking diverted street" methadone to its diversion source. The gum formulation mentioned above, although giving identical methadone blood levels to those obtained from oral ingestion of a solution, 24 hours after dosing of each, produces less sedation and fewer "highs" than are seen with solutions. The addition of 1 mg of naloxone to 100 ml of paregoric 230 produces a product which is indistinguishable from paregoric alone when taken orally as intended. When boiled down, filtered, and injected, however, the combination will produce abstinence in the dependent subject, as does the methadone-naloxone. Other agonists are also being combined with naloxone t o deter oral abuse (e.g. oxycodone). Development of Totally Synthetic Analgesics and Antitussives. There has been a long standing interest in developing non-abusable analgetics and antitussives which do not depend on opium supplies s4955. As a result of limitations in cultivation of opium in Turkey, and crop failures in India, the U . S . has had to dip into opium stockpiles, and this has accentuated the interest in synthetic analgetics and antitussives. Two agents of current interest are butorphanol 1469147, 230 and nalbuphine 17. Butorpha-
Bu torphiu~: (levo-DC-2627)
Nalbuphine
no1 is approximately equivalent in analgesic potency to cyclazocine and approximately equal in antagonist potency to nalorphine. In animals, the analgesic activity of butorphanol is 4-10 times that of morphine, 25-70 times that of pentazocine and 1-2.5 times that of nalbuphine, which is chemically related to butorphanol. Butorphanol has antagonist activity which is approximately 30 times that of pentazocine and 4-6 times that of na lbuphine
.
Butorphanol demonstrated less physical dependence liability than pentazocine a determined in the mouse jumping test 131,172. In the Rhesus monkey 219 butorphanol did not suppress abstinence in the withdrawn mor-
44
Sect. I
- CNS Agents
Gordon, Ed.
phine dependent animal. I n a d d i t i o n , exacerbation of abstinence was observed. Physical dependence l i a b i l i t y t e s t i n g i s now i n progress by Dr.D. R. J a s i n s k i a t t h e Addiction Research Center, Lexington, Kentucky. Nalbuphine showed mixed agonist/antagonist e f f e c t s i n dependence t e s t i n g , with p r e c i p i t a t i o n of abstinence i n morphine dependent s u b j e c t s , but a l s o drugseeking behavior i n persons subjected t o d i r e c t a d d i c t i o n experiments. C l i n i c a l l y , butorphanol has been evaluated i n normal volunteers f o r s a f e t y and tolerance both o r a l l y and p a r e n t e r a l l y . Single intramuscular doses ranging from 0.1 t o 20 mg were studied. There was no i n d i c a t i o n of hallucinogenic a c t i v i t y even i n one volunteer who received the 20 mg dose 230. Butorphanol 230 and nalbuphine 231 have been t e s t e d c l i n i c a l l y f o r analgesia p a r e n t e r a l l y and found t o be approximately 10 times morphine and equipotent t o morphine respectively. I n summary, then, w e see t h a t progress has been made i n the a r e a of o p i a t e abuse by a p p l i c a t i o n of c l a s s i c a l medicinal chemical approaches of modifying various components of b i o l o g i c a l a c t i v i t y by s t r u c t u r a l modificat i o n , finding s y n t h e t i c s u b s t i t u t e s f o r n a t u r a l products which improve on nature, optimizing agonist and antagonist properties, etc. It is hoped t h a t these r e s u l t s w i l l encourage f u t u r e researchers t o make s i m i l a r prog r e s s i n d i f f i c u l t a r e a s l i k e b a r b i t u r a t e abuse, alcoholism, e t c . References 1. 2.
3. 4. 5.
c. 7. 8. 9.
10. 11. 12.
13. 14.
15. 16. 17.
18. 19. 20. 21. 22.
23. 24.
2s. 26.
A. Abrams, Contemporary Dmg P robl ems,Fal l 1973.p. 353 ( F e d e r a l Legal F’ublic a tions , N . ? . > J. R. A l l e n and L. J. West, Am. J . P s y c h i a t . , 125, 364 (1968). H. Andina, D. Kurg, L. E ergner, S . P a t r i c k and S. Whitman, Contemporary 3rug Problems, F a l l 1972, p. 707. H. L. Andrews and W. Workman, J. P h a m . & E x p t l . Therap.. 73, 99 (1941). B. A n g r i s t and S. Gershcn, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i g e r , 1972. p . 2 6 3 . J . D. Armstrong. Am. J. Hosp. Pharm. g,149 (1965). I4. H. Baden, Human P at hol ., 3 , 9 1 (1972). S. L. Baker, Am. J . Pub. Heal t h, 62, 857 (1972). J . Becker, P. C o v g i l l , M. Drago, E . H e l t s l e y a nd B. Waters, Contemporary Drug Problems, Sunmer 1972, p. 413. E. L. B e l l i t o , i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea a nd P e b i g e r , 1972, p. 545. 8 . Bensnn and K. W al l ace, E,p. 369. T. H. Bevley. Bull. on Harcoc.rcs, 21, 13 (1969). T. H. Bewlsy, in Yearbook o f Drug Abuse, L. B r i l l and E. Harm, Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y. 1973 p . 207.Mahon, in Drug Abuse, Proc. I n t e r n . Conf., C . J . D . H Bewley, P. Jamr; and T * k r a f o n e t i s , Ea:, Lea and F e b i g e r , 1972, p . 73. 1. B i t z , J . Langrod and K . Colgan, Am. J . Pharmacy, Jan-Feb. 1972, p. 29. K. H. B l a c k e r , R. T. J o n e s , C. C . S t one and D. Pfefferbaum, Am. J . Psychtat..=, 361(1968). H. Blumberg, P. S. Wolfe and H. B. Dayton, Proc. SOC. Exp. B i o l . , 763 (1968). C. E. Bovling, A. D. H o f f e t f and W, J. R. T a y l o r , C l i n . Toxic ol. , 2, 66 (1972). P. Boyd, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Zarafonetis. Ed., Lea a nd F e b i g e r , 1972, p. 399. 0. J. Braenden, Contemporary Drug Problems, Sunnner 1973, p. 257. J . H. Brenner, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 115. L. b r i l l and H. H e i s e l a s , in Yearbook o f Drug Abuse. L. B r i l l a nd E. H.m, Eds., L h a v i o r n l P u b l i c a t i o n s , N. Y., 1973, p. 49. E. B r i l l , G. Nash and J. L angrol , in Major M o d a l i t i e s i n t h e Treatment o f Drug Abuse. L. B r i l l and L. L i e b e m a n , Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y., 1972, p. 287. B. S. Brovn, C l i n i c a l Xesearch, 3,618 (1971). 8. S. Brown, N. Y. Lab! Journal, Mar. 27, 1972, p. 25. 8 . S. Brown, R. L . WPant, 1’. P. Sass, S. T. G le ndinninp, N. J. Kaeei and M. B. Meyors, Compr. P s y c h i a t r y , l3, 391 (1972).
118,
Chap. 5 27. 28.
29. 30. 31. 32.
33. 36.
35. 36. 37. 38. 39. 40. 41. 42. 43.
44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60 61. 62. 63. 60.
65. 66. 67. 68. 69. 70. 71.
Abuse of CNS Agents
Gordon
45 -
8. S. B r m , S. K. Gauvey. M. B. Meyers and S. D. S t a r k , I n t l . J . of A d d i c t i o n s , 5, 635 (1971). J. L. Buckley, N. I. Lpw Jouraal, Mar. 28, 1972. A. J . C a i l i o s t r o . J . R. Knop. I. Unx and R. G. Newman. Contemporary Drug, P r o b l e m . Slmmer 1972. p. 561. W. Cahn, J. Darney, A . H. Levine, R. Millman. H. Noulis and P. Wald, i b f d , F a l l 1972.p.829. D. C. Cameron, i n Drug Abuse. Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 17. F. S. Caruso, M. Gordon, I. J . P a c h t e r , F i f t h N a t i O M l Conference on Methadone Treatment, 2, 1336 (1973). W. Cazalaa and A. G. Bucaro. C l i n . T o x i c o l . , 1, 7 0 (1972). C. D. Chambers, i n Major M o d a l i t i e s in t h e Treatment of Drug Abuse, L. B r i l l and L. Lieberman. Eds.. Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 143. C. D. Chambers and L. B r i l l , *rf, p. 203. C. D. Chambers and A. D. N o f f e t t , in Yearbook o f Dtug Abuse, L. B r i l l and E. Harms, Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y . , 1973, p. 129. P. A. L. Chapple, D. E. Somekh and M. E. T a y l o r , B r i t . J . Addict., 2, 33 (1972). J . A. Cimino, R. M. Wad, H. S. Andim8 and S. A. West, Contemporary Drug P r o b l e m , P a l l 1973, p. 401. L. D. C l a r k and E. N. Nakashinu, Am. J. P s y c h i a t r y , 125, 379 (1968). S. Cohen, Contemporary Drug Problems, P a l l 1973. p. 431. S. Cohen. in Drug Abuse. Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s . Ed., Lea a n d Febiger. 1972, p. 333. T. Connor and E. Kremen, I n t e r n . J. of A d d i c t i o n s , 5. 279 (1971). A. T. Conrad, in Major M o d a l i t i e s in t h e Treatment of Drug Abuse. L. Brill a n d L. Lieberman. Eds.. Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 23. P. Cushman. N. Y. S t a t e J . of Medicine, J u l y 1, 1972, p. 1752. F. E . D‘Amour and D. L. Smith, J. Pharm. L E x p t l . Therap., 72, 74, (1941). K. J . p e i a s l e r , Drug Dependence (5) O c t . 19’70. J . V. &Long, Dea1ir.q w i t h Drug Abuae. A Report t o t h e Ford Poundstion, P. M. Weld and P. Praexer P u b l i s h e r s , New York, 1972, p. 62. . B. - h t t . Eds.. J. V. &Long, i b c p. 173. J. Cenwn-Gerber, H. Wiener and R. Hochstedler, Contemporary Drug Problems, F a l l 1972, p. 783. A. H. Der Marderosian, K. H. Kensinger, J . M . Chao and P. J . G o l d s t e i n , Drug Dependence (NIMH) (5) Oct. 1970, p. 7 . V. P. Dole. e t e l . , Arch. I n t e r n . Ned. 118, 304 (1966). E. P. Domino. In Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and F e b i g e r . 1572, p . 30:. J . a r n b e r x-. .. The J c u r n a l , Addiction Research Foundation, Toronto, 2, 8 (1974). N. B. Eddy, Am. J. Hoap. Pharm. 22, 131 (1965). N. B. Eddy and D. Leimbach. J . Pharm. and Exptl. Therap., 107, 385 (1953). C. C. Edvards, H. Y. Law J c u r n a l , Mar. 27, 1972, p. 25. R. E. Edwards, Am. J . Hosp. Pharm. 22, 145 (1965). H. W. s l l i o t t . i n DYUR Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i a , Ed., Lea and F e b i g e r , 1972; p. 1371 C. P. E s s i g . An. 3. Hosp. Pharm. 22. 140 (1965). C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i g e r , C. F. Essig, - . i n 3rug Abuse, Proc. i n t e r n . Conf., 1972, p. 2 0 5 . C. F. E s s i g , Drug Dependence (IMH) (5) O c t . 1970, p. 24. M . Fink, Contemporaq Drug Problems, S p r i n g 1972, p. 245. M. Fink. Fall 1972, p. 875. M. P i n k , i n Drug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i a , Ed., Lea and P e b i g e r , 1972. p. 1 7 1 . L. P. Finnegan, J . F. Connauphton, J. P. Emich and W. F. Wieland, Contemporary Drug Problems, F a l l 1972, p . 795. G. S. Finney, i n Yearbook of Drug Abuse, L. B r i l l and E. R a m s , Eds., B e h a v i o r a l Publicat i o n s , N. Y.. 1973, D. 63. J . F o r t , i n Ecajor M o d a l i t i e s i n t h e Treatment of Drug Abuse. L. B r i l l and L. Lieberman, Eda., Behavioral P u b l i c a t i o n s , N. Y . , 1972, p. 237. J. F o r t , i n Yearbook of Drug Abuse, L. B r i l l and E. Harma. Eds.. B e h a v i o r a l P u b l i c a t i o n s , N. Y., 1973, p. 333. Z a r a f o n e t i a . Ed., Lea and 8. F. P r a s e r , i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. F e b i g e r , 1972, p. 141. A. M. Preednan, f’mptehcnsive P s y c h i a t r y , g,586 (1971). S. Freud, Dm3 Dependence (NIMH). (5) O c t . 1970, p. 15.
n.
s.
46 72.
73. 74. 75. 76.
77. 78. 19. 80.
81. 82 * 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 96. 95. 96. 97. 98. 99. 100. 101. 102.
103. 104. 105.
136. 107. 108. 109. 110. 111. 112.
113.
114. lls. 116. 117. 118. 119.
Sect. I
-
CNS Agents
Gordon, Ed.
J. 8. Prykmdn, i n Drug Abuse, Proc. I n t e r n . C o d . , C.J.D. Z a r a f o n e t i r , Ed., Lea and P e b i g e r , 1972, p. 527. C. R. Gay, Contemporary Drug Problems, P a l l 1972. p. 735. 1 . P. G a r f i e l d , I=, p. 953. F. R. Gearing, i!):~j, Sprinq 1972, p. 191. B. J. George, J r T n Drug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i a , Ed., Lea and F e b i g e r , 1962, p. 459. F. B. G l a s e r , I n t l . J. of Addictions, 6, 615 (1971). M. M. G l a t t , Brit. J . A d d i c t i o n s , 63, 111 (1968). L. Goldberg, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and P e b i g e r , 1972, p . 27. P. 8. Goldberg, 3eaiing w i t h Drug Abuse. A Report t o t h e Ford Foundation, Ed. by P. M. Wald and P. B. R u t t , Praeger P u b l i s h e r s , New York, 1972, p. 300. I. Goldenberg and E . Keatinae, Contemporary Drug Problems, F a l l 1973, p. 363. B. M . Goldsmith, W . C . Capel, K. J. Waddel and G. T. S t e w a r t , C l i n . Toxicol. 2 - 7 3 (1972). A. G o l d s t e i n , The Journal, Addiction Research Foundation, Toronto, 2, 7 (1974). C. W. Corodetsky. Drug Dependence (NMH)(51) Oct. 1970, p. 18. L. Grinspoon, Contemporary Crug Problems, F n l l 1972, p. 811. P. G. Hansnond, i>-L< , Summer 1973, p. 247. L. S. H a r r i s and A. K. P i e r s o n , J. Pharm. and E x p t l . Therap., 1 4). 141 (1964). L. S. H a r r i s , A. K. P i e r s o n , J. R. Dembinski and W. L. Dtwey. Arch. I n t . Pharmcodyn., 165, 165 (1967). T H e l p e r n , Buman Pathol., 2. 13 (1972). M. Helpern. N. Y. Lnw J o u r n a l , Mar. 28. 1972. R. M. Hochstedler, Contemporary !Jrug Problems, S m e r 1972, p. 517. J. F. Holahan, Dealing v r t h Drug Abuse. A Report t o t h e Ford Foundation, Ed. by P. @I. Walt and P. B. H u t t , Praeger P u b l i s h e r s , New York, 1972, p. 255. L. E. H o l l i s t e r , i n !kug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i e , Ed., Lea and F e b i g e r , 1972, p. 321. L. E. Hollfs:er, i-, p. 421. 8. Holmscedt and A . Linnarson. p. 291. C. M. IdestrClol. i n 2 u g Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and FebtgGr, 1972. p. 217. J. E . I n g e r s o l l , Committee on Problems o f Drug Dependence Mtg., May 22, 1972, Ann Arbor, Mich., p . 14. J. E . I n g e r s o l l , in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i q e r , 1972, p. 449. J. E. I n g e r s o l l , 14. Y. Law J o u r n a l , Mar. 2 7 , 1972, p . 25. C. E. I n t u r i s s i and K. Verebely, C l i n . Pharmacol. Therap. 2,633 (1972). J. H. J a f f e , i n Crug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i s , Ed.. Lea and F e b i g e r , 1972, p. 161.. J. H. J a f f e , in Yearbook of Drug Abuse, L. B r i l l and E. H a m , Eds., B e h a v i o r a l P u b l i c a t i o n s , N . Y. 1373, p . 103. D. R. J a s i n s k i e t a l . , Co!mfttce on Problems o f Drug Dependence, 442, (1972). D. R. J a s i n s k i , i n Yearbook of Drug Abuse, L. Brill and E. Harms, Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y. 1973, p. 37. Z a r a f o n e t i s . Ed., Lea and P e b i g e r , A. Koplan, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. 1972, p. 191. M. Kato, , p. 67. E. Kaufrnan. Contemporary Drug Problems, Spring 1972, p. 207. D. C. Kay, i n Yearbook of Drug Abuse, L. B r i l l and E. Harms, Eds., Behavioral P u b l i c a t i o n s , H. Y . 1973, p . 17. M. H. K e e l e r , Am. J . P s y c h i a t r y , 125, 386 (1968). K. H. Keeler, C. B. R e i f l e r and M. 8. L i p r i n , Am. J. P s y c h i a t . 384 (1968). E. M. Kennedy, N. Y. Law J o u r n a l , Mar. 28, 1972. P. K i e l h o l z , i n Drug Abuse, Proc. I n t e m . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea a n d P e b i g e r , 1972. p. 361. P. X i e l h e l z , Sb,p. 363. E. I. Koch, N. 1. Law J o u r n a l , Mar. 28, 1972. A. J . R. Koumans, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n o t i s , Bd., Lea and P c b i g e r , 1972. p. 331. A. J. R. Koumans, i 3 g , p. 385. J. C . Iramer, ibbi, p. 253. J. C. Kraner, i n Yearbook of Drug Abuse, L. B r i l l and E. Harm, Eds., B e h a v i o r a l Publicat i o n s , N. Y.. 1973, p. 265. M. J. Kreek, L. %dcs, 5 . Kane, J. Knoblcr and R. M a r t i n , 4nn. I n t e r n . Mod. 77,598 (1972).
!b-e,,
N,
Chap. 5
Abuse of CNS Agents
Gordon
47 -
120* T. b n d , che J o u r n a i , Addaction Research Foundation, Toronto, 3. 8 (1976). 121. J . 8 . b n g e r , Contemporary Drug Problemr, F a l l 1972. p. 8U. 122. J. Langrod, L. B r i l l . J. Lowinson and H. Joseph, in Major Modalities in t h e Treatment o f Drug Abuse, L. B r i l l and L. L i e b e m a n , Eds.. Behavioral P u b l i c a t i o n r , N.Y., 1972. p. 107. 123. L. Langrod , H. Joseph and K. Colgan. ibid, p. 167. Contemporary Drug Probtcmr, F a l l 1972. 124. D. L a r r i e r , M. C l i n e , P. Brophy and A. >=hen, p. 707. 125. D. Laskowitr, L. B r i l l and J. B. J a f f e , in Major M o d d i t i e s in t h e Treatment o f Dmg Abuse, L. B r i l l and L. Lieberman. Edr., Behavioral P u b l i c a t i o n s , N. Y . , 1972, p. 65. 126. L. b n s f o d . i n Yearbook of Drug Abure, L. B r i l l and E. Hams, Eds., B e h a v i o r a l P u b i i c a t i o n s , N. Y . 1973, p . 303. 127. H. L. b n n a r d , L. J. E p s t e i n and M. S. Rosenthal, Science, 176,881 (1972). 128* A. C. L e s l i e , H. Y. Law J o u t n a i , Uar. 28, 1972, p. 35. 129. L. Lieberman and L . B r i l l , in Yajor M o d a l i t i e s in t h e Treatment of Dmg Abuae. L. B r i l l and L. Lieberman, Eds., Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 67. 130. D. 8. Louria, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r . Ed., Lea and P e b i g e r , 1972. p. 505. 131. C. Maggiolo and F. Huidobro, Acta Phvsiol. Latinamer., y. 70 (1961). 132. S. T. Maidlow and A. Berman. Am. J . Pub. Health, 62, 1357 (1972). 133. W. R. M a r t i n & . W. Corodetsky and T. R. McClane, C l i n . Pharmacol.Ther.,L, 455 (1966). 134. W. R. M a r t i n , Am. J . Hosp. Pharm., 22, 133 (1965). 135. W. R. U a r t i n , in Dmg Abuse, R o c . I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed.. Lea and P e b i p e r , 1972, p. 153. 136. W. R. M a r t i n , in Yearbook of Drug Abuse, L. B r i l l and E. b m r , Edr., B e h a v i o r a l P u b l l c a t r o n . N. Y . , 1973, p . 1. 137. H. M. Mason, W. J. R. T a y l o r and M. V. Deming, C l i n . T o x i c o l . 2. 70 (1972). 138. D. W . Hatheson. S. J. Lynch and R. W. E a r l , Clin. T o x i c o l . , 2, 67 (1962). 139. E. May, a a l i n g w i t h W g Abuse. A Report t o t h e Ford Foundation, Ed. by P. M. Wdld and P. 8. h t t , Praeger F u b l i s h e r s , Nev York, 1972, p. 345. 140. E. W. Maynert, in Orug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and P e b f g e r , 1972, p. 199. 141. W. H. McClothlin, Contemporary Drug Problems, Summer 1972, p. 467. 142. W. H. McGothlin and L. U. Werc, Am. J . P s y c h i a t . , 125, 370 (1968). 163. J . Mendelson, The J o u r n a l , Addiction Research Foundation, Toronto, 2, 7 (1973. 164. P. H. Meyers, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea a n d P e b i g e r , 1972, p. 515. 145. A . D. M o f f e t t , I. H. Soloway and M. X . C l i c k , Clin. T o x i c o l . 5, 68 (1972). 146. I. Monkovic. A b s t r a c t s of 1 3 t h N a t i o n a l Med. Chem. Symp., ACS Div. Med. Chem., Iova C i t y , Iowa (1972). 147. I. Monkovic, T. T. Conway, H. Wang, Y. G. Perron, I. J. P a c h t e r and 8. B e l l e a u , J. Am. Cham. SOC. 95, 7910 (1973). 148. R. Morales-Boyer, in Yearbook of Drug Abuse, L. B r i l l and E. Harms. Eds., k h a v i o r a l P u b l i c a t i o n s , N. Y . 1973, p. 179. 149. J . C. Hunns, G. Geis and B. H. J u l l i n g t o n , i n Major M o d a l i t i e s in t h e Treatment of Dmg Abuse, L. B r i l l and L. L i e b e m a n , Eds., Behavioral R t b l i c a t i o n s , N. Y.,1972, p. 191. 150. J . Nepote. in Drug Abuse, W o e . I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed. Lea and F e b i g e r , 1972, p. 491. 151. R. G. Newman, Contemporary Drug Problems, Spring 1972, p. 183. 152. R. G. Newman, @, F a l l 1972, p. 605. 153. R. C. tiewman, S. Bashkow and M . C a r e s , i b f d , P a l l 1973, p. 417. 154. A. W. Nichols and P. R. Torrens, Arch. I r M e d . 127, 903 (1971). 155. W. W. Nichols, in Crug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 93. 156. J . T. Nix, C l i n . T o x i c o l . 2. 62 (1972). ls7. J . W. O l i v e r , in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i a , Ed., Lea a n d F e b i g e r , 1972, p. 429, 158. K. D. P a r k e r , ;Sld , p. 129. 159. C. Pepper. N. Y. Law JOUrMl. Mar. 28. 1972. 160. C. C . - P e t e r s o n and M. R. Wilson, J r . , Mayo C l i n . Proc. 46, 468 (1971). 161. J. C. P o l l a r d , in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r . 1972. D. 377. 162. T. G f a l s k y , Contemporary Drug Problems, SuPsler 1972, p. 399. 163. E. Ramiret. in Hajor k l o d a l i t i e s in t n e Treatment o f Drug Abuse, L. B r i l l and L. Lieberman, Eds., Behavioral P u b l i c a t i o n s , N. Y . 1972. p. 43. 164. E. Ramiret. i s , p. 55. 165. C. R. Rangel, N. Y. 5aw JOutM1, Mar. 20, 1972. I~
48
Sect.
L
166. 167. 168. 169.
170. 171. 172. 173. 174. 175. 176. 177. 178. 179.
180. 181. 182. 183. 184. 185. 186. 107.
186. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202 * 203. 204. 205. 206. 207. 208. 209. 210. 211. 212.
213.
I
-
CNS Agents
Gordon, Ed.
i n Major M o d a l i t i e s in t h e Treatment of Drug Abura, L. B r i l l and L. Lieberman, Edr., Behavioral P u b l i c a t i o n r , N. Y., 1972, p. 7. 0. S. Ray, C. V. Mosby Co.. S t . Louis, 1972. A. Richman. M. E. P e r k i n r , 8. B i h a r i and J. J. Pishman, Am. J. P u b l i c H e a l t h 62, 1002(1972). L. Robbine, B. S. Robhins and M. Stem, Druq IBwndmnce, (NMII) (5) O c t . 1970, p. 1. C. C. Rohrs, J . P. Murphy and J. Desen-Cerber, in D r u g Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i g e r , 1972, p. 571. M. S. Rosenthal. i n Yearbook of D r u g Abuse, L. B r i l l and E. Harrps. Eds., B e h a v i o r a l F u b l i c a t i o n s , N. Y. 1973, p. 83. J. K. S a e l e n s , P. R. Granat and W. K . Sawyer, Arch. I n t . Pharaucodya., E. 213 (1971). H. Samuels, Contemporary D r u g Problems, S m e r 1972. p. 517. J. 8 . Scheuer, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1 9 i 2 , p. 423. S. H. Schuman, p. 513. p. 233. J. W. Schweitzer and A. J. F r e i d h o f f , M. H. Seevers, , p. 9 . M. L. S e e v e r s , N. Y. Lav J o u r n a l , Mar. 28, 1972. S. 8. S e l l s , L. R. Chatham and R. L. Retka, Contemporary Drug Problems, P a l l 1972, p.665. R. P. S h a f e r , e t a l , Second Report o f N a t i o n a l C&ssion on Marihuana a n d Drug Abuse, March 1973. M. Shepherd, Lancet 1 (7636) 31 (1970). A. T. S h u l g i n , in Psychotomimetic Drugs, D. H. Efron. Ed., Raven Prarr, 1970, p. 21. A. T. S h u l g i n , T. Sargent and C. Naranjo, Nature, 221, 537 (1969). R. E. S h u l t e s . B u l l . N a r c o t i c s , 3.15 (1969). E. Siegmund, R. Cadnus and P. Lu, R o c . SOC. Exp. Biol., 9s. 729 (1957). J. M. Singh, M. D. C a a t e t and J. T. Nix, C l i n . Toxicol. 5, 72 (1972). C.J.D. Z a r a f o n e t i s , Ed., i c a a d D. - . E. Smith. i n Drug Abuse. Proc. I n t e r n . Conf., P e b i g e r , 1 9 j 2 , p. 271. D. E. Smith, i n Major M o d a l i t i e s i n t h e Treatment of Drug Abure, L. Brill and L. Lieberman, Eds., Behavioral P u b l i c a t i o m , N. Y., 1972, p. 267. D. E. Smith and A . J . Rose, i n Major M o d a l i t i e s i n t h e Treacment of h g Abuse, L. B r i l l 6nd L. Lieberman, Eds., Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 257. D. E. Smith and D. Bentel, in Yearbook of Drug Abuse, L. B r i l l and E. Halmu, E d i . . Behavioral P u b l i c a t i o n s . N. Y., 1973. p. 157. R. C . Smith, in Drug Abuse, Proc. I n t e r n . Conf., C . J . 3 . Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 455. R. C. SmFrn, =$ , p. 519. S. H. Snyder, L. A . ? a i l l a c a and H. W e i q a r t n e r , Am. J . P s y c h i a t . 125, 357 (1969). R. Stephens and E. C o r c r e l l , Brit. J . Addict. 67, 45 (1972). J. Sokol, i n Yearbook of Drug Abuse, L. B r i l l and E. Hams, Edn., Behavioral P u b l i c a t i o n s , N. Y., 1973. p. 169. W. J. R. T a y l o r , C . D. Chambers and C. E. Bowling, I n t l , J. C l i n . Pharmacol. Therap. T o x i c o l . 6, 28 (1972). D. A. T r e f i e r t , Contemporary D r u g Problems, Suxner 1973, p. 239. D. A. T r e f f e r t . l&, F a l l 1973, p. 393. J . T. U n g e r l e i d e r , in b h g Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed.. Lea arid Pebiger. - . 1972. D. 339. J. T. U n s e r l e i d e r , :I=, p . 501. J. T. U n g e r l e i d e r , D. D. F i s h e r , S . R. Goldsmith. M. Fuller and E. Forgy. Am. J . P s y c h i a t . 125, 352 (1958). T T . U n g e r l e i d e r and M. P u l l e r , in Yearbook of Drug Abuse, L. B r i l l and E. Harms, Eds., Behavioral P u b l i c a t i o n s , N. Y. 1973. p. 367. B. A . Van Der Kolk, Contemporary Drug Problems, Summer 1973, p. 263. P. M. Wald and P. B. Hutt, Dealing w i t h D r u g Abuse. A Report t o t h e Ford Foundation, Ed. by P. M. Wald and P. B. Hurt, P r a e g e r P u b l i s h e r s , New York, 1972, p. 3. P. M. Wald and A. Atrams, , p. 123. A. T. Weil, , p. 329. N. Weiner, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n c t i s , Ed.. Lea and P e b i g e r , 1972, p. 243. D. R. Uesson. C. R. Gay and D. E. Smith, Contemporary Drug Roblem6, Sunmer 1972, p. 453. J. H. Willis, Contemoorary D r u g Problems, Summer 1972. p. 501. L. L. Wolff, N. Y. Law J o u r n a l , Mar. 28, 1972. B. A. Wolfson and D. B. Louria, p. 225. S. F. Yoller, i n Yearbook of Drug Abuse, L. Brill and E. Harms, Ed.., B e h a v i o r a l Publicat i o n s , N. Y. 1973, p. 239. A. Zaks and M. Peldzmn. J . Am. Ned. Ansn. 222, 1279 (1972).
B. W. Rasor,
G,
m,
-.
w,
Chap. 5 214. 215. 216. 217, 718.
219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234.
Abuse of CNS Agents
Gordon
49 -
N. E. Zi a b e rg, Contemporary Drug Problems, S p r i n g 1972, p. 263. 1. E. Z in b e rg, ib:d , P a l l 1972, p. 747. W. R. M a r t i n and H. F. F r a s e r , J. Pharm. E xptl. Therap. 133, 388 (1961). J. R. J a f f e , Arch. Gen. P sychi at . 15, 525 (1971). It. Goodall, Psvchol. Today, 6 , 1 3 6 ( 1 9 7 2 ) . I. J . P a c h t e r , S ci ence, 179, (1923). M. Moore, P o l i c y Concerning Drug Abuse i n New York S t a t e , Vol. 111, t h e Hudson I n s t i t u t e (1970). pps. 67-73. E. A. P r e b l e and J . 3. Casey, I n t . J. Addi ction, 4 , 12 (1967). P. M. Brecher. (1972) " L i c i t and I l l i c i t Drugs" L i t t l e . Brown. p. 42. R. Dougherty, unpubl i shed d a t a . S. D. P a m a t i k a r and S. R. Knowles, Clin.Pharmaco1.Therap. 1 4 ,941 (1973). A. V. P i r c i o , H. Gordon and I. J . P a c h t e r , Pharmacologist 1 2,263 (1971). A. W . P i r c i o . Htg. Ned. Chem. 3 i v . Am. Chem. SOC., Iowa C i t y , June 1972. J . F . C a l i m l i n , W. :I. W ardel l , L. Lasagna, A. 3. G i l l i e s and H. T. Davis, C l i n . Pharmacol. Therap., I n P r e s s . H. Blumberg, H. 8. Dayton, and P. S . Wolf, Pharmacologist lo, 159 (1968). H. H. Swain, J . E. Villareal and H. H. S eeve rs , C o m t e on Problems of Drug Dcpendencc, 1973, p. 695, 696. M. Gordon, A. U. P i r c i o , F. S. Caruso, and I. J. P a c h t e r , Mtg. Cmte o n Problems of Drug Dependence, Mexico C i t y. March 11. 1974. R. W. Houde i n "Diagnosis and Management of Cancer," ed. by R. L. Cla rk, Yearbook M e d i c a l P u b l i c a t i o n , Chicago, I l l . (1971) p. 489, Vol. 111. U. H. F o r r e s t , Ccste on Problems of Drug Dependence. p. 247 (1971). N. 8 . Eddy, The N a t i o n a l Research Council Involvement i n t h e O pia te Problem, 192801971, N a t i o n a l Academy o f S ci ence, Vashington, D. C., 1973. D. J a s i n s k i , Mtg. Comte on Problems cf Drug Dependence, Mexico C i t y , M a r c h 11, 1974.
VL
S e c t i o n I1 Editor:
-
Pharmacodynamic Agents
Frank H. Clarke, Ciba-Geigy L t d . , A r d s l e y , New York Chapter 6 .
The E t i o l o g y of Hypertension
Donald W. DuCharme, The Upjohn Company, Kalamazoo, Michigan Hypertension i s one of t h e g r e a t e s t medical c h a l l e n g e s of o u r t i m e . I t i s e s t i m a t e d t h a t upwards of 40 m i l l i o n Americans a r e a f f l i c t e d by t h i s " s i l e n t disease",l Although g r e a t p r o g r e s s i n t h e t r e a t m e n t o f h y p e r t e n s i v e d i s e a s e u n q u e s t i o n a b l y h a s been made i n r e c e n t y e a r s , t h e u l t i m a t e t h e r a p y remains t o b e d i s c o v e r e d . The development of d r u g s which a c t s p e c i f i c a l l y upon v a r i o u s systems t o a m e l i o r a t e t h e symptom ( e l e v a t e d a r t e r i a l p r e s s u r e ) of t h i s d i s e a s e have, indeed, c o n t r i b u t e d a g r e a t d e a l t o c l i n i c a l management. They have enabled c l i n i c i a n s t o e f f e c t i v e l y lower blood p r e s s u r e i n t h e m a j o r i t y of p a t i e n t s , and minimize many of t h e a d v e r s e s i d e e f f e c t s which were a s s o c i a t e d w i t h e a r l i e r forms of therapy. There i s l i t t l e doubt t h a t s t i l l b e t t e r d r u g s can b e developed. For example, a d i u r e t i c which does n o t a l t e r potassium and u r i c a c i d e x c r e t i o n o r g l u c o s e metabolism, a c e n t r a l l y a c t i n g s u p p r e s s a n t of s y m p a t h e t i c v a s o c o n s t r i c t o r n e r v e f u n c t i o n which i s devoid of s e d a t i v e a c t i v i t y , a p e r i p h e r a l v a s o d i l a t o r which does n o t cause f l u i d r e t e n t i o n , a b e t a a d r e n e r g i c b l o c k i n g a g e n t which does n o t a f f e c t b r o n c h i a l smooth muscle f u n c t i o n , o r an a n t a g o n i s t of p e r i p h e r a l a d r e n e r g i c neurones which i s s p e c i f i c t o t h o s e neurones i n n e r v a t i n g blood v e s s e l s . The l i s t of pot e n t i a l improvements i n e x i s t i n g a g e n t s i s v i r t u a l l y e n d l e s s , and many would v e r y s i g n i f i c a n t l y improve c l i n i c a l therapy. The p o i n t remains, however, t h a t r e g a r d l e s s of how s p e c i f i c t h e s e a g e n t s become t h e y s t i l l p r o v i d e o n l y p a l l i a t i v e therapy. The r e a l c h a l l e n g e and hope i s t o d i s cover and develop a g e n t s which c o r r e c t t h e u n d e r l y i n g cause of t h e d i s ease. Before one can d e s i g n a r a t i o n a l program t o d i s c o v e r a g e n t s which w i l l "cure" h y p e r t e n s i o n , t h e c a u s e must b e d e f i n e d , While t h e c a u s e of h i g h blood p r e s s u r e can be d e f i n e d and c o r r e c t e d s u r g i c a l l y o r t h e r a p e u t i c a l l y i n a s m a l l p e r c e n t a g e of t h e h y p e r t e n s i v e p o p u l a t i o n , f o r t h e v a s t m a j o r i t y i t cannot, This l a r g e group of p a t i e n t s w i t h h y p e r t e n s i o n of unknown e t i o l o g y a r e c a t e g o r i z e d a s having " e s s e n t i a l " h y p e r t e n s i o n . I t i s t h i s group of p a t i e n t s which d i c t a t e s t h e need f o r a major r e s e a r c h e f f o r t t o uncover t h e cause o r causes of t h e d i s e a s e p r o c e s s and t o d i s cover and develop a g e n t s which w i l l e f f o r d o p t i m a l t h e r a p e u t i c c o n t r o l . I n t e r e s t i n g l y , i t h a s been p o s s i b l e t o induce h y p e r t e n s i o n i n l a b o r a t o r y animals a t w i l l by a v a r i e t y of methods f o r n e a r l y f o r t y y e a r s 2 , y e t t h e primary d i s t u r b a n c e which promotes t h e h i g h blood p r e s s u r e i n t h e s e a n i mals remains an enigma,
-
Vascular R e s i s t a n c e The major hemodynarnic a b n o r m a l i t y i n h y p e r t e n s i v e p a t i e n t s and l a b o r a t o r y animals i s an e l e v a t e d p e r i p h e r a l v a s c u l a r res i s t a n c e . Suggested e t i o l o g i c f a c t o r s which may c o n t r i b u t e t o t h e i n c r e a s e d v a s c u l a r r e s i s t a n c e a r e enhanced humoral v a s o c o n s t r i c t o r s u b s t a n c e s , d e c r e a s e d humoral v a s o d i l a t o r s u b s t a n c e s , enhanced neurogenic v a s o c o n s t r i c t o r a c t i v i t y , expanded e x t r a c e l l u l a r f l u i d volume, "auto-
Chap. 6
Etiology of Hypertension
DuCharme
51 -
regulatory" vasoconstriction and structural changes in the arterial walls. There is little question that the composition of arteriolar walls in hypertensive animals is modified. The wall is thickened in relation to the l ~ m e n 3 - 7 ~Furthermore, resistance to flow in hypertensive vessels is increased even after maximal vas~dilatation~,~, and reactivity of hypertensive vessels to vasoconstrictor stimuli is enhanceds,l0. Although most investigators believe the structural changes in the vessel walls are secondary to the increased intravascular pressure, some question remains as to whether the functional changes represent primary or secondary events'
Renin-Angiotensin-Aldosterone System - The major unresolved problem is the mechanism responsible for initiation of the abnormal vascular resistance. Humoral vasoconstrictor substances released from the kidney have been prime suspects since it was through restriction of renal blood flow that Dr. Goldblatt first induced hypertension in laboratory animals? The subsequent discovery and elucidation of the renin-angiotensin-aldosterone system, and the participation of this system in the hypertensive process has occupied the minds and efforts of many researchers and has been reviewed frequentl?l2 - I 4 . Recent studies which employed immunologic techniques to render animals insensitive to the vasoconstrictor action of angiotensin or specific angiotensin receptor blocking agents have demonstrated that the renin-angiotensin system is involved in the development of some but not all forms of experimental hypertension. Animals made hypertensive by restricting blood flow to one kidney and leaving the contralateral kidney intact generally exhibit a lowered blood pressure in response to angiotensin I1 blockade15'le. This is particularly true during the first weeks after onset of the hypertensive process. After the hypertension is well established, however, the blood pressure response to angiotensin I1 antagonism is much less consistent. On the other hand spontaneously hypertensive animals, metacorticoid hypertensive animals or animals rendered hypertensive by unilateral renal artery constriction and contralateral nephrectomy generally fail to demonstrate a decreased blood pressure in response to angiotensin I1 blo~kade~~'~~. Interestingly, immunization with a crude renal cortical extract markedly lowered the blood pressure of dogs with renal hypertension (bilateral renal artery constriction or unilateral renal artery constriction and contralateral This observation, coupled nephrectomy) of several years duratioli?o'2'. with those in which a specific angiotensin I1 antagonist was employed, suggests the possibility that the animals were immunized against a substance of renal cortical origin other than renin. This possibility is supported by more recent work which demonstrated that passive transfer of renin immunity to dogs with chronic renal hypertension did not restore blood pressure to n~rmal"~.Furthermore, active immunization of rabbits against angiotensin I1 failed to prevent the development of either perinephritic hypertension or single kidney Goldblatt hypertensionz4," 5. It is apparent that the results obtained with immunization procedures have varied considerably depending upon the animal species, the specific immunization technique, and the type of experimental hypertension employed. The causative role of the renin-angiotensin-aldosterone system in the genesis of hypertension, therefore, remains in question.
52
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
Other Renal Prohypertensive Factors - The lack of agreement between in-vestigators as to the etiologic significance of the renin-angiotensin system in experimental hypertension has prompted some to search for other renal factors which might be involved. Grollman has described a substance designated nephrotensin which was isolated from renal venous blood of patients with surgically remediable hypertension and from animals with renal ischemia hypertension?6'"7. Nephrotensin is presumably a polypeptide different from angiotensin I or I1 which exerts a potent vasoconstrictor action, and appears to be causally related to the hypertension associated with renal ischemia. The participation of this substance in human essential hypertension remains to be determined. Several investigators have suggested that the increase in vascular resistance associated with hypertension is a secondary, "autoregulatoryll response triggered by an increase in cardiac outpu?""l. If this is true, then the factors responsible for the increased cardiac output could become of greater etiologic importance than those which increase only vascular resistance. Cardiac output may be increased because of a change in renal function which promotes fluid retention and thereby enhances venous return to the heart?". Alternatively, venous return and cardiac output may be enhanced in response to increased venous smooth muscle tone-?-?.A vasoconstrictor material of renal origin different from angiotensin I1 which markedly contracts vascular capacity has been demonstrated ,35. ~ ~ The chemical in dogs subjected to severe hypovolemic h y p ~ t e n s i o n nature of this material and its role in the pathogenesis of hypertension remain to be determined.
-
Kallidin-Kinin System Recent work has also suggested a role for the kallidin-kinin system in the pathogenesis of hypertensiod 6 . Significant increases in urinary excretion of kallikrein were found in spontaneously hypertensive and DOCA-salt hypertensive rats, while levels found in rats with renal hypertension and patients with essential hypertension were lower than those in respective controls. Additional data suggests that the kallidin-kinin system may be intimately involved in the regulation of salt and water excretion by the kidnef6, ,?',
-
Renal Antihypertensive Factors In addition to a prohypertensive mechanism it has been recognized for many years that the kidney possesses an antihypertensive mechanism. Loss of the antihypertensive function may be as important to the pathogenesis of hypertension as activation of the hypertensive mechanism. Work in this area has been kindled in recent years by the demonstration that explants of renomedullary tissue will prevent the onset of renoprival hypertension or lower the blood pressure of Extracts of renal medullary tissue animals with renal hyperten~ion~"'~' have been shown to lower the blood pressure of animals with experimental hypertension by a number of investigators. Extracts possess both an acute transient hypotensive action and a slow onset, protracted effect. The The substance acute effect is due to the presence of prostaglandin^^'^^^ responsible for the delayed response is also lipid in character, however, it appears to be a neutral lipid and not in the prostaglandin fa~nily~"~~.
_ I _
.
.
Chap. 6
E t i o l o g y of Hypertension
DuCharme
53
The s o u r c e of t h e r e n a l medullary a n t i h y p e r t e n s i v e s u b s t a n c e s app e a r s t o be t h e i n t e r s t i t i a l c e l l s l o c a t e d p r i m a r i l y i n t h e p a p i l l a . G r a n u l a t i o n of t h e s e c e l l s and presumably s e c r e t i o n h a s been demonstrated t o r e f l e c t changes i n blood p r e s s u r e of animals s u b j e c t e d t o e x p e r i m e n t a l hyperten~ion~~~ R e~c'e.n t l y , r a b b i t i n t e r s t i t i a l c e l l s have been grown i n t i s s u e c u l t u r e * 9 . The c e l l s were o b t a i n e d from a u t o t r a n s p l a n t s of r e n a l medulla which prevented r e n o v a s c u l a r and r e n o p r i v a l t y p e s of h y p e r t e n s i o n . E x t r a c t s of t h e c u l t u r e d c e l l s were shown t o c o n t a i n t h e t h r e e r e n a l medullary p r o s t a g l a n d i n s PGE2, PG% and PGF2 The p o s s i b l e r o l e of p r o s t a g l a n d i n s i n t h e p a t h o g e n e s i s of a r t e r i a l h y p e r t e n s i o n i s of g r e a t i n t e r e s t , s i n c e some p r o s t a g l a n d i n s n o t o n l y d i l a t e p e r i p h e r a l r e s i s t a n c e v e s s e l s but a l s o possess n a t r i u r e t i c a c t i v i t y 0 . I t i s t h e r e f o r e tempting t o s p e c u l a t e t h a t a d e f i c i e n c y of r e n a l p r o s t a g l a n d i n s might lead t o a r t e r i a l h y p e r t e n s i o n . R e l e a s e of p r o s t a g l a n d i n s i n t o t h e r e n a l venous blood has been demonstrated i n r e s p o n s e t o vasoc o n s t r i c t o r s t i m u l i o r r e n a l i ~ c h e m i a ' ~ ' ~ ~Most . s t u d i e s have suggested t h a t t h e primary v a s o d i l a t o r p r o s t a g l a n d i n r e l e a s e d from t h e kidney i s PGE2, b u t because of i t s r a p i d metabolism by t h e lungs PGE2 could n o t f u n c t i o n a s a g e n e r a l v a s o d i l a t o r hormone. A l t e r n a t i v e l y , r e n a l p r o s t a g l a n d i n s may e x e r t an a n t i h y p e r t e n s i v e a f f e c t through an a c t i o n w i t h i n t h e kidney t o m a i n t a i n normal r e n a l r e s i s t a n c e and p r e v e n t sodium and water accumulation. Lee has suggested t h a t PGAs, on t h e o t h e r hand, may be c i r c u l a t i n g a n t i h y p e r t e n s i v e hormones, s i n c e t h e y a r e much more r e s i s t a n t t o m e t a b o l i c d e g r a d a t i o n on p a s s i n g through t h e lungs55. There i s c o n t r o v e r s y , however, p e r t a i n i n g t o t h e a b i l i t y of t h e kidney t o form A prostaglandin^^^. Nonet h e l e s s , two groups have r e p o r t e d t h a t c i r c u l a t i n g l e v e l s of PGA a r e lower i n h y p e r t e n s i v e t h a n normotensive i n d i v i d u a l s , and a r e v i r t u a l l y a b s e n t i n t h e blood of a n e p h r i c 5y. While t h e h y p o t h e s i s t h a t p r o s t a g l a n d i n s f u n c t i o n a s a n t i h y p e r t e n s i v e hormones i s c e r t a i n l y a t t r a c t i v e , i t i s obvious t h a t much a d d i t i o n a l work i s n e c e s s a r y f o r v e r i f i c a t i o n .
-
The autonomic nervous system a l s o i s i m p l i c a t e d Autonomic Nervous System i n t h e p a t h o g e n e s i s of h y p e r t e n s i o n . S e v e r a l i n v e s t i g a t o r s have suggested t h a t heightened s y m p a t h e t i c nerve a c t i v i t y may u n d e r l i e t h e i n i t i a l l a b i l e phase of hypertension6"' 'O. This h y p o t h e s i s i s supported by e x p e r i m e n t a l s t u d i e s which demonstrated t h a t removal of t h e sympathetic nervous system c h e m i c a l l y o r immunologically prevented t h e o n s e t of g e n e t i c o r mineraloc o r t i c o i d hypertension60, 61. On t h e o t h e r hand, t h e s e p r o c e d u r e s were i n e f f e c t i v e i n r e d u c i n g t h e blood p r e s s u r e of animals i n which t h e hypertension w a s established p r i o r t o Conversely, t h e o n s e t of r e n a l h y p e r t e n s i o n i s n o t prevented by sympathectomy, b u t maintenance of t h i s form of e x p e r i m e n t a l h y p e r t e n s i o n a p p e a r s t o be dependent upon a n i n t a c t , f u n c t i o n a l s y m p a t h e t i c nervous system64. Involvement of t h e sympat h e t i c nervous system i n h y p e r t e n s i v e d i s e a s e i s a l s o suggested by t h e a n t i h y p e r t e n s i v e e f f i c a c y of t h e many sympathetic s u p p r e s s a n t drugs. Many c l i n i c a l s t u d i e s have been conducted i n an a t t e m p t t o q u a n t i t a t e t h e d e g r e e of s y m p a t h e t i c n e u r o n a l involvement i n v a r i o u s forms of human h y p e r t e n s i o n . These s t u d i e s have shown t h a t n e u r a l l y mediated v a s o c o n s t r i c t o r t o n e i s en-
54 -
Sect, I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
hanced i n most h y p e r t e n s i v e s u b j e c t s , b u t i t s r o l e i n t h e maintenance of t h e h y p e r t e n s i v e s t a t e i s c o n t r o v e r s i a l . The r e a d e r i s r e f e r r e d t o two . r e c e n t a r t i c l e s which a d d r e s s t h i s q u e s t i o n i n g r e a t e r d e t a i l 6 5 Y ~ ~There would seem t o be l i t t l e doubt t h a t t h e autonomic nervous system i s i n volved i n t h e h y p e r t e n s i v e process. Whether i t p l a y s a primary o r p e r missive r o l e i n t h e p a t h o g e n e s i s of t h e d i s e a s e , however, i s i n q u e s t i o n .
-
Genetic F a c t o r s The f a c t t h a t t h r e e independent groups have s u c c e s s f u l l y bred s t r a i n s of h y p e r t e n s i v e r a t s i n d i c a t e s t h a t g e n e t i c f a c t o r s a r e a l s o e x t e n s i v e l y involved i n t h e g e n e s i s of h y p e r t e n ~ i o n ~ ~ ' ~Many ". investig a t o r s b e l i e v e t h a t t h e spontaneously h y p e r t e n s i v e r a t (SHR) i s t h e model of e x p e r i m e n t a l h y p e r t e n s i o n which most c l o s e l y resembles e s s e n t i a l human h y p e r t e n ~ i o 70. n ~ ~ ~The e t i o l o g y of t h e h y p e r t e n s i o n which occurs i n t h e s e s t r a i n s , however, has n o t been d e f i n e d . The r e s u l t s of many s t u d i e s which have been conducted w i t h SH r a t s a r e h i g h l y q u e s t i o n a b l e , because app r o p r i a t e c o n t r o l animals a r e u n a v a i l a b l e . Normotensive r a t s of even t h e same s t r a i n o b v i o u s l y a r e g e n e t i c a l l y d i f f e r e n t from t h e i r h y p e r t e n s i v e r e l a t i v e s , and, t h e r e f o r e , a r e q u e s t i o n a b l e c o n t r o l s . The one e x c e p t i o n appears t o be t h e Dahl s t r a i n . These animals r e q u i r e a d m i n i s t r a t i o n of s a l t t o induce t h e hypertension. Therefore, one can have g e n e t i c a l l y s i m i l a r animals w i t h and w i t h o u t h y p e r t e n s i o n . Renal t r a n s p l a n t a t i o n experiments w i t h t h e Dahl SH r a t s have shown t h a t t h e kidney i s d e f i n i t e l y involved i n t h e p a t h o g e n e s i s of t h e h y p e r t e n ~ i o n ~ ~ - ~The ' . specific etio l o g i c f a c t o r s , however, have n o t been d e f i n e d . Although many f a c t o r s undoubtedly modify t h e p a t h o g e n e s i s of hypert e n s i o n , t h e b u l k of evidence p o i n t s toward t h e kidney a s t h e f o c a l p o i n t . F u t u r e s t u d i e s d i r e c t e d toward a c a r e f u l d e f i n i t i o n of r e n a l prohypert e n s i v e and a n t i h y p e r t e n s i v e f a c t o r s coupled w i t h r e n a l e x c r e t o r y f u n c t i o n and autonomic nerve a c t i v i t y would appear t o be most l i k e l y t o y i e l d t h e u l t i m a t e s o l u t i o n t o t h i s complex problem. References 1. 2.
3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.
E. D. F r o h l i c h , Ann. I n t . Med., 78, 7 1 7 , 1973. H. G o l d b l a t t , S. Lynch, R. F. Hanzel and W. W. Summerville, J. Exp. Med., 5 9 , 347, 1934. L. Tobian, J. Janecek, A. Tomboulian and D. F e r r e i r a , J. C l i n . I n v e s t . , 40, 1922, 1961. L. Tobian, R. Olson and G. Chesley, Amer. J. P h y s i o l . , 216, 2 2 , 1969. L. Tobian and G. Chesley, Proc. SOC. Exptl. Biol. Med., 340, 1966. L. Tobian and J. T. Binion, C i r c u l a t i o n , 5 , 754, 1952. D. S h o r t , B r i t . Heart J . , 28, 184, 1966. B. Folkow, Clin. S c i . , i l , 1, 1971. R. S i v e r t s s o n , Acta Physiol. Scand., Suppl. 343, 1970. P. Redleaf and L. Tobian, Circ. Res., 6 , 185, 1958. D. F. Bohr, Fed. Proc., 33, 1 2 7 , 1974. S. Koletsky, I n t . Rev. Exp. Path., 2, 203, 1973. J. H. S t e i n and T. F. F e r r i s , Arch. I n t . Med., 860, 1973. J. H. Laragh, L. Baer, H. R. Brunner, F. R. Buhler, J. E. S e a l e y and E. D. Vaughan, Amer. J. Med., 52, 633, 1972.
-
121,
131,
Chap. 6
E t i o l o g y of Hypertension
DuCharme
55
15. A. R. C h r i s t l i e b , T.U.L. B i b e r , and R. B. H i c k l e r , J. Clin. I n v e s t . , 48, 1506, 1969. 16. 7 Bing and K. Poulsen, Acta Path, Microbiol. Scand., 7 8 , 6, 1970. 17. H. R. Brunner, J. D. Kirshman, J. E. S e a l e y and J. H. Laragh, Science, 174, 1344, 1971. 18. T T . P a l s , F. D. Masucci, G. S. Denning, F. Sipos and D. C. F e s s l e r , C i r c . Res., 2, 673, 1971. 19. F. M. Bumpus, S. Sen, R. R. Smeby, C. Sweet, C. M. F e r r a r i o and M. C. Khosla, Circ. Res., 32, Suppl. 1, 150, 1973. 20. G. E. Wakerlin, R. B. B i r d , B. B. Brennan, M. H. Frank, S. H. Kremen, I. Kuperman and J. H. Skom, J. Lab. Clin. Med., 4 l , 708, 1953. 2 1 . S. H. Kremen and G. E. Wakerlin, Proc. SOC. Exptl. B i o l . Med., 90, 9 9 , 1955. 22. E. Haas and H. G o l d b l a t t , Amer. J. P h y s i o l . , 197, 1303, 1959. 23. R. W. H i l l , J. E. Chester and P. E. Wisenbaugh, Lab. I n v e s t . , 22, 404, 1970. 24. I. Eide and H. Aars, Nature (London), 222, 571, 1969. 25. W. J. Louis, G. J. Macdonald, V. R e n z i n i , G. W. Boyd and W. S. P e a r t , Lancet, 1, 333, 1970. 26. A. Grollman, Proc. Soc. Exptl. Biol. Med., 1120, 1970. 27. A. Grollman and V. S. R. Krishnamurty, Amer. J. P h y s i o l . , 221, 1499, 197 1. 28. J. M. Ledingham and R. D. Cohen, Clin. S c i . , 22, 69, 1962. 29. J. M. Ledingham and R. D. Cohen, Can. Med. Assoc. J., 90, 292, 1964. 30. C. M. F e r r a r i o , I. H. Page and J. W. McCubbin, Circ. R e s . , 27, 799, 1970. 31. T. G. Coleman, H. J. Granger and A. C. Guyton, Circ. Res., 28, Suppl. 11, 76, 1971. 32. T. G. Coleman, J. D. Bower and H. G. Langford, C i r c . , 42, 509, 1970. 33. J. Brod, M. Cachovan, H. -U. Pixburg and P. Harmjanz, Therapiewoche, 45, 4258, 1973. 34. W. DuCharme and L. Beck, J. Pharmacol. Exp. Ther., 177, 56, 1971. 35. J. R. Powell and D. W. DuCharme, Amer. J. Physiol., 2,168, 1974. 36, H. S. Margolius, R. G. Geller, W. deJong, J. J. P i s a n o , and A. Sjoerdsma,Circ. Res., 2, Suppl. 11, 125, 1972. 37. M. Marin-Grez, P. Cottone and 0. A. C a r r e t e r o , Amer. J. P h y s i o l . , 9, 794, 1972. 38. E. E. Muirhead, J. A. Stirman, W. Lesch and F. Jones, Surg. Gynecol. O b s t e t . , 103, 673, 1956. 39. E. E. Muirhead, F. Jones and J. A. Stirman, J. Lab, Clin. Med., 56, 1 6 7 , 1960. 40. E. E. Muirhead, J. A. Stirman and F. Jones, J. Clin. I n v e s t . , 39, 266, 1960. 41. E. E. Muirhead, G. B. Brown, G. S. Germain and B. E. Leach, J. Lab. Clin. Med., 7 6 , 641, 1970. 42. R. B. H i c k l e r , D. P. L a u l e r , C. A. S a r a v i s , P. I. Vagnucci, G. S t e i n e r and G. W. Thorn, Can. Med. Ass. J., 90, 280, 1964. 43. E. G. D a n i e l s , J. W. Hinman, B. E. Leach and E. E. Muirhead, Nature (London), 215, 1298, 1967. 44. E. E. Muirhead, J. W. Hinman, E. G. D a n i e l s , M. Kosinski and B. Brooks, J. C l i n . I n v e s t . , 41, 1387, 1962.
134,
56
Sect. I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
45. J. B. Lee, R. B. H i c k l e r , C. A. S a r a v i s and G. W. Thorn, C i r c . Res., 13, 359, 1963. 46. E. E. Muirhead, B. Brooks, M. K o s i n s k i , E. G. Daniels and J. W. Hinman, J. Lab, Clin. Med., 67, 778, 1966. 47. R. C. Muehrcke, A. K. Mandal, M. E p s t e i n and F. I. V o l i n i , J. Lab. C l i n , Med., 7 3 , 299, 1969. 48. L. Tobian, M. I s h i i and M. Duke, J. Lab. Clin. Med., 73, 309, 1969, 49. E. E. Muirhead, G. Germain, B. E. Leach, 3. A. P i t c o c k , P. Stephenson, B. Brooks, W. L. B r o s i u s , E. G. D a n i e l s and J. W. Hinman, C i r c . Res., 31, Suppl. 11, 161, 1972. 50. 7 C. McGiff and H. D. I t s k o v i t z , Circ. Res., 33, 479, 1973. 51. J. C. McGiff, K. Crowshaw, N. A. Terragno and A. J. Lonigro, Circ. Res., 27, Suppl. I , 121, 1970. 52. J. C. McGiff, K. Crowshaw, N. A. Terragno, K. U. Malik and A. J. Lonigro, Clin. S c i . , 42, 223, 1972. 53. E. W. Dunham and B. G. Zimmerman, Amer. J. P h y s i o l . , 219, 1279, 1970. 54. J. C. McGiff, K. Crowshaw, N. A. Terragno, A. J. Lonigro, J. C. S t r a n d , M. A. Williamson, J. B. Lee and K. K. F. Ng, Circ. Res., 27, 765, 1970. 55. J.' B. Lee, New Engl. J. Med. , 277, 1073, 1967, 56. R. M. Zusman, B. V. Caldwell, P. J. Mulrow and L. S p e r o f f , P r o s t a g l a n d i n s , 2 , 679, 1973. 57. J. B. Lee, A. A t t a l l a , V. K. Vance, C. Elwood and A. Prezyna, J. Clin. I n v e s t . , 52, SOa, 1973. 58. E. D. F r o h l i c h , V. J. Kozul, R. C. T a r a z i and H. P. Dustan, Circ. Res., 27, Suppl. I , 55, 1970. 59. B. Folkow, M. H a l l b i c k , Y. Lundgren, R. S i v e r t s s o n and L. Weiss, C i r c . Res., 32, Suppl. I , 2 , 1973. 60. G. H a e u s l e r , L. Finch and H. Thoenen, E x p e r i e n t i a , 28, 1200, 1 9 7 2 . 61. B. Folkow, M. Hallbxck, Y. Lundgren and L. Weiss, Acta P h y s i o l . Scand., 84, 512, 1972. 62. Ayitey-Smith and D. R. Varma, B r i t . J. Pharma., 40, 175, 1970. 63. D. W. C l a r k , C i r c . Res., 28, 330, 1971. 64. L. D. Dorr and M. J. Brody, Proc. SOC. Exptl. B i o l . Med., 123, 155, 1966. 65. R. C. T a r a z i and H. P. Dustan, Clin. S c i . , 44, 1 9 7 , 1973. 66. P. I. Korner, J. Shaw, J. B. Uther, M. J. West, R. J. McRitchie and J. G. Richards, Circ. 48, 107, 1973. 2 2 7 , 1969. 67. K. Okamoto, I n t . Rev, Exp. Path. , 7 2 7 , 1958. 68. F. H. Smirk and W. H. H a l l , Nature (London), 69. L. K. Dahl, M. Heine and L. T a s s i n a r i , Nature (London), 3,480, 1962. 70. S. Udenfriend and S. S p e c t o r , Science, 1155, 1972. 71. L. K. Dahl, K. D. Knudsen and 2. J u n e c h i , Circ. Res., 27, Suppl. 11, 277, 1970. 7 2 . L. K. Dahl, M. Heine and K. Thompson, C i r c . Res., 34, 94, 1974. 73. L. Tobian, Am. J. Med., 52, 595, 1972.
1,
182,
176,
Chapter 7.
A n t i h y p e r t e n s i v e Agents
John E . F r a n c i s , R e s e a r c h Department, P h a r m a c e u t i c a l s D i v i s i o n CIBA-GEIGY C o r p o r a t i o n , A r d s l e y , N. Y. 10502 New P r o d u c t s - I n F e b r u a r y 1973, S c h e r i n g C o r p o r a t i o n i n t r o d u c e d d i a z o x i d e ( I ) as H y p e r s t a t I . V . l , t h e f i r s t a n t i h y p e r t e n s i v e a g e n t t o r e a c h t h e U. S . market i n t e n y e a r s . I t was a l s o marketed t h i s y e a r i n S w i t z e r l a n d and Germany? S u g g e s t e d u s e i s f o r emergency i n t r a v e n o u s a d m i n i s t r a t i o n t o h o s p i t a l i z e d p a t i e n t s w i t h m a l i g n a n t h y p e r t e n s i o n , f o r which i t i s claimed t o b e a welcome and e f f e c t i v e t r e a t m e n t ? I n a r e c e n t c l i n i c a l s t u d y i t was o r a l l y e f f e c t i v e , sometimes combined w i t h a B - a d r e n e r g i c b l o c k e r , i n some p a t i e n t s w i t h s e v e r e and r e f r a c t o r y forms of h y p e r t e n s i o n : Debrisoquin ( D e c l i n a x , 11) w a s i n t r o d u c e d i n October i n S w i t z e r l a n d by HoffmannLaRoche? Long known f o r i t s u t i l i t y i n s e v e r e h y p e r t e n s i o n , t h i s d r u g gave good r e s u l t s i n a r e c e n t s t u d y o f m i l d t o m o d e r a t e l y s e v e r e hypert e n s i v e s ? P r o p r a n o l o l ( I n d e r a l , 111) t h e o n l y @ - b l o c k e r a v a i l a b l e on t h e U. S . m a r k e t 6 , i s n o t y e t i n d i c a t e d f o r t h e t r e a t m e n t of h y p e r t e n s i o n i n t h e U.S.A!
CI
Me 9” OCHzCHCI$ NH-CH /
aye
I
Me
P”
0“ “0
II
NH
I
I1
-
111
Drups i n C l i n i c a l I n v e s t i g a t i o n Although many s i n g l e d r u g s were e v a l u a t e d , c l i n i c a l s t u d i e s i n 1973 r e f l e c t e d a growing t r e n d t o c o m b i n a t i o n t h e r a p y . C l o n i d i n e ( C a t a p r e s , ST-155 , IVa) , marketed i n Europe, w a s found t o b e e f f e c t i v e a t low d o s e s w i t h o u t p o s t u r a l h y p o t e n s i o n o r l a s t i n g s e d a t i v e s i d e e f f e c t s i n two l o n g term s t u d i e s ? y g A comparison w i t h r e s e r p i n e i l l u s t r a t e d c l o n i d i n e ’ s l a c k of d e p r e s s i v e r e a c t i o n s ” and t h e c o m b i n a t i o n w i t h c h l o r t h a l i d o n e (Combipres) w a s even more e f f e c t i v e t h a n c l o n i d i n e alone:’ The d a n g e r o f h y p e r t e n s i v e rebound and o t h e r s i d e e f f e c t s on One s t u d y d e s c r i b e d t h e sudden w i t h d r a w a l from c l o n i d i n e was n o t e d ? ,1 d r u g as s a f e and e f f e c t i v e f o r emergency t r e a t m e n t 1 4 whereas a n o t h e r r e p o r t e d s e r i o u s p r e s s o r e f f e c t s when p a t i e n t s w i t h a c c e l e r a t e d h y p e r t e n s i o n were t r e a t e d i n t r a v e n o u s l y ! New p h a r m a c o l o g i c a l s t u d i e s ’ 6 - 2 1 on t h e d r u g and i t s m a j o r m e t a b o l i t e , 4 - h y d r o x y - c l o n i d i n e Y s u p p o r t a mode of a c t i o n i n v o l v i n g s t i m u l a t i o n o f c e n t r a l a - r e c e p t o r s . These r e c e p t o r s may b e c o n n e c t e d t o a n i n h i b i t o r y n e u r o n , t h e a c t i v a t i o n of which c a u s e s a d e p r e s s i o n of p e r i p h e r a l s y m p a t h e t i c a c t i o n and a b l o o d p r e s s u r e f a l l ? ’ The r e l a t e d compound IVb, i n p h a s e I o f c l i n i c a l t r i a l s i n Europe, i s a c t i v e a t 0.2-0.4 mg./day i n man w i t h maximal h y p o t e n s i o n a t 4-5 hoursZ3
58 -
Sect. I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
The mechanism of a c t i o n o f indoramine ( V ) has been r e ~ i e w e d ? A~ r e c e n t c l i n i c a l t r i a l , however, was d i s a p p o i n t i n g due t o t h e s i d e e f f e c t s ~bserved?~ Guanabenz (WY 8678, BR 750, FLA 137, V I ) i n a n i m a l s shows a potency l e s s t h a n c l o n i d i n e b u t g r e a t e r t h a n g u a n e t h i d i n e w i t h a mechanism I n i t i a l c l i n i c a l t r i a l s showed showing s i m i l a r i t i e s t o b o t h d r u g s ? 6,2 t h e same potency r a n k i n g ? 8 y 2 9 The d r u g w a s e f f e c t i v e and f u r t h e r improved by h y d r o c h l o r t h i a z i d e a d d i t i o n T 8 The p r i n c i p a l s i d e e f f e c t w a s d r o w s i n e s s .
Ar=2 ,6 - d i c h l o r o p h e n y l N-CO- CGH5 Ar-3-( 2-chloro-4-methyl) V H VI th ieny 1 Guanadrel (U-28288D, V I I ) , e q u i p o t e n t t o g u a n e t h i d i n e i n t h e c l i n i c , a p p e a r s t o o f f e r more s t a b l e b l o o d p r e s s u r e c o n t r o l d u r i n g t h e day w i t h less f r e q u e n t d i a r r h e a ? ' S t u d i e s on g u a n c y d i n e ( V I I I ) c o n t i n u e d t o s u p p o r t t h e mechanism of a d i r e c t v a s c u l a r e f f e c t 3 ' w i t h p a r t i a l d e p l e t i o n o f norepinephrine s t o r e s observed only a f t e r high c h r o n i c d o s i n g under certain conditions?' I
IVa: IVb:
NH
V II
VIII
IX
M i n o x i d i l (U-10,858, I X ) i s a u s e f u l h y p o t e n s i v e a g e n t i n uremic p a t i e n t s w i t h s e v e r e h y p e r t e n ~ i o no~r ~ t h o s e w i t h m a l i g n a n t o r a c c e l e r a t e d h y p e r t e n s i o n r e f r a c t o r y t o c o n v e n t i o n a l d r u g s ? 4 Compared t o h y d r a l a ~ i n e ? ~ t h e d r u g was more p o t e n t , l o n g e r a c t i n g and showed no s i g n s o f t o l e r a n c e development. It c a u s e s a marked i n c r e a s e i n serum r e n i n a c t i v i t y , 3 6 ' 3 7 c a r d i a c h y p e r a ~ t i v i t y qand ~ sodium r e t e n t i o n 3 4 ' 3 5 b u t c o - a d m i n i s t r a t i o n of a @ - b l o c k e r and a d i u r e t i c c o u n t e r a c t s t h e s e s i d e effect^$'^^-^^ The pharmacological p r o f i l e i s t h a t of a p o t e n t , o r a l l y e f f e c t i v e , long a c t i n g h y p o t e n s i v e i n r a t s , dogs and monkeys w h i c h works p r i m a r i l y by a p e r i M i n o x i d i l i s n o n - t o x i c i n r a t s , monkeys p h e r a l v a s o d i l a t o r mechanism? and m i n i p i g s b u t c a u s e s a d e g e n e r a t i v e l e s i o n i n t h e r i g h t a t r i u m of dogs a f t e r p r o l o n g e d d a i l y d o s i n g . D i s c r e p a n c y between t h e p r o l o n g e d a c t i o n and r a p i d c l e a r a n c e from plasma was e x p l a i n e d by s p e c i f i c r e t e n t i o n of t h e I t may i n t e r f e r e w i t h some c e l l u l a r comd r u g i n v a s c u l a r smooth muscle. ponent ( c a l c i u m ? ) of t h e c o n t r a c t i l e p r o c e s s ? ' Another p e r i p h e r a l d i l a t o r , p r a z o s i n (CP-12299-1, X ) gave good r e s u l t s i n a r e c e n t t r i a l (1.5 t o 15 mg./day) even w i t h o u t a d i u r e t i c 4 ' i n m o d e r a t e l y s e v e r e hypert e n s i v e s . A n o t h e r member o f t h i s s t r u c t u r a l t y p e , t r i m a z o s i n (CP-19106, X I )
Chap. 7
A n t i h y p e r t e n s i v e Agents
Francis
59 -
showed a s t a t i s t i c a l l y s i g n i f i c a n t a n t i h y p e r t e n s i v e e f f e c t a t 50-150 mg/ day i n a group of p a t i e n t s w i t h e s s e n t i a l h y p e r t e n s i o n t 2 The combination drug B r i n e r d i n e ( dihydroergocr i s t i n e -c lopamide -res e r p i n e ) i s c 1i n i c a 1l y e f f e ~ t i v e and ~ ~ more , ~ ~ a c t i v e than any o f i t s s e p a r a t e i n g r e d i e n t s o r combination of two.
Recent c l i n i c a l t r i a l s of p r o p r a n o l o l (111) c o n t i n u e t o i l l u s t r a t e i t s u t i l i t y a s a h y p ~ t e n s i v ew~i t~h a c t i v i t y improved by a d d i t i o n of a v a s o d i l a t o r such as h y d r a l a z i n e i n s e v e r e h y p e r t e n ~ i o no~r ~w i t h hydroc h l o r t h i a z i d e i n mild t o moderate h y p e r t e n s i o n t 7 There i s i n c r e a s i n g evidence t h a t t h e drug reduces plasma r e n i n t 8 - 5 1 Combining p r o p r a n o l o l w i t h a d r e n e r g i c b l o c k e r s and a d i u r e t i c has a l s o been recommended?2 Int r a c e r e b r o v e n t r i c u l a r ( i c v ) s t u d i e s of p r o p r a n o l o l i n animals by a number of investigator^^^-^^ have l e d t o t h e view t h a t i t s hypotensive a c t i v i t y i s c e n t r a l l y mediated and depends on t h e i n t e g r i t y of n o r a d r e n e r g i c neurons. Blockade of p-adrenoceptors i n t h e b r a i n i s claimed t o cause hypotension and b r a d y ~ a r d i a ? ~However, i t i s noteworthy t h a t p r a c t o l o l which does n o t ( E r a l d i n , I C I 50172, X I I ) , a c a r d i o s e l e c t i v e c r o s s t h e b l o o d - b r a i n b a r r i e r 5 lowers blood p r e s s u r e v e r y w e l l i n This i s a l s o t r u e f o r a l p r e n o l o l ( A p t i n , X I I I ) 6 2 - 6 5 and I . C . I . 66082 Other p-blockers shown t o lower blood p r e s s u r e i n c l i n i c a l (XIV)$6'67 t r i a l s t h i s y e a r were p i n d o l o l (Visken, LB-46, XV) f 8 - 7 1 t i m o l o l (MK-950,
R-OC$
HChN-C(Meh " H
Li
X I I I : R'=Allyl
XII
XIV
CONH2
X V I I : R'=Allyloxy
0
n
O U N W OCH2F$NH- C(Me& OH N N
's'
XVI
-CH2FHCH2NCH&4 OH H
QO
Me XVIII
60 -
S e c t . I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
X V I ) j 2 - 7 4 ~ h i w~ ahs c o n s i d e r a b l y more p o t e n t t h a n p r o p r a n o l o l i n animals 7 5 ~ 7 6 and man, and o x p r e n o l o l ( T r a s i c o r , X V I I ) j 7 - 7 9 w h i c h w a s a l s o v e r y s u c c e s s f u l when combined w i t h c y c l o p e n t h i a z i d e s O i n a l a r g e s c a l e s t u d y . Tolamolol (m 6558, XVIII) c a u s e d a pronounced b l o o d p r e s s u r e f a l l i n 3 o f 4 normot e n s i v e humans?' Many a n a l o g s have b e e n d e s c r i b e d Though c a r d i o s e l e c t i v e @ - b l o c k e r s a r e a n improvement o v e r n o n - s e l e c t i v e @ - b l o c k e r s , f o r example, i n p a t i e n t s w i t h a s t h m a , e a c h r e d u c e s c o n t r a c t i l e f o r c e a l o n g w i t h h e a r t r a t e . A " c h r o n o s e l e c t i v e " B-blocker i s s t i l l t o b e f o u n d . 8 3
N a t u r a l P r o d u c t s and R e l a t e d Compounds - A v a s o d e p r e s s o r f a c t o r (VDF) was i s o l a t e d from c a n i n e plasma and a o r t i c t i s s u e and human plasma.84 The p o l y p e p t i d e , m o l e c u l a r w e i g h t -G!OOO, c o n t a i n i n g g l u t a m i c a c i d , p r o l i n e and g l y c i n e as p r i n c i p a l components , r a p i d l y lowers b l o o d p r e s s u r e i n r a t s when g i v e n i . v . VDF l e v e l s i n c r e a s e i n dogs d u r i n g induced hemorrhagic shock and h i g h l e v e l s a r e s e e n i n p a t i e n t s w i t h d i f f e r e n t t y p e s o f shock. A t r i d e c a p e p t i d e c a l l e d n e u r o t e n s i n i s o l a t e d from b o v i n e h y p o t h a l a m i i s composed o f Lys, Arg,, Asx, Glx,, P r o 2 , I l e u , L e u 2 , T y r Z a 5 and i s a c t i v e i n r a t s a t 100 pmoles/kg. S y n t h e t i c p e p t i d e s o r i g i n a l l y i s o l a t e d from Bothrops jararaca venom, s p e c i f i c i n h i b i t o r s of a n g i o t e n s i n - c o n v e r t i n g enzyme, c o n t i n u e t o a p p e a r p r o m i s i n g as d i a g n o s t i c t o o l s and p e r h a p s i n t r e a t m e n t o f r e n a l h y p e r t e n s i o n ? 6 - 8 8 A s t u d y of 57 r e l a t e d p e p t i d e s i n d i c a t e s t h a t t h e C-terminal sequence Pro-Gln-Ileu-Pro-Pro is r e q u i r e d f o r The significant i n h i b i t i ~ n . ~ ~ a n g i o t e n s i n I1 a n t a g o n i s t e f f e c t o f S a r 1 - a l a 8 - a n g i o t e n s i n I1 was confirmed i n dog m o d e l s g 0 ,91 and i n man.92 Hypotension w a s a c h i e v e d i n h y p e r t e n s i v e p a t i e n t s w i t h h i g h r e n i n l e v e l s b u t n o t i n t h o s e w i t h low o r normal l e v e l s . In vitro studies indicate ( I l e u 8 ) - a n g i o t e n s i n I1 t o b e t h e most p o t e n t a n t a g o n i s t y e t d e v e l o p e d , b u t s u b s t i t u t i o n o f s a r c o s i n e f o r a s p a r t i c a c i d i n t h e one p o s i t i o n i n c r e a s e s i n v i v o a ~ t i v i t y . ' The ~ p e p t i d e from t h e n a t i v e r e n i n s u b s t r a t e Asp-Arg-Val-Tyr-Ileu-His-Pro-Phe-His-Leu-Leu-Val-wr-Ser has b e e n m o d i f i e d s l i g h t l y t o produce c o m p e t i t i v e i n h i b i t o r s of r e n i n . 9 4 The s h o r t e r p e p t i d e His-Pro-Phe-His-Leu-D-Leu-Val-wr is a l s o a potent i n h i b i t o r . 95 A r a c h i d o n i c a c i d is h y p o t e n s i v e i n s p o n t a n e o u s h y p e r t e n s i v e r a t s l i k e l y due t o c o n v e r s i o n t o PGE, s i n c e a c t i v i t y i s i n h i b i t e d by a n t i i n f l a m matory a g e n t s ? 6 The a n t i h y p e r t e n s i v e e f f e c t of PGA, i n man i s t h o u g h t m a i n l y due t o i t s e f f e c t on r e n a l c i r c u l a t i o n where it c a u s e s v a s o d i l a t a t i o n and e x c r e t i o n o f water and sodium. I t a l s o i n h i b i t s a n g i ~ t e n s i n . ~ ~ The h y p o t e n s i v e a c t i v i t y o f A 9 - t e t r a h y d r o c a n n a b i n o l ( X I X ) i n a n i m a l s s u g g e s t s i t as a new l e a d . 9 8 , 9 9 Development of t o l e r a n c e t o t h i s e f f e c t may i n v o l v e a n immunogenic r e a c t i o n . ' O O Methylapogalanthamine ( X X ) , h y p o t e n s i v e i n c a t s , dogs and r a b b i t s , has a d r e n o l y t i c , s p a s m o l y t i c and s e d a t i v e p r o p e r t i e s . I t h a s b e e n approved f o r w i d e c l i n i c a l u s e i n t h e U.S.S.R?" A naphthoquinone ( X X I ) from t h e fungus Corynespora c a s s i c o l a i n h i b i t s catechol-o-methyltransferase i n v i t r o and i s a h y p o t e n s i v e o f l o n g d u r a t i o n ( 2 4 h r s . ) i n s p o n t a n e o u s h y p e r t e n s i v e r a t s a f t e r 12.5 mg/kg i . p . l o 2 F u s a r i c a c i d ( 5 - n - b u t y l p i c o l i n i c a c i d ) a n a l o g s w i t h c h l o r i n e o r bromine i n t h e 3- a n d / o r 4 - p o s i t i o n o f t h e s i d e
Chap. 7
A n t i h y p e r t e n s i v e Agents
Francis
61
c h a i n a r e more p o t e n t dopamine-@-hydroxylase i n h i b i t o r s t h a n t h e p a r e n t compound!03,104 The 4 ' - c h l o r o a n a l o g (FD-008) c a u s e s marked s u s t a i n e d h y p o t e n s i o n i n s p o n t a n e o u s h y p e r t e n s i v e r a t s a t 12.5-25 mg/kg. p . o . I o 5
OH M e I- C H C H $ % q O HOH
Me= (=@ Me
Me0
C5H11
Me
Nhle
xx
xI X
XXI
-
O t h e r Compounds A f f e c t i n g A d r e n e r g i c T r a n s m i s s i o n The p r e d o m i n a n t l y c e n t r a l mode of a c t i o n o f a-methyldopa h a s r e c e i v e d s t r o n g support106-110 and t h e mechanism has been more p r e c i s e l y d e f i n e d . The d r u g is m e t a b o l i z e d i n t h e CNS t o a - m e t h y l n o r e p i n e p h r i n e which may a c t on b r a i n a - a d r e n o c e p t o r s t o c a u s e h y p o t e n s i o n , as do o t h e r p o t e n t a - s t i m u l a n t s g i v e n i c v , 2 2 y 1 1 1 o r may a c t i n d i r e c t l y by r e l e a s i n g n o r e p i n e p h r i n e from a d r e n e r g i c n e u r o n s . The h y p o t e n s i o n c a u s e d by p-hydroxynorephedrine (PHN) i n man i s more l i k e l y due m a i n l y t o a p e r i p h e r a l f a l s e t r a n s m i t t e r mechanism s i n c e t h i s compound d o e s n o t p e n e t r a t e t h e b l o o d - b r a i n b a r r i e r . l 1
*
The p o t e n t a - b l o c k e r 12473JL ( X X I I ) has been s e l e c t e d f o r c l i n i c a l t r i a l from a number o f o x a z o l i d o n e s w i t h a n t i h y p e r t e n s i v e , a n t i a r r h y t h m i c and a n a l g e s i c a ~ t i v i t y . ' ~ Compound ~ , ~ ~ ~ X X I I I i s reported t o be a potent a - b l o c k e r w i t h prolonged action.'15 The p i p e r a z i n e X X I V , p r o b a b l y a n
Et XXII
I
O 1NHOH XXIII
XXIV
@ H
a - b l o c k e r , i s a c t i v e a t 0.2 mg/kg S . C . i n m e t a c o r t i c o i d r a t s 1 1 6 b u t d i s p l a y s CNS d e p r e s s a n t p r o p e r t i e s . Methoxyl s u b s t i t u t i o n i n t h e i n d o l e nucl e i r e d u c e s a c t i v i t y . The t r i c y c l i c s t r u c t u r e XXVa, o r a l l y a c t i v e a t low d o s e s i n h y p e r t e n s i v e r a t s and n e u r o g e n i c d o g s , shows a - b l o c k i n g and n o r e p i n e p h r i n e r e l e a s i n g p r o p e r t i e s : l 7 Several r e l a t e d t r i c y c l i c compounds a r e q u i t e a c t i v e though none a s a c t i v e i n a l l models as XXVa.118y119 L i n e a r i t y of t h e t r i c y c l i c system a p p e a r s e s s e n t i a l f o r a c t i v i t y .
62 -
Sect. I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
R e l a t e d compounds r e p o r t e d as a c t i v e i n animal models are XXVb'20 ( a l s o a p l a t e l e t a g g r e g a t i o n i n h i b i t o r ) and XXVI?21 W-9465-2 (XXVIIa), a c t i v e i n r e n a l and DOCA h y p e r t e n s i v e rats a p p e a r s g u a n e t h i d i n e - l i k e : 2 2 b u t may a l s o r e l e a s e a n t i d i u r e t i c hormone.'23 The most a c t i v e member of a s e r i e s of 48 a n a l o g s i s XXVIIb.lZ4
XXVa
R'H,
XXVb
R=CH3, X=O
X=Hz
XXVIIa
X=H
XXVIIb
X=C1
\S-2395 ( X X V I I I ) , though a n o n - s p e c i f i c p - b l o c k e r , i s much more p o t e n t than p r o p r a n o l ~ l ~ CP-240-S ~~ ( X X I X ) i s more a c t i v e t h a n p r o p r a n s l o l a s a h y p o t e n s i v e i n spontaneous h y p e r t e n s i v e r a t s though less B-blocking.126 The D C I v a r i a n t XXX i s t h e most p o t e n t i n a s e r i e s of @ - b l o c k e r s showing p o s i t i v e i n o t r o p i c and h y p o t e n s i v e a c t i v i t y o r a l l y i n r a t s and d o g s ? 2 7 A s t u d y of t h e a-methyl a n a l o g s of p r o p r a n o l o l and p r a c t o l o l shows t h a t t h e s u b s t i t u t i o n reduces potency b u t i n c r e a s e s c a r d i o s e l e c t i v i t y . '
OH OCH~CHCH~NHCH(M~)~
a XXVIII
OH
Me
xxx
XXIX
-
P e r i p h e r a l V a s o d i l a t o r s and Other A n t i h y p e r t e n s i v e s L-6150 ( X X X I ) , which has h y d r a l a z i n e - l i k e a c t i v i t y w i t h l e s s t o x i c i t y , shows no lupus erythemat o s u s - l i k e syndrome i n C o l l i e dog s t u d i e ~ . ~A ~group ~ , ~of ~3-amino-4~ halosydnone imines r e l a t e d t o PR-G-138 ( X X X I I ) show comparable o r a l a c t i v i t y t o t h e p a r e n t compound i n h y p e r t e n s i v e r a t s (ca. 10 mg/kg).13' Diazoxide a n a l o g s w i t h t h e benzene r i n g r e p l a c e d by t h i o p h e n e , e.g. XXXIII, a r e a c t i v e i n DOCA r a t s and i n dogs.132 The n i c o t i n i c a c i d ester H - 1 ( X X X I V ) i s a h y p o t e n s i v e and v a s o d i l a t o r i n spontaneous h y p e r t e n s i v e rats.l33
n
XXXIII
Ant i h yp er t e n s i v e Ag en ts
Chap. 7
Francis
63 -
XXXV lowers b l o o d p r e s s u r e i n h y p e r t e n s i v e r a t s m a i n l y by a p e r i p h e r a l mechanism.134 Abbott 41596 ( X X X V I ) , t h e b e s t o f a s e r i e s of amino a c i d amides o f dopamine, c a u s e s r e n a l v a s o d i l a t i o n o f 3 h o u r s d u r a t i o n a t 12 mg/kg p.0. i n d o g s ? 3 5 It w i l l b e t e s t e d c l i n i c a l l y f o r p o t e n t i a l p r o p h y l a c t i c u s e i n h y p e r t e n s i o n and i n r e n a l d i s e a s e s . A s e r i e s o f phosp h o d i e s t e r a s e i n h i b i t o r s from Merck show c a r d i o s t i m u l a n t , b r o n c h o d i l a t o r and h y p o t e n s i v e p r o p e r t i e s i n a n i m a l s , I n t h i s s e r i e s , compound X X X V I I shows good h y p o t e n s i o n a t d o s e s t h a t show no c a r d i a c ~ t i m u 1 a t i o n . l ~The ~ c l o n i d i n e a n a l o g X X X V I I I i s a c t i v e a t 0.5 mg/kg p . o . i n r e n a 1 h y p e r t e n s i v e
0
OH
o$ O C H 2 & H C0IH 2
xxx I V
M ee0o a i > , C O M e
HOp , & M e
xxxv
.I
CI
HO
0
Et
J!
AN AN H
XXXVII
XXXVIII
xxx I X
rats? Sandoz 44-549 (XXXIX) c a u s e s s u s t a i n e d h y p o t e n s i o n and bradycardia i n n o r m o t e n s i v e and DOCA rats a t v e r y low d o s e s b u t s l i g h t s t r u c t u r e modif i c a t i o n s d e c r e a s e a c t i v i t y markedly? 3 8 The h y d r o x y g u a n i d i n e s XL, a c t i v e i n low d o s e s i n r e n a l h y p e r t e n s i v e r a t s and h y p e r t e n s i v e d o g s , a p p e a r t o a c t by a d i r e c t c e n t r a l e f f e c t . 1 3 ’ W-1984 ( H C 1 s a l t : W-2587) ( X L I ) i s o r a l l y a c t i v e i n h y p e r t e n s i v e r a t s , dogs and monkeys and i t , t o o , i s t h o u g h t t o a c t ~ e n t r a 1 l y . l C~e~r t a i n 2-carbamoyl-4-nitropyridine-N-oxides a r e h y p o t e n s i v e i n r a t s , dogs and humans. The b e s t of t h e s e a p p e a r s t o b e ~
~
1
1
.
~
4
~
@ N b
I
(MekNCH2CO XL
XLI
XLI I
64 -
Sect.
TI
- Phanwcodynamic
Clarke, E d .
Agents
References 1. 2. 3. 4. 5. 6. 7. 8. 9.
10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36.
37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49.
P. DeHaen, New Product Surveya, 13 (1973) P. DeHaen, ibid.. 70 (1973)
J.ArenaandD.C.McLeod,Drug Intell.,Z,459(1973) P. Kincaid-Smith, Arner. J. Cardiol., 32,575 (1973) A. Buckert, E. Schweda andV. Vich., Schweiz. Rdsch. Med. (Praxis), @, 1453 (1973) M.E. Kosrnan,J. Arner. Med.Ass., 225,1380 (1973) “Physician’s Desk Reference”, B.B. Huff, Ed., Medical EconornicsCo., Oradell, N.J. (1974) S.W. Hoobler, Univ. Mich. Med. Cent. J.,38,98 (1972) J.Raftos,G.E. Bauer, R.G. Lewis, GSStokes, A.S. Mitchell,A.A.Youngand I.MacLachlan, Med. J.Aust.,1,786(1973) D.Schwarz, D.Micheland F. Strain,Arch. Psychiat. Nervenkr.,=8,41 (1973) M. C. Igloe, Curr. Ther. Res., Clin. Exp., 15,559 (1973) S.N.Hunyor, L. Hansson,T.S. Harris0nandS.W. Hoobler, Brit. Med. J.2,209(1973) , 605 (1973) i ! L. Hansson, S.N. Hunyor, S. Juliusand S.W. Hoobler, Arner. Heart J., 8 A.P. Niarchos,andA.K. Baksi, Postgrad. Med. J.42,908 (1973) W.J. Mroczek, M. Davidovand F. A. Finnerty, Jr., Clin. Pharmacol. Ther., 14,847 (1973) J.D. Ehrhardt, Therapie&7,947 (1972) T.J. Bucher, R.E. Buckingharn. L. Finchand R.A. Moore, J. Pharrn. Pharmacol.2_5(Suppl.) 139P (1973) C.T. Dolleryand J.L. Reid, Brit. J. Pharmacol.4_7,206(1973) G. Haeusler, Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharrnakol.. 278,231 (1973) J.R. Reid, R.H. Briantand C.T. Dollery, Life Sci. 12,459 (1973) H. Schrnitt, H. Schrnitt and S. Fenard, Arzneirn.-Forsch. 3 , 4 0 (1973) P.A. VanZwieten, J. Pharrn. Pharrnacol.s.89 (1973) F. Kersting, Arzneirn.-Forsch, 23,1657 (1973) T. Baurn, A.T. Shropshire, D. K. Eckfeld, N. Metz, J. L. Dinish, J.R. Peters, F. Butzand M.I. Gluckrnan, Arch. int. Pharrnacodyn. Ther., &4,390 (1973) P. J. Lewis, C. F. Georgeand C.T. Dollery, Europ. J. Clin. Pharrnacol.,G_,211 (1973) P. Bolrne. H. Corrodi and K.Fuxe, Acta pharrnacol. toxicol.,a (Suppl. I)65 (1972) R. K. Saini, A.P. Caputi and E. Marrno, Farrnaco, Ed. Prat., 359 (1973) F.G. McMahon and P.A. Cole, Clin. Pharrnacol. Therap., 14,142 (1973) D.T. Nash, J. Clin. Pharrnacol. 13,416 (1973) L. Hansson, A. Pascualand S. Julius, Clin. Pharrnacol. Therap. 14,204 (1973) C. Russoand M. Medlowitz, Clin. Pharrnacol. Therap. 13,875 (1973) L. Ellenbogen, P. S. Chan and J. R. Curnmings, Federation Proc.a,522Abstr., Abstr. 1739 (1972) C. J. Lirnasand E. D. Freis, Arner. J. Cardiol.3_!,355 (1973) W.A. Pettingerand H. C. Mitchell, New Engl. J. Med.=9,167 (1973); Clin. Pharrnacol. Therap., 14, 143 (1973) C.D.Chidsey,Clin.Sci.Molec.Med.Q(Suppl. I),171s(1973) W. A. Pettinger, W. B. Campbell and K. Keeton, Circulation Res.a,82 (1973): Federation Proc.32. 765Abstr., Abstr. 31 10 (1973) K. O’Malley, M.Velascoand J.L. McNay, Clin. Res.,a, 953 (1973) W. A. Pettingerand K. Keeton, Clin. Res. 21,472 (1973 D.W. DuCharrne.W. A. Freyburger. B.E. Graham and R.G. Carlson, J. Pharmacol. Exp. Therap., 184, 662 (1973) R.G. Pluss, Orcuttand C.A. Chidsey, J. Lab. Clin. Med., 639 (1972) P. Kincaid-Smith, P. Fang and M.C. Laver, Clin. Sci. Molec. Med.45 (Suppl. I)75s (1973) D. DeGuia, M. Mendlowitz, C. Russo, N. D. Vlachakisand S. Antrarn, Curr. Ther. Res. 12,339 (1973) Y. Goto, K. Hagino,and K.Hara. J. Int. Med. Res. 1,71 (1973) A. N. Britovand L. M. Grebeshkova, Kardiologiya 12,46 (1972) G. Berglund, 0.Andersson, L. Hansson and R . Olander, Acta. Med. Scand. 194,513 (1973) L. Hansson,and A.J. Zweifler, Mich. Med. 72,695 (1973) P. D. Nigarn, R. Ravishankar, K. A. Rarnachandren and P.C. Sikand, J. Int. Med. Res. 1,616 (1973) L.Hansson,Acta.Med.Scand.,Suppl.&0,36 (1973) P. Harnet, 0. Kuchel, J.L.Cuche, R. Boucherand J. Genest,Can. Med. Assoc. J. 1099 (1973)
a,
a,
lm,
Chap. 7
Antihypertensive Agents
Francis
65
50. F. R. Buhler, J.H. Laragh, E. D.Vaughan, H. R. Brunner, H.Gavrasand L.Baer,Amer. J.Cardiol.,Z, 511 (1973) 51. E. L. Bravo, R.C.Taraziand H. P. Dustan, J. Lab. Clin. Med. 83,119 (1974) 52. F. O.Simpson, Curr. Ther. 14,91 (1973) 53. C.T. Dollery, P.J. Lewis, M.G. Myersand J.L. Reid, Brit. J. Pharmacol.a,343P (1973) 54. N. Winer. Clin. Res.2,15A (1974) 55. M. D. DayandA.G. Roach, Federation Proc.a,724Abstr.,Abstr.2879(1973) 56. N. Ram and H.L. Garvey, Federation Proc. g,724Abstr., Abstr. 2880 (1973) 57. R.K. Srivastava,V. K. Kulshrestha, N. Singh and K.P. Bhargava, Eur. J. Pharmacol.a,222 (1973) 58. B.L. Bayer, P. Mentzand W. Foerster, Arch. Int. Pharmacodyn. Ther.a0,341 (1972) 59. L. Offerhausand P.A. Van Zwieten, Europ. J. Clin. Invest.,& 258 (1973) 60. M.D. Eslerand P. J. Nestel, Brit. Heart J.%,469 (1973) 61. R.A. Wood,T.M. Forrester, A.W. Johnstonand K.N.V. Palmer,Clin. Trials J. lJ,53 (1973) 62. J.A. Vedin, C.-E. Wilhelmsson and L. Werko, Brit. Heart J. 1285 (1973) 63. G. Berglund and L. Hansson, Acta Med. Scand. 193,547 (1973) 64. J.Castenfors, H. Johnsson and L. Oro, Acta. Med. Scand., 193,189 (1973) 65. C. FarsangandZ. Nagy,Orv. Hetil.,l-, 196 (1973);C.A.B, 143784e(1973) 549 (1973) 66. L. Hansson, H. Aberg, S. Jameson, B. Karlberg and R. Malmcrona, Acta. Med. Scand. 67. B.R.Graham, D.W. Littlejohns, B.N.C. Pritchard, B.Scalesand P. Southorn, Brit. J. Pharmacol.,@, 154 P (1973) 68. S. deMuckadell and F. Gyntelberg,Europ. J. Clin. Pharmacol.,S, 210 (1973) 69. I. Persson and J. Ulrich, Europ. J. Clin. Pharmacol.5,151 (1973) 70. M. Safar. Y. Weiss, A. Sobel, G. Lagrue and P. Milliez, Nouv. Presse Med. 2,2685 (1973) 71. P.E. Van Coller, J. Int. Med. Res. 1,561 (1973) 72. G. Lohmolleand E. D. Frohlich, Europ. J. Clin. Invest.& 251 (1973) 73. J.A. Franciosa, E.D. Freisand J. Conway, Circulationg, 118 (1973) 74. P.A. Poole-Wilson, J. Int. Med. Res. 1,580 (1973) 75. A.Scriabine,M.L.Torchiana, J.M.Stavorski,C.T. Ludden, D.H. MinskerandC.A.Stone,Arch. Int. Pharmacodyn.a5,76 (1973) 76. R.A.Hall, R.D. Robsonand N.N.Share, Proc. Canad. Fed. Biol.Sci.,lL3,113(1970) 77. A.J. Marshall and D.W. Barritt, Brit. J. Clin. Pract.z,337 (1973) 78. J.Tuckman, F. Messerli and J. Hodler, Clin. Sci. Molec. M e d . , g (Suppl I),159s (1973) 79. G. Muiesan, M. Motoleseand A. Colombi, Clin. Sci. Molec. M e d . 9 (Suppl I),163s(1973) 80. W.A. Forrest, Brit. J. Clin. Pract.,z, 331 (1973) 81. R.H. Briant, C.T. Dollery, T. Fenyvesi and C. F. George, Brit. J. Pharmacol. @, 106 (1973) 82. J. Augstein, D.A. Cox, A.L. Ham, P.R. Leeming and M. Snarey, J. Med. Chem 11,1245 (1973) 83. R.E. Goldstein, Circulation 4_2,443 (1973) 84. J. Rosenthal, J. Paddock and W. Hollander, Circulation Res. 32/33,Suppl. I, 1-169 (1973) 85. R. Carrawayand S.E. Leeman, J. Biol. Chem. 6854 (1973) 86. H.S. Cheung and D.W. Cushman, Biochem. Biophys. Acta, 23,451 (1973) 87. H.F. Loyke, J. Lab. Clin. Med. 82,406 (1973) 88. A. Bianchi, D.B. Evans, M. Cobb, M.T. Peschka.T. R. Schaefferand R.J. Laffan, Europ. J. Pharmacol. 23,90 (1973) 89. D.W. Cushman, J. Pluscec, N.J. Williams, E.R. Weaver, E.F.Sabo, 0.Kocy, H.S. Cheungand M.A. Ondetti, ExperientiaD, 1032 (1973) 90. D.T. Palsand F.D. Masucci, Europ. J. Pharmacol. 23,115 (1973) 91. B.G. Zimmerman, J. Pharmacol. Exp. Therap. l-,486 (1973) 92. H.R. Brunner, H. Gavras,J.H. Laragh and R. Keenan, Lancet W/11,1045 93. F.M. Bumpus, S.Sen, R.R. Smeby, C.Sweet, C.M. Ferrarioand M.C. Khosla, Circulation Res.32/33, SUPPI.I, 1-150 (1973) 94. I . Parikhand P. Cuatrecasas, Biochem. Biophys. Res. Commun.,&I, 1356 (1973) 95. E. Haber, K. Poulsen and J. Burton, Clin. Res. 716 (1973) 96. M. Cohen, J. Sztokalo and E. Hinsch, LifeSci. 13,317 (1973) 97. A. Hornych, M. Safar, N. Papanicolaou, P. Meyerand P. Milliez, Ann. Med. interne I.%, 355 (1973) 98. R.B. Williams, K.R. Lamprecht and I.J. Kopin, Psychopharmacologiaa, 269 (1973) 99. I.Cavero,T. Solomon, J.T. Buckleyand B.S. Jandhyala, Res. Commun, Chem. Pathol. Pharmacol. 6. 527 (1973)
s,
m,
w,
a,
_-66
Sect. I1 - Pharmacodynamic Agents
Clarke, Ed.
100. G. Nahas, I.Schwartz, J. Palacekand D.Zagury, C.R.Acad. Sci., Ser. D , m , 6 6 7 (1973) 101.U. B. Zakirov, Kh. U. Alievand I.M. Karnilov, Farrnakol. Toksikol.tj, 708 (1972) 102.H. Chimura, T. Sawa, Y. Kumada, F. Nakamura, M. Matsuzaki,T.Takita, T.Takeuchi and H. Umezawa, J. Antibiot.z, 618 (1973) 103. H. Hidaka,T,Asanoand N.Takernoto, Mol. Pharmacol.,Q,172 (1973) 104. H. Umezawa,T.Takeuchi, K. Miyano,T. KoshigoeandH.Harnano,J.Antibiot.,& 189(1973) 105. Y. Ishii, Y. Fujii,and H. Urnezawa,Jap. J. Pharrnacol.a, Supp1.,53,Abstr. 76 (1973) 106. M. D. Day, A.G. Roach and R.L. Whiting, Europ. J. Pharrnacol., 21,271 (1973) 107. L. Finchand G. Haeusler, Brit. J. PharrnacoI.,a,217 (1973) 108. A. Heiseand G. Kroneberg, Naunyn-Schrniedebergs Arch. Pharrn.279,285 (1973) 109. M.L.Torchiana,V.J. L0tti.C. M. Clarkand C.A.Stone,Arch. Int. Pharrnacodyn.2&5,103(1973) 110. M.J.Antonaccio, R.D. Robson and R. Burrell, Europ. J. Pharrnacol.,a, 9 (1974) lll.T.BaurnandA.T.Shropshire, NeuropharrnacologyQ,49(1973) 112. R. E. Rangno, J. S. Kaufrnan, J. H. Cavanaugh, D. Island, J. T. Watson and J. Oates, J. Clin. Invest., 52,952 (1973) 113.TMaillard, M.Langlois,V.V.Tri, P. Delaunay, R. Morin, M. Benharkate, C. Manuel and F. Motosso. Chim.Ther.8,393 (1973) 114. J. Maillard, M. Langlois, P. Delaunay, T. V. Van, J. Chenu, R. Morin, M. Benhartake, C. Manuel and F. Motosso, J. Med. Chern. 13,1123 (1972) 115. L. I.Wiebe,R.T.CouttsandA.A. Noujaim,Arzneirn.-Forsch.,a,466 (1973) 116. K. Brewster, D.M. Green, R. M. Pinderand P.B.J.Thornpson, Clin. Ther.,& 169 (1973) 117. J.P. Buyniski, R.L. Cavanaugh and M.E. Bierwagen, Res. Cornrnun. Chern. Pathol. Pharmacol.5, 647 (1973) 118.T. Jen, P. Bender, H. Van Hoeven, B. Loev, J. Med. Chern. 16,407 (1973) 119. T. Jen, B. Daniel, F. Dowalo, H. Van Hoeven, P. Bender and 8. Loev, J. Med. Chern. 12,633 (1973) 120. Bristol-Myers Co., Ger. Offen. 2,305,575 (9.22.72) 121. G.V. Kovalev,S.M. Gofrnan,S.V. Ivanovskaya, M.V. Punshina,V.I. Petrov,A.M. Sirnonovand I. N. 88 (1973) Tyurenkov. Farrnakol. Toksikol. 122. D. Deitchrnan, A. W. Gornoll and G. R. McKinney, Federation Proc. =,750Abstr., abstr. 3021 (1973) 123.D.Deitchrnan and A.W. Gornoll, Proc. SOC.Exp. Biol 144,203 (1973) 124. W.L. Matier, D.A. Owens, W.T. Comer, D. Deitchrnan, H. C. Ferguson, R.J. Seideharnel and J.R. Young, J. Med. Chern. 13,901 (1973) 125. M. Laubie, H. Schrnitt, P. Mouille, G. Cheyrnol and J.C. Gilbert, Arch. Intern. Pharrnacodyn. 201,334 (1973) 126.J. Roba, G. Larnbelin and A. F. deschaepdryver, Arch. Inter. Pharrnacodyn. 200,182 (1972) 127. E. Bellasio and F. Cristiani, Ger. Offen 2,220,337 (11.23.72) 128. B. Levy, Brit. J. Pharmaco1.@,514 (1973) 129. E. Baldoli,A.Sardi, V. Dezulian, M. Capelliniand G. Bianchi,Arzneirn.-Forsch.,a, 1591 (1973) 130. A. Sardi, A. M. Caravaggi and E. Baldoli, Naunyn-Schrniedebergs Arch. Pharrnacol. 279,301 (1973) 131.M.Gotz,K.GrozingerandJ.T.Oliver, J.Med.Chern. 13,671 (1973) 132. Schering Corporation, US. 3,641,017 (2.8.72); U S . 3,733,409 (5.15.73) 133. K.Tsururni, H. FujimuraandY. Suzuki,OyoYakuriZ, 175 (1973) 134. E. Bellasio, A. Carnpi, A. Trani, E. Baldoli, A. M. Caravaggi and G . Nathansohn, Farmaco, Ed. Sci., 164 (1973) 135. P.H. Jones, J.H. Biel, C.W. Ours, I.L. Klundt and R. L. Lenga, 165th A.C.S. Metting, Dallas (April) MEDI-9 (1973); F.N. Minard, J.C. Cain and D.S. Grant, ibid., MEDI-10; P. Sornani, R. Hollingerand F.N. Minard, ibid., MEDI-11. 136.J.H. Jones,W.J. Holtz and E.J.Cragoe, J. Med. Chern 16,537 (1973) 137.WanderAG.,Ger.Offen.2,258,318 (10.12.72) 138. L.D. Boyajy, R.E. Manning, R. Mclntosh, F. Schaefer, M. Herzig, J. Schaafand H.H.Trapold, 166th A.C.S. Meeting, Chicago (August), MEDI-22 (1973) 151 (1973) 139. D.M. Bailey,C.G.DeGrazia,H.E. Lape,R. Frering,D. FortandT.Skulan, J. Med.Chern. E, 140.J.F. SchaeferJr., R.R. Loetzer, G. B. Phillips, B. J. Kletzkin and F.M. Berger, Federation Proc. 32,750 Abstr.,abstr. 3020 (1973) 141.J.M.D. Aron-Samueland J.J. Sterne, Ger. Offen. 2,213,843 (10.12.72)
s,
a,
Chapter 8. Antiarrhythmic and Antianginal A g e n t s Gilbert W. Adelstein and Richard R. Dean, Searle Laboratories, Chicago, 111.
ANTIARRHYTHMIC AGENTS Introduction - Cardiac arrhythmias generally result from enhanced automaticity or disturbances in conduction. These disturbances cause alterations in cardiac rate, regularity, origin of cardiac impulse or sequence of activation of the atria and ventricles.1-6 8-Receptor Blocking Agents - Current synthetic efforts in @-blockers has focused mainly on compounds of generic structure 1. By alteration of the ArOCH2CH (OH)CH2NHCH (CH3)2
3,4-dihydro-1(2H)-naphthalenon-5-yl 4-ACNHCgHq4-MeOCH2CH2C6H44-MeOCH2CH20C6H42-CH2=CHCH2C6H48-thiochromanyl 1,2,3,4-tetrahydro-l,4-ethano-5-naphthyl 2-acetyl-7-benzofuranyl 7-indenyl 5-methyl-8-coumarinyl 2,3-Me2CgH34-CgHqCONH2 2,3,4,5-tetrahydro-1H-2-benzazepin-l-on-7-y1 4-indolyl 4-CH2=CHCH2C&-
nature of Ar-, compounds of greater cardioselectivity and lesser cardiac depressant activity have been sought. Schwender and co-workers studied the effects of aromatic substitution7 and carbonyl-containing analogs8 on the 8-blocking properties of bunalol (la) and concluded that no enhancement of cardioselectivity could be obtained. Tolamolol (2) - was the most cardio-
OCH2CH (OH)CH 2NHCH (R) (CH2) no
-2
(R=H, n=1, RV=4-CONH2)
selective member of a series of @-blockers and clinical studies indicated negligible myocardial depression9 Practolol (Ib) was effective in treating supraventricular tachyarrhythmias in patients who could not tolerate
.
-68
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
propranolol because of i t s bronchoconstrictor a c t i v i t y . 1 ° The (-) - isomer of p r a c t o l o l r e t a i n s t h e 6-blocking a c t i v i t y and, u n l i k e p r o r a n o l o l , l i t t l e The a b s o l u t e anti-arrhythmic a c t i v i t y i s r e t a i n e d i n t h e (+) -enantiomer.lf c o n f i g u r a t i o n of ( + ) - p r a c t o l o l w a s determined t o be (R) by t o t a l s y n t h e s i s . 1 2 H 93/26 ( l c ) and H 87/07 ( l a ) were r e p o r t e d t o possess considerable c a r d i o s e l e c t i v i t y and H 87/07 had i n t r i n s i c a c t i v i t y s i m i l a r t o a l p r e n o l o l ( l e ) and p r a c t 0 1 o l . l ~ N o improvement i n anti-arrhythmic a c t i v i t y over prop r a n o l o l w a s seen f o r 5-2395 (lf)14, K-4423 (Lg)15, BFE-60 (1h116, o r YB-2 (li) 17. Greater potency and less c a r d i a c depressant p r o p e r t i e s than prop r a n o l o l were a s c r i b e d t o CS-359 (1j)18 and D-32 (1k).19 N o improvement over p r a c t o l o l could be obtained f o r a r e v e r s e amide (11) o r c y c l i z e d r e v e r s e amide (l m ) .20 A s e r i e s of N-substituted-2-amino-l-(thienyl)ethanols were evaluated a s $-blockers and found t o be less p o t e n t than propranolol a s i n h i b i t o r s of t h e tachycardic response t o i s o p r o t e r e n o l . 21 A s e r i e s of h e t e r o c y c l i c propanolamines had 6-blocking a c t i v i t y , t h e most p o t e n t ( 3 ) having t e n times t h e a c t i v i t y of propranolol on t h e guinea p i g a t r i a l
ArCH2CH (OH) CH2NHC (CH3)3
3 (Ar=6-phenanthridinyl) C l i n i c a l e v a l u a t i o n of b u n i t r o l o l (Koe 1366)23 and t i m o l 0 1 ~shows ~ no c l e a r advantages over propranolol f o r i n c r e a s i n g e x e r c i s e t o l e r a n c e o r t r e a t i n g arrhythmias. I n dogs, p i n d o l o l (LB 46, _In) produced no depression of v e n t r i c u l a r function and increased myocardial performance, while K8 592 depressed myocardial performance and propranolol produced an even g r e a t e r depression i n v e n t r i c u l a r function. 25 Thus , s u b t l e changes i n s t r u c t u r e confer s u b t l e changes i n pharmacological p r o f i l e whose s i g n i f i c a n c e i s n o t r e a d i l y understood. Vaughan-Williams has suggested t h a t p - s u b s t i t u t e d phenyl groups tend t o make a 6-blocker more c a r d i o s e l e c t i v e , s i n c e t h e orthos u b s t i t u t e d isomer of p r a c t o l o l has no c a r d i o s e l e c t i v i t y , whereas 2-oxprenolol The r o l e ( l o ) w a s h i g h l y c a r d i o s e l e c t i v e and more p o t e n t than p r a c t o l o l . 26 o T metabolism i n d e l i n e a t i n g t h e p r o f i l e of a c t i v i t y of a 6-blocking agent i s not c l e a r , b u t evidence f o r s e p a r a t i o n of 6-blocking a c t i v i t y and a n t i arrhythmic a c t i v i t y v i a m e t a b o l i t e s e x i s t s . l 9
-
Quaternary Ammonium Derivatives Quaternization of arnine-containing a n t i arrhythmic agents has sometimes r e s u l t e d i n improved a c t i v i t y with a r e duction i n c e r t a i n s i d e e f f e c t s . UM-272 ( 4 ) , t h e dimethyl d e r i v a t i v e of propranolol , e x h i b i t s n e i t h e r t h e 6-blocking p r o p e r t i e s nor t h e l o c a l a n e s t h e t i c p r o p e r t i e s of propranolol. UM-272 is e f f e c t i v e a g a i n s t d i g i t a l i s and myocardial i n f a r c t i o n arrhythmias i n t h e dog. 27 128 I n a d d i t i o n , UM-272 was shown t o s i g n i f i c a n t l y i n c r e a s e v e n t r i c u l a r f i b r i l l a t i o n threshold29 1 3o and reduce t h e occurrence of v e n t r i c u l a r f i b r i l l a t i o n following a c u t e occlusion of t h e l e f t a n t e r i o r descending coronary a r t e r y and i t s subsequent de-occlusion. Miura and co-workers have found t h a t t h i s compound e x h i b i t s e l e c t r o p h y s i o l o g i c a l e f f e c t s s i m i l a r t o propranolol on i s o l a t e d canine
Chap. 8
Antiarrhythmic, Antianginal Agents
Adelstein, Dean
3
Purkinje fibers and rabbit atria.31 Quaternized lidocaine (methyl lidocaine) exhibited the therapeutic efficacy of lidocaine without the CNS side effects of the latter.32 On the other hand, the dimethyl ammonium quaternary salt of bunalol exhibited only weak anti-arrhythmic activity with pronounced myocardial depression. 33
Bretylium tosylate, a neuronal blocking agent, has generated interest as an anti-fibrillatory agent.34 Counsel1 and co-workers have synthesized a series of bretylium analogs and found that 2-iodobenzyltrimeth lammonium iodide showed high uptake by myocardial tissue. 35 Ring-labeled I3lI bretylium analogs (RIBA) were useful as myocardial scanning agents.36 Miscellaneous Agents - Clinical studies indicate that disopyramide phosphate (?a, R=CONH2, Norpace@) was effective in treating both atrial and ventricular arrhythmia~.37-~0Adelstein found that replacement of the amide by heterocyclic rings (rb, 5c) did not significantly enhance activity.41 Cusic and co-workers found that substitutions on phenyl or pyridyl groups did not improve the therapeutic index of disopyramide.42 Aprindine (6) is a new anti-arrhythmic agent that is 20 times more potent than lidocaine as a local anesthetic. Clinical studies have shown that aprindine is a long-acting, orally effective anti-arrhythmic agent which compares favorably with intravenous lidocaine in preventing ventricular arrhythmias after acute myocardial infarction.43
-5
a) R=CONH2 b) R=5-tetrazolyl c) R=2-methyl-1,3,4-oxadiazol-5-yl
6 -
Diphenidol (1) was recently shown to effectively protect dogs against digitalis into~ication.~~ Its mechanism of action was found to result from a shortening of the atrium-to-His bundle conduction time and a suppression of ventricular automaticity. Studies on a group of patients exhibiting digitalis-induced arrhythmias confirmed the animal data and strongly suggest a clinical role for diphenid01.~~ A similar type of action has been suggested for the steroidal antialdosterone agent, potassium canrenoate.46
DCAA (17,21-di-monochloroacetyl ajmaline) abolished digitalis-induced arrhythmias in the majority of dogs and significantly reduced mortality rate. No adverse effect on myocardial function was 0bserved.~7
Sect. I1
70 -
-
Clarke, Ed.
Pharmacodynamic Agents OH
Verapamil (iproveratril) was shown to be an anti-arrhythmic agent several years ago48 I 49 and Singh and Vaughan-Williams postulated that this drug acts by a unique mechanism of action; namely, blockade of the calciumcarrying depolarizing current.50 Recent studies have confirmed the electrophysiological characteristics and effectiveness of verapamil both in vitro and in ouabain intoxicated dogs. In each case, the effect of verapamil was readily reversed by administration of calcium, thus lending support to Singh and Vaughan-Williams ' hypothesis.51 52 In isolated guinea pig atria, BL-3676 and BL-3677 (isomers of 5-endobenzoyloxy-N- (dimethylaminopropyl)-bicycle (2.2.1) heptane-2 ,3 - e dicarboxylic acid hide HC1) increased stimulus threshold but did not alter the resting membrane potential.53 In dogs, W36095 (2-amino-2',6'-propionoxylidide) was an orally effective, long-acting anti-arrhythmic agent with little depressant effect on the cardiovascular system. 54 CRD-401, the benzothiazepine derivative 2, reversed epinephrine-induced arrhythmias in guinea pigs, but failed to reverse arrhythmias due to twostage coronary ligation.55 LL-1530 (10) , whose structure is reminiscent of propranolol, was not a &blocker and was found to have a better therapeutic index and anti-arrhythmic activity of longer duration than quinidine in dogs56 and was effective clinically with minimal myocardial depressant effects.57 OCH2CH (OH)CH2C (=NOH)NH2'HC1 I
10 -
CH CH NMe2.HC1 2 2 PGF7, is reportedly effective in reversing ouabain-induced arrhythmias in ~ a t s ~ ~ - aanclinical d study verified the therapeutic effects.59 The mechanism of action has not been studied. ANTIANGINAL AGENTS Angina pectoris is the result of a disparity between myocardial oxygen demand and oxygen supply. Factors which determine oxygen demand include heart ratelarterialpressure, preload, ventricular volume and mass, and contractility.60 Oxygen supply is determined by the caliber of the coronary arteries, arterial p02, oxygen carrying capacity of the blood, affinity of hemoglobin for oxygen and viscosity of the blood. 61
Chap. 8
Antiarrhythmic, Antianginal Agents
Adelstein, Dean
2
Current a n t i a n g i n a l therapy i s aimed a t reducing oxygen demand and/or i n c r e a s i n g oxygen supply. The n i t r i t e s and organic i n t r a t e s reduce preload by causing venous pooling of blood. These agents have a l s o been shown t o r e d i s t r i b u t e myocardial blood flow, thereby improving oxygen d e l i v e r y t o ischmic areas even though t o t a l coronary blood flow i s n o t increased. 62163 Nitrates continue t o b e drugs of choice i n a l l e v i a t i n g a n g i n a l pain, b u t c o n t r o v e r s i e s e x i s t as t o the e f f i c a c y of long-acting n i t r a t e s . 6 4 A r e c e n t study i n d i c a t e d t h a t cutaneous absorption of n i t r o g l y c e r i n from an oiniment base may be d i s t i n c t l y s u p e r i o r t o t h a t of s u b l i n g u a l o r o r a l n i t r a t e s i n angina pro phyla xi^,^^ suggesting t h a t t h e search f o r more e f f e c t i v e n i t r a t e s might be b e t t e r served by exploring new r o u t e s of administrat i o n f o r nitroglycerin.
Propranolol reduces oxygen needs through a 6-adrenergic blocking a c t i o n which r e s u l t s i n reduced h e a r t r a t e , blood p r e s s u r e and c o n t r a c t i l i t y . 66 ,67 Propranolol a l s o decreases t h e a f f i n i t y of hemoglobin f o r oxygen a t low oxygen tension.68 This increased P50 r e s u l t s i n a greater r e l e a s e of oxygen i n hypoxic t i s s u e s . A study comparing t h e e f f e c t i v e n e s s of propranolol, oxprenolol, and p r a c t o l o l i n anginal p a t i e n t s suggests similar a n t i a n g i n a l a c t i v i t y f o r a l l t h r e e drugs. 69
The p r e v i o u s l y described dimethyl quaternary analog of p r o p r a n o l o l , UM-272, i s n o t a 6-adrenergic blocker. Like propranolol, UM-272 was r e c e n t l y shown t o reduce t h e ST segment s h i f t s observed i n canine e l e c t r o c a r d i o grams d u r i n g c a r d i a c ischemia. 70 This f i n d i n g i n d i c a t e s t h a t 6-adrenergic blockade per se may n o t be necessary f o r e f f e c t i v e a n t i a n g i n a l a c t i o n . The e f f e c t of UM-272 on t h e hemoglobin-oxygen d i s s o c i a t i o n curve has n o t been studied. L 8040 (ll), an analog of t h e coronary v a s o d i l a t o r amiodarone, w a s shown t o b e e f z c t i v e i n decreasing myocardial oxygen consumption by an adrenergic blocking e f f e c t , b u t n o t by competitive 6-blockade. 71 Cardiac o u t p u t w a s n o t reduced.
Br
Chlorthalidone (Hygroton@), a d i u r e t i c , has an a n t i a n g i n a l e f f e c t u n r e l a t e d t o i t s hypotensive e f f e c t . 72 A double-blind study of perhexilene @exid@) i n angina p a t i e n t s showed improved e x e r c i s e t o l e r a n c e . 7 3
Although t h e s e a r c h f o r b e t t e r a n t i a n g i n a l drugs continues, t h e r e is no consensus of opinion regarding t h e most d e s i r a b l e mechanism of a c t i o n .
72 -
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
The controversy over t h e a c t i o n s of n i t r o g l y c e r i n and propranolol continues and, t h e r e f o r e , t h e r e l a t i v e importance of s e l e c t i v e d i l a t a t i o n of coll a t e r a l coronary a r t e r i e s compared t o reduction i n myocardial oxygen needs p e r s e has n o t been e s t a b l i s h e d . While propranolol appears e f f e c t i v e i n t h e p r o p h y l a c t i c therapy of angina p e c t o r i s , concern has been r a i s e d over t h e apparent "rebound" i n c r e a s e i n anginal a t t a c k s a f t e r c e s s a t i o n of therapy. Therefore, f u r t h e r i n v e s t i g a t i o n i s needed before propranolol i s accepted a s t h e s i n e qua non of a n t i - a n g i n a l drugs.
--
References
1. 2. 3. 4. 5. 6.
7. 8. 9. 10.
11. 12. 13. 14.
15. 16.
17. 18. 19. 20.
21.
s. -.
G. W. Adelstein and R. R. Dean, Ann. 9. , 1972, R. V. Heinzelman, ed., p. 63, Academic Press, New York, 1973. P. F. C r a n e f i e l d , A. L. W i t , and B. F. Hoffman, C i r c u l a t i o n 47, 190 (1973). B. F. Hoffman and P. F. Cranefield, Am. J. Med. 37, 670 (1964). D. H. Singer, R. Lazzara, and B. F. Hoffman, Circ. R e s . 21, 537 (1967). S. Weidmann, J. Physiol. 213 (1955). B. F. Hoffman, P. F. Cranefield, and A. G. Wallace, Mod. Conc. Cardiov. D i s . 35, 103 (1966). C. F. Schwender, R. E. Pike, and J. Shavel, Jr., J. Med. Chem. 2, 254 (1973). C. F. Schwender, R. E. Pike, B. R. Sunday, and J. Shavel, J r . , i b i d , 16, 585 (1973). J. Augstein, D. A. Cos, A. L. Ham, P. R. Lemming, and M. Snarey, 16, 1245 (1973). P. Van Durme, L. Bossaert, P. Vermeire, and R. Rannier, Am. Heart J. 86, 284 (1973). G. J. K e l l i h e r and J. Roberts, Eur, J. Pharmacol. 20, 243 (1972). J. C. Danilewicz and J. E. G. Kemp, J. Med. Chem. 16,168 (1973). B. Ablad, E. Carlsson, and L. Ek, L i f e S c i . I , 107 (1973). M. Lauble, G. Cheymol, P. Mouille, J. C. G i l b e r t , and H. Schmitt, Arch. I n t . Pharmacodyn. Ther. 201, 323 (1973). M. Bergamaschi, V. Mandelli, R. Tommasini, C. Turba, and M. M. Usardi, 667 (1972). Boll. Chim. Farm. Y. Maruyama, T. I s h i h a r a , I. H i r a k i , M. Nozaki, and F. Takenaka, Jap. J. Pharmacol. 23, Suppl. 35 (1973). H. Kato, Y. Noguchi, K. Nakao, and K. Takagi, H ISuppl. 39 (1973). T. Oshima, S. Krimakura, H. Koike, and K. Nakayama, E l497 (1973). A. Izumi, M. Mieda, S. Nishida, and Y. Hiramatsu, Suppl 37 (1973). G. Shtacher, M. Erez, and S. Cohen, J. Med. Chem. 16, 516 (1973). C. C o r r a l , V. Darias, M. P. Fernandez Tome, R. Madronero, and J. d e l 882 (1973). Rio, H I R. F. Meyer, C. D. S t r a t t o n , S. G. Hastings, and R. M. Corey, H I 16, 1113 (1973). W. Klempt and F. Bender, Arzneim.-Forsch. 23, 1064 (1973). J. A. Franciosa, E. D. F r e i s , and J. Conway, C i r c u l a t i o n 48, 118 (1973). R. D. Smith and C. B. Nash, Arch. I n t e r n . Pharmacodyn. Ther. 203, 151 (1973). E. M. Vaughan-Williams, Schweiz. Med. Wochenschr. 262 (1973). F. J. Kniffen, D. P. Schuster, and B. R. Lucchesi, C i r c u l a t i o n , Suppl. 11, 46, 177 (1972).
127,
g,
12,
111,
g,
16,
22.
23. 24. 25. 26. 27.
103,
Chap. 8
Antiarrhythmic, Antianginal Agents
Adelstein, Dean
73
28. D. P. Schuster, B. R. Lucchesi, N. L. Noven, M. N. Mimnaugh, R. E. Counsell, and F. J . Kniffen, J. Pharmacol. Exp. Ther. 213 ( 1 9 7 3 ) . 29. F. J. Kniffen, D. P. Schuster, and B. R. Lucchesi, J. Pharmacol. Exp. Ther. 260 ( 1 9 7 3 ) . 30. F. J. Kniffen and B. R. Lucchesi, Am. J. Cardiol. 142 (1973). 475, 31. D. S. Miura, A. B. Hodess, and M. R. Rosen, Fed. Proc. a b s t r . #1491 (1974). 32. R. A. G i l l i s , F. H. Levine, H. Thibodeaux, A. Raines, and F. G. S t a n d a e r t , C i r c u l a t i o n 47, 697 ( 1 9 73). 33. H. R. Kaplan, J. Barker, D. Dugan, J . Fox, and E. Giardino, Pharmacologist 192 (1973). 34. G. Sanna and R. Arcidiacono, Am. J. Cardiol. 32, 982 (1973). 35. R. E. Counsell, T. Yu, V. V. Ranade, and A. Buswink, J. Med. Chem. 16, 1038 (1973). 36. E. A. C a r r , Jr., R. E . Counsell, and M. C a r r o l l , C l i n . Pharmacol. Ther. 14, 132 (1973 ) . 37. D r e i f u s , Am. J. Cardiol. 1 2 9 (1973). 38. R. B. Kalmansohn and R. W. Kalmansohn, Cardiov. R e s . , V I World Congr. Cardiol. , 179 ( 1 9 7 0 ) . 39. L. Vismara, J. Lies, R. MaSSumi, R. Z e l i s , D. T. Mason, and E. A. Amsterdam, C l i n . Res. 456 (1973). 40. B. B e f e l e r , A. C a s t e l l a n o s , Jr., D. E. Wells, M. C. Vagueiro, B. K. Yeh, and R. J. Myerburg, Am. J. Cardiol. 31, 119 (1973). 41. G. W. Adelstein, J. Med. Chem. 16, 3 0 9 (1973). 42. H. W. Sause, J. W. Cusic, and K . .P Yonan, Abstr. Papers, Am. Chem. SOC. 165 Meet. MEDI 1 2 ( 1 9 7 3 ) . 43. F. Hagemeijer and P. G. Hugenholtz, Am. Cardiol. 33, 142 (1974). 44. W. J. Mandel, H. Hayakama, J. K. Vyden, M. Carvalho, W. W. Parmley, and E. Corday, Am. J. Cardiol. 2, 67 (1972). 45. A. F e l i p e and S. Cecgna, Am. J. Cardiol. 33, 130 (1974). 915 (1972). 46. B. K. Yeh, P-K Sung, and A. K. Saha, CircTRes. 47. M. Dalmastro, T-W Lang, S.